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ABSTRACT 
An attempt has been made to isolate Saccharomyces cerevisiae homologues 
of mammalian small nuclear ribonucleoprotein particle (snRNP) proteins, more 
specifically the common snRNP (or Sm) proteins; B, B', Dl, D2, D3, E, F and G. 
Human antisera obtained from patients suffering from systemic lupus 
erytherematosus (SLE), often has the ability to immunoprecipitate mammalian 
snRNPs. The most immunogenic peptides appear to be the B, B' and D (1, 2 and 3) 
proteins. Pre-messenger RNA processing and therefore elements of the splicing 
machinery (such as snRNPs) are evolutionarily conserved from man to yeast. A 
serum was obtained which demonstrated reactivity with S.cerevisiae snRNPs, by 
virtue of immunoprecipitation of snRNP-associated UsnRNA molecules. This 
serum was used to screen an S. cerevisiae cDNA Xgtl 1 library, from which fourteen 
strong and twenty-two weak positive clones were obtained (M.Dalrymple, 
unpublished results). The nucleotide sequences of the cDNAs contained within the 
2gt1l clones were obtained, from which peptide sequences were predicted. 
Database searches indicated that twenty-five cDNAs were derived from previously 
reported genes or nucleotide sequences. The remaining eleven cDNAs were found 
to be original in sequence and therefore predicted to encode novel yeast species. 
One cDNA sequence however, showed approximately 70% identity to a rat 
ribosomal protein (S5). 
No identities were observed between the nucleotide and predicted amino acid 
sequences of the novel yeast species and those of the mammalian Sm proteins. 
However, sequence comparisons indicated that four of the novel cDNA sequences 
may be derived from one messenger RNA and possibly one gene. The independent 
isolation of this cDNA (SM 14) sequence on four occasions may imply strong 
immunoreactivity with SLE autoantibodies. Therefore, the corresponding protein 
(SM 14) was a potential candidate for a yeast snRNP constituent. On this basis, 
identification of the S. cerevisiae SM14 gene and characterisation of its product were 
attempted. Inverse PCR was performed from yeast genomic DNA, in order to obtain 
the full SM14 genomic sequence, while rabbit antibodies were raised against an E. 
coli fusion protein (3-galactosidase-SM14). Anti-5M14 sera facilitated 
immunoprecipitation experiments, from which SM 14-associated proteins and RNA 
species were analysed. Another E. coli fusion protein (TrpE-SM14) enabled 
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alanine Ala A 
arginine Arg R 
asparagine Asn N 
aspartate Asp D 
cysteine Cys C 
glutamate Glu E 
glutamine Gin Q 
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1.1 	Systemic Lupus Erythematosus 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in 
which sufferers produce antibodies to a diverse array of host antigens. It is one of 
many autoimmune disorders whose etiology is unknown. Several of these diseases 
have overlapping symptoms and in accordance with this share antibody specificities 
This presents difficulties in terms of clinical diagnoses. Consequently, it is often the 
presence of antibodies to specific autoantigens, accompanied by ill-defined clinical 
symptoms which categorise these autoimmune conditions. 
Most autoimmune diseases have limited heterogeneity in terms of 
autoantibody specificity. However, the SLE patient tends to have autoantibodies 
directed against a wide range of host antigens. Presently, up to nine specific 
autoantigens have been identified as targets in this disease (Table 1.1). These 
species are often components of subcellular particles or constituents of nucleic 
acid/protein complexes. Two autoantibody specificities are said to be diagnostic of 
SLE; (1) those reacting with double-stranded DNA and (2) those directed against the 
common snRNP (or Sm) proteins. Despite the potential array of immunogenic 
targets, the SLE patient has an average of only three different circulating 
autoantibodies, increasing to six at times of disease exacerbation. The ailments 
associated with SLE are a consequence of antibody- autoantigen complex formation 
and deposition in tissues such as the skin, salivary glands or kidneys. Furthermore, a 
high level of immune complex deposition may result in the malfunction of affected 
organs. The molecular basis of SLE and other autoimmune diseases have been 
extensively reviewed by Tan. E.M. (1989). Proposed etiological models of SLE 
have included polyclonal B-cell activation (Klinman, D.M. and Steinberg, A.D., 
1987), antigen driven response (Habets, W.J. et al., 1990) and molecular mimicry 
(Oldstone, M.B.A., 1987). 
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1.2 	Autoantibody Detection Methods 
The detection of specific autoantibodies in sera of people with autoimmune 
diseases is important for diagnostic reasons (Section 1.1) and also in attempting to 
understand the etiology of these disorders. Several methods have been employed in 
identifying SLE host targets as well as defining the location and nature of individual 
epitopes. The success of these methods in detecting circulating antibodies depends 
on the nature of the presented antigen and epitope. A brief description and 
assessment of the most commonly used methods are given below. 
Double Immunodiffusion (DI) and Counter Immune Electrophoresis (CIE) 
Extract (typically human spleen) and antisera are diffused (DI) or 
electrophoresed (CIE) through agarose gels until a specific autoantibody reacts with 
its target antigen, thereby forming a precipitin arc. The lines are visualised using 
Coomassie brilliant blue stain and a reference arc containing purified autoantigen 
serves as a direct comparison. Due to the large number of SLE autoantigens and 
overlapping antibody specificities, results are often confusing and so these methods 
are not generally approved. 
Immunoblotting 
Cell extracts and purified autoantigen are electrophoresed through SDS-
polyacrylamide gels. Following electrophoretic transfer to membranes, test sera are 
used to probe blotted proteins. Unlike the previous method, this technique usually 
presents the antigen in a denatured form, so that antibodies reacting with linear only 
epitopes may be detected. Hence, immunoreactive species with conformational 
epitopes may not be identified by this method. 
Enzyme Linked Immunosorbent Assay (ELISA) and Radio-immunoassay 
(RIA) 
PVC microtitre plates are coated with purified autoantigen. Specific 
autoantibodies are absorbed onto the plate as a result of incubation with a test serum. 
The absorbance (ELISA) or level of radioactivity (RIA) are measured following 
incubation with enzyme-conjugated (e.g. peroxidase) or radiolabelled secondary 
antibody respectively. These readings indicate the presence and titre of specific 
autoantibodies. This method has also been used to fine map epitopes of some SLE 
autoantigens, by analysing the immunoreactivity of synthetic overlapping 
oligopeptides (or oligonucleotides) with a panel of sera. In this case, the assay 
permits detection of specific autoepitopes and also reflects immunodominance. 
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The advantage of this method over immunoblotting is that the autoantigen is 
presented to the autoantibody in a nondenatured form. This permits interaction with 
both linear and conformational epitopes. However, when short oligopeptides or 
purified antigen are scrutinised, large discontinuous epitopes and/or those requiring 
the tertiary structure of a complex for immunoreactivity will not be detected. 
(3) 	Immunoprecipitation 
Many autoantigens are associated with nucleic acids or proteins in 
subcellular particles, e.g. histones with DNA, ribosomal proteins in rRNPs and the 
Sm proteins in snRNPs (Tan E.M., 1989). Therefore, it is possible to ascertain the 
presence of a particular autoantibody by immunoprecipitating the antigen or an 
associated species. To achieve this, autoantibodies are first immobilised on protein 
A-sepharose beads or affinity columns and an extract containing the autoantigen is 
circulated. The immunoprecipitate is subsequently analysed by Southern, Northern 
or Western blot. 
This method allows detection of linear and discontinuous autoepitopes. It 
also permits antibody recognition of epitopes which require the tertiary structure of 
an autoantigen-containing complex or subcellular particle, since whole cell or 
nuclear extracts buffered appropriately may not disrupt these heterogeneous 
complexes. 
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1.3 	SLE Cellular Autoantigens 
Species identified as major autoantigens and the frequency of their 
corresponding antibodies occurring in SLE sera are shown in Table 1.1. The cellular 
functions and locality of these autoreactive species are discussed in this work, in 
addition to the nature and dominance of any defined autoepitopes. 
Table 1.1 	The Cellular Antigens and Autoantibodies of SLE 
(taken fron Tan, E.M., Antinuclear Antibodies: Diagnostic Markers for Autoimmune 
Diseases and Probes for Cell Biology, 1989) 
Cellular Autoantigen Autoantibody frequency 
DNA 
Double stranded 40 
Single stranded 70 
Histones 70 
Ku complex (Ku76/86) 10 
Hsp9O 50 
Ro factor 35 
La factor 15 
Ribosomal RNP 10 
SnRNPs 
(1)U1,U2,U4IU6 and U5 30 
(2)U1 32 
1.3.1 DNA 
The form and physical structure of DNA varies enormously during the cell 
cycle. Autoantibodies have been detected against three categories of species which 
are components of native DNA. 
Single-stranded DNA antibodies (anti-ssDNA) are thought to 
recognise polymers of purine or pyrimidine. These regions are only accessible in 
this form of naked DNA, hence these antibodies have single specificity. 
Double-stranded DNA antibodies (anti-dsDNA) appear to have dual 
specificity, in that they may also bind ssDNA. The explanation for this lies in the 
nature of the epitope(s). The deoxyribose phosphate backbone is accessible in both 
forms of DNA and certain helical structures. Single-stranded DNA can base pair 
with complementary nucleotide sequences, forming such secondary structures. 
Hence, helical DNA and the sugar phosphate backbone of nucleic acids may act as 
immunogens in SLE. 
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(3) 	Histone proteins (Hi, H2A, H2B, H3 and H4) may be targeted by the 
immune system when complexed with DNA or as individual species. In addition, 
autoantibodies reacting with dimer (H2A-H2B) and tetramer (H3-H4) histone 
complexes, have been demonstrated in SLE sera. Patterns of autoantibody 
specificity differ between sera, but Hi and H213 (in this order of reactivity), appear 
to be the most highly targeted proteins of this class. 
Nuclear DNA of higher eukaryotes is compacted into dense structures, part 
of which is protein in nature. These proteins or histories function in creating 
'repeating units' or nucleosomes, which contain a specified length of helical DNA. 
The structure of the nucleosome is such that two H2A-H2B dimers and an H3-H4 
tetramer comprise a 'core' around which the DNA helix is wound. Histone Hl seals 
this unit, by interacting with 10 base pairs of incoming and outgoing DNA. 
The mammalian Hi protein (calf thymus) is extremely lysine-rich and 
consists of; (1) a randomly coiled N-terminus of 33 amino acids, (2) a central 
globular domain of 75 amino acids, (3) a 100 residue C-terminus which is highly 
basic and also randomly coiled (Allan, J. et at., 1980). Both the amino and carboxy 
termini are evolutionarily more variable than the highly conserved globular central 
region. It is these terminal regions which are implicated in chromosome 
condensation, i.e. the folding and maintenance of the intermediate higher order 
structure of chromatin (Böhm, L and Crane-Robinson, C., 1984). This regional 
variation is observed in the Hl subtypes (Hl' and H5) which perhaps reflects their 
cellular role in facilitating different degrees of chromosome condensation. It is the 
highly charged C-terminal half which appears to be the main target for Hi SLE 
autoantibodies. This was demonstrated by ELISA of trypsin-cleaved Hi and 
immunoblotting (Gohill, J. et at., 1987). 
The H5 protein is an avian Hi variant which is present in inactive 
erythrocyte nuclei and thought to be more tightly associated with chromatin than the 
latter. Hi and H5 share 70% amino acid similarity in their globular domains, but 
less than 10% in the autoreactive C-terminal domain. Although H5 is not a 
mammalian historic protein and therefore cannot be said to be an autoantigen, 
immunoblotting of the C-terminal region with SLE sera has shown that Hi and H5 
share at least one epitope and that this region of the latter contains an 
immunodominant epitope (Pauls, J.D. et at., 1990). In view of the limited primary 
sequence identity between human Hi and H5, this is surprising. However, this could 
indicate that the shared epitope is of a conformational nature. 
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In determining linear epitopes of mammalian histone proteins and H5, SLE 
sera were used by Pauls, J.D. et al. (1993), in overlapping hexapeptide analysis. 
Synthetic H5 hexamers were immobilised on multi-peg supports and scanned for 
reactivity with SLE sera by ELISA. Surprisingly, the main autoreactive hexamer 
SSRQSI was found to locate within the globular domain of H5. This is contrary to 
previous observations which implied that the Hi and H5 C-termini act as 
immunodominant regions (Gohill et al., 1987; Pauls et al., 1990). This led Pauls et 
al. (1993), to propose that peptide renaturation had occurred during the 
immunoblotting experiments of previous workers, thereby explaining the lack of 
detection of dominant linear epitopes in the Hi and H5 (highly similar) globular 
domains. This infers that the Hl and H5 C-termini contain the majority of 
conformational epitopes. However, the prior experiments utilised mammalian H1 
and H5 proteins, which may explain the discrepancy in the observed results. It is 
possible that a eukaryotic modification (of a post-translational specificity) is 
responsible for the immunodominance of the epitopes within these C-terminal 
regions, since this factor is absent from the overlapping synthetic peptides. 
Fine mapping of Hl SLE autoepitopes was attempted by Minota, S. et al. 
(1992). Truncated -galactosidase-H1 fusion proteins were electroblotted onto 
membranes and assayed for immunoreactivity with a panel of SLE IgG. The results 
indicated at least two distinct linear epitopes (A and B), each contained within a 20 
amino acid stretch of the C-terminal two-thirds of HI (within the globular or C-
terminal regions). One of these epitopes (A) may coincide with a DNA-binding 
domain, since binding of affinity-purified anti-epitope A antibodies was abolished 
when blotted Hi fusion protein was previously incubated with single-stranded DNA. 
All of the anti-Hi positive sera tested reacted with epitope A, but less than 25% 
recognised epitope B. This implies that epitope A is an immunodominant epitope as 
assessed by these techniques. Since the amino acid sequences of epitopes A or B 
were not ascertained, it is not clear whether the latter are contained within the 
globular or evolutionarily variable C-terminal domain. However, it is apparent that a 
peptide region targeted by SLE autoantibodies, may correspond to an essential 
functional domain. That SLE autoantibodies can inhibit the functional activity of 
their targets in vitro has been previously observed (Tan, E.M., 1991). 
The N-termini of the histone core proteins 112A, H2B, H3 and H4, as well as 
the C-terminal ten and six amino acids of H2A and H3 respectively, have been 
shown by immunoblotting and ELISA to contain autoreactive epitopes (Thomas, 
J.O. et al., 1984). These N-terminal regions have been proposed to be particularly 
exposed within the structure of native DNA. 
1.3.2 Ku Complex 
Autoantibodies to the Ku cellular complex are present in approximately 10% 
of SLE patient sera (Table 1.1). Immunofluorescense of human cells with anti-Ku 
monoclonal antibodies reveals both speckled nucleoplasmic and diffuse nucleolar 
staining. Molecular characterisation showed the autoantigen to be a lOS heterodimer 
consisting of two non-covalently linked proteins with approximate molecular masses 
of 70 and 80kDa (p70/Ku70 and p80/Ku 80 respectively). More precise localisation 
of this autoreactive complex demonstrated an association with DNAse-sensitive 
regions of the cell and condensing chromosomes, particularly at certain stages of the 
cell cycle. These properties, in addition to its ability to bind DNA in vitro, led to the 
initial identification of this species as a non-histone, DNA-binding complex (Reeves, 
W.H., 1985). The SLE epitopes and molecular masses of the Ku70 and Ku80 
species are highly conserved in mammals (e.g. from man to rabbit to rat). In 
addition, these two proteins share at least one autoepitope despite having no primary 
sequence similarity (Francoeur, A-M. et al., 1985). 
Participation of this complex in gene expression and DNA repair 
mechanisms have been suggested. The Ku heterodimer has recently been shown to 
be identical to a transcription initiation factor (Factor B), which associates with a 
340kDa species (Factor A) and stimulates phosphorylation of RNA polymerase II. 
By binding to DNA in a promoter specific manner, Factor B (Ku) confers DNA 
dependence on RNA polymerase II hyperphosphorylation (Dvir, A. et al., 1993). In 
accordance with this, the Ku70 protein has been shown to stimulate transcription of 
the Ui snRNA gene in vitro (Knuth, M.W. et al., 1990). 
The Ku complex has also been implicated in RNA polymerase I systems. El 
binding factor (Ku) from rat hepatoma cells binds a region of DNA proximal to the 
promoter of a rat rRNA gene, thereby stimulating transcription initiation (Hoff, C.M. 
and Samson, T.J., 1993). Further evidence of the enhancer binding properties of the 
Ku complex has been demonstrated (Messier, H. et al., 1993), where bacterially 
expressed Ku70 (p70) was isolated in a screen of a ?gtl 1 library using the T-cell 
receptor 0 chain (E3) promoter as a probe. 
A role in DNA repair for the Ku70/80 complex has been suggested (Falzon, 
M. et al., 1993). The nucleic acid binding affinities of Ku80 vary depending on the 
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nature of the DNA (e.g. blunt ended, double-stranded, or hair-pin loop). As a result 
of these discrepancies, it has been suggested that the Ku complex recognises single 
to double-stranded transitions. 
Reeves, W. H. et al. (1991), have localised at three independant, sequentially 
and immunologically distinct epitopes on each of the Ku proteins. In addition, a 
further two were identified solely in the Ku70/Ku80 complex. A major epitope of 
Ku70 (as part of a TrpE fusion protein) was demonstrated in the C-terminal region 
between residues 560-609. This epitope was shown to be complex and 
discontinuous in nature, since deletion of residues 560-571 or 601-609 abolished 
autoantibody binding. In their study of Ku80 epitopes, it was demonstrated that a 
major autoreactive domain resided within the C-terminal 270 amino acids. This was 
further localised to residues 682-732, where the first nine amino acids were found to 
be critical for antigenicity. It was concluded that a general tendency for 
discontinuous or conformational C-terminal epitopes exists, since sera were often 
found to be anti-Ku autoantibody positive by ELISA or immunoprecipitation, but 
simultaneously negative by immunoblot. 
An immunodominant region of the Ku80 protein has been suggested to be 
contained within its C-terminal 40 amino acids (residues 667-708), since bacterially 
expressed fusion proteins tested by ELISA, demonstrated reactivity with 50% of 
SLE sera (Wen, J. and Yaneva, M., 1992). This region contains highly charged 
amino acids and when either of two such residues (699-E or 703-K) were substituted 
by alanine, 65% of sera previously reactive with this domain, were no longer so. 
This domain has a 20 amino acid overlap (which contains 40% of charged residues) 
with the major Ku80 epitope region described by Reeves et al. (1991), thereby 
verifying the antigenicity of the residues in this locality. In addition, charged 
residues have been suggested as a factor common to many SLE autoantigens 
(Brendel, V. et al., 199 1) 
Abu-Elheiga L. and Yaneva M. (1992), created various bacterially expressed 
Ku70-fusion protein deletion mutants These were used to demonstrate that the 
DNA-binding domain and majority of anti-Ku70 SLE sera require the C-terminal 
514-609 amino acids in a conformational state to permit interaction with DNA and 
autoantibodies respectively. However, pre-incubation of blotted Ku70 with either 
DNA or purified autoantibodies did not inhibit the complementary interaction, 
implying that the nucleic acid and antibody binding regions were not identical. 
Furthermore, an artificially raised mouse monoclonal antibody was found only to 
react with denatured Ku70-fusion proteins, leading to the proposal that SLE 
autoantibodies target epitopes in the native Ku70 species, whereas the former select 
linear domains. In contrast to the results of Reeves et al. (1991), it was found that 
the C-terminal residues 560-609 of Ku70 (as part of a f3—galactosidase fusion protein) 
were not sufficient for interaction with SLE antibodies on immunoblots. This 
discrepancy was attributed to genetic differences in patient populations. However, 
Reeves et al. (1991), tested the immunoreactivity of these Ku70 residues as TrpE 
fusions. Hence, the N-terminal portions of the Ku70 fusions may determine the 
antigenicity of the latter in these experiments This implies that the 3—galactosidase 
protein may have a negative effect on the ability of the Ku70 C-terminal peptide to 
bind autoantibodies. 
1.3.3 Heat Shock Protein 90 (HSP90) 
Heat shock proteins (HSP5) are highly conserved proteins, which are induced 
under conditions of elevated temperature and cellular stress. These species often 
facilitate the correct folding and transport of other cellular proteins. Some HSPs are 
constitutively expressed and adapt their cellular function following heat shock. 
Autoantibodies directed against the HSP90 are found in 50% of SLE sera (Table 
1.1). This constitutively expressed species, binds and inactivates steroid hormone 
receptors in the cytoplasm (Miyata, Y and Yahara, I., 1991). Epitope mapping of 
this protein has been carried out with SLE sera (Al-Dughaym, A.M. et al., 1994). 
Overlapping nonapeptides representing the entire amino acid sequence of the human 
HSP90 protein were synthesised on polyethlylene pins. Eight peptides were found 
to be immunoreactive by ELISA, six of these recognised by 50% or more of the SLE 
sera tested. These peptides were located at positions 57, 497, 549, 580, 642 and 655 
(Table 1.3). The most C-terminal epitope (KNDK) was also the most 
immunoreactive as it was recognised by antibodies in over 80% of the sera tested. In 
addition, the pattern of epitopes recognised by anti-HSP90 autoantibodies in SLE 
sera were found to be specific to this autoimmune condition. 
ro' 
Table 1.3 	Epitopes of some SLE Cellular Antigens 
Autoantigen Immunodominant Description/Comments 
Regions/Epitopes  
Histones 
Hi C-terminal half Highly 	charged 	and 	possibly 
conformation-dependant. 
Ku Complex 
Ku70 560-609 Conformational (since both 560-571 
and 	601-609 	are 	required 	for 
reactivity). 
Ku80 682-732 Conformational (first 9 amino acids 
critical for antigenicity). 
667-708 Highly charged (699-E and 703-K 
(All C-terminal) strongly required for reactivity) 
HSP Factors 
HSP90 57-60 (JURY) Linear epitopes of which KNDK was 
101-105 (SKEQV) the most immunoreactive and the most 
549-554 (GLELPE) C-terminal. 
580-583 (LDKK) 
642-646 (PT VET) 
655-658 (KNDK)  
Ro/La Factors 
Ro52 216-292 Contains part of a Leucine zipper. 
Ro60 215-255 Hydrophilic,cc-helical 	and 	highly 
charged (probably linear). 
181-320 Contains many epitopes, a proportion 
of which may be conformational. 
485-491 Linear (5/7 residues charged) 
(EYRKKMD) 
Ro46 Epitopes may require post-translational 
modification 	and/or 	a specific 
conformation. 






P0 296-317 C-terminal 22 amino acids contain a 
P1 93-114 shared linear epitope. 	This region is 
P2 94-115 highly charged (14/22 residues). 
(KKDEKKEESEESD 
DDMGFGLFD), P2  
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1.3.4 Ro and La Factors 
Ro autoantigen factor was first identified by Clark, G. et al., in 1969. Using 
immunodiffusion techniques, it was demonstrated that autoantibodies in the sera of 
SLE or Sjorgens syndrome (SS) patients precipitated this novel antigen from human 
tissue extracts. This was confirmed by Alspaugh, M.A. and Tan, E.M. (1975), who 
also identified two other autoantibody specificities associated with SS. The 
corresponding autoantigens were named SS-A (Ro), SS-B (La) and SS-C. 
Autoantibodies directed against the Ro and La factors commonly occur 
simultaneously in the sera of SS sufferers, whereas SLE sera tend often, although not 
exclusively to contain only those of the former specificity. Bozic, B. et al., (1993) 
showed that 59-68% of SLE sufferers with anti-Ro antibodies had sera containing 
anti-Ro but not anti-La, whereas SS patients (87%) had both. Both Ro and La 
factors can be found in cell nuclei, but may also have cytoplasmic roles. 
1.3.4.1 	Molecular Characterisation of the Ro Autoantigen 
The Ro autoantigen factor, presumed initially to be a single protein, has 
proved to be of a more complex nature. Two species of 60 and 52kDa were 
identified by immunoblotting of lymphocyte cell extracts using anti-Ro sera. 
Immunoprecipitation indicated an association between these proteins and several 
small previously unidentified RNAs. Further analysis disclosed a set of four distinct 
ribonucleoprotein particles (R0RNPs), each containing one of four hYRNAs (human 
cYtoplasmic) associated with the two Ro proteins (Ro60 and Ro52). The hYRNAs 
(hYl, hY3, hY4 and hY5) have conserved elements within their sequences, 
suggesting that the 5' and 3' termini base pair. This proposal is well supported 
experimentally, in that this region is protected against cleavage in RNAse H 
protection assays (Pruijn, G.J.M. et al., 1991). 
Two genes for the Ro60 protein have been cloned. Sequencing has revealed 
that the genes from human placenta (Deutscher, S.L. et al., 1988) and T-cell (Ben-
Chetrit, E. et al., 1989) sources are identical, apart from a few C-terminal amino 
acids. Both Ro60 amino acid sequences are predicted to contain zinc fingers and 
RNA binding domains (or RNA recognition motifs). The latter is defined around a 
highly conserved octamer of amino acids K(R).G.F(T).G(A).F.V.X.F(T). This 
octamer (also known as the RNP consensus sequence) was first recognised by 
Adam, S.A. et al., (1986) in the polyA-binding and hnRNP Al proteins. The much 
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larger RNA recognition motif (RRM), spanning 80 amino acids was defined by 
Theissen, H. et at., (1986) in comparing the RNP consensus sequence-containing 
regions of these proteins with that of the Ui snRNP-associated 70K species. 
Although the presence of an RRM in a protein signifies its ability to bind RNA, not 
all proteins which bind this nucleic acid contain such a sequence. However, Pruijn 
et at. (1991), has shown that it is most likely to be the RRM containing Ro60 protein 
which contacts the double-stranded region of the hYRNA, the bulged-C residue 
playing an essential role in this interaction. 
The Ro52 protein is predicted to contain a leucine zipper (implicated in 
protein-protein or protein-nucleic acid interactions) and zinc binding finger motifs. 
Based on amino acid homologies with regulatory proteins, this factor is predicted to 
play a role in gene regulation (Chan, E.K.L. et al., 1991). No evidence of 
Ro52IhYRNA interaction has been observed, therefore Ro52 protein is thought to 
associate with RoRNPs, either via interaction with Ro60 or an as yet unidentified 
RoRNP factor (Pruijn et at., 1991). 
An additional autoantigen of 46kDa may be associated with the RoRNP 
complex. This protein, which migrates aberrantly upon SDS-gel electrophoresis at 
60kDa and reacts with some anti-Ro sera, has been isolated and identified as 
caireticulin. This calcium binding protein is thought to reside in the endoplasmic 
reticulum and may also be involved in protein assembly (McCauliffe, D.P. et at., 
1990). Density gradient analysis, however indicates that the RoRNP complex has a 
molecular mass of approximately 300-35OkDa, implying that more (as yet unknown) 
associated proteins/factors exist (Boire, G. and Craft, J., 1990). 
1.3.4.2 	Ro Factor Autoepitopes 
Autoantibodies are often directed against species which have a close 
molecular association. This is supported by the finding that 87% of anti-Ro SLE 
sera react with both Ro60 and Ro52 proteins (Barakat, S. et at., 1992). The pattern 
of autoepitopes on individual Ro antigens varies according to the specificity of the 
autoimmune condition. This fact was demonstrated by Bozic et at. (1993), who 
identified an epitope in the N-terminal region of Ro60 which was reactive with 57% 
of SS patient sera, but only 7% of SLE. In addition, a major SLE epitope of the 
Ro52 protein was located (residues 216-292) by immunoblotting. Deletion of this 
region (which contains part of the leucine zipper sequence) was found to abolish the 
reactivity of some sera. 
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The autoepitopes of the Ro60 protein have been studied in more detail. An 
immunodominant region of this species has been localised to amino acids 181-320, 
where several autoepitopes are thought to reside (Wahren, M. et at., 1992). 
Although other epitopes were found in both amino and carboxy termini, an attempt 
was made to map more precisely this immunoreactive region. Using ELISA of 
synthetic, overlapping 20mer peptides, the region 215-255 was found to react 
strongly with SLE/SS sera. This region is hydrophilic, alpha-helical, and highly 
charged. These properties are synonymous with those previously described as 
pertaining to some SLE autoantigens (Brendel et at., 1991). Interestingly, several 
sera reactive with region 181-320 by immunoblotting were found to be negative by 
ELISA. This could be a result of partial renaturation of a discontinuous epitope 
(requiring more than 20 amino acids) within this Ro60 region on the immunoblot. 
Alternatively, the synthetic peptides used in ELISA may not contain a factor 
required for interaction with SLE autoantibodies. 
Boire, G. et at. (1991), concluded that the conformation of Ro60 epitopes is 
imperative in detecting antibody interactions. It was found that 31 of 70 anti-Ro60 
sera were positive by immunoblot, whereas 69 of the same sera were positive by 
immunoprecipitation. Two distinct antigenic determinants on Ro60 were 
demonstrated, one of which was only detectable by immunoprecipitation. This 
finding was supported by antibody absorption experiments Linear Ro60 absorbed 
reactive autoantibodies on an immunoblot, however the residual antiserum still had 
the capacity to bind Ro60 protein in native blots. The prevalence of conformational 
epitopes has been further affirmed by Boire, G. and Craft, J. (1989), who suggested 
that one particular autoantibody required the protein-RNA interactions only present 
in the tertiary structure of the hY5IRo-RNP complex. 
A major linear epitope has been located in the C-terminal region of Ro60 (, 
R.H. and Harley, J.B., 1991a). The sequence EYRKKMD (residues 485-491) was 
shown to be highly immunoreactive in overlapping peptide analysis using ELISA. 
Incidentally, a highly similar peptide region has been found in a Vesicular Stomatitis 
Virus (VSV) protein. These seven amino acids (with one interruption) are present in 
the nucleocapsid protein of VSV, possibly implying a role for molecular mimicry in 
the etiology of SLE. 
The study of the autoepitopes of the 46kDa Ro factor has been hampered by 
the apparent lack of reactivity of sera with bacterially expressed and/or recombinant 
forms of this protein. This led McCauliffe, D.P. et at. (1993), to propose that post- 
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translational modification and the tertiary structure of the RoRNP complex may be 
required for autoantibody interaction with the Ro46 species. 
	
1.3.4.3 	Molecular Characterisation of the La Autoantigen Factor 
Although the cellular function of the RoRNP complex is unknown, the 
50kDa La protein has been suggested to play a role in RNA polymerase HI 
transcript maturation (Gottlieb, E. and Steitz, J.A., 1989). Specifically, it binds the 
3' ends of the appropriate immature pre-messenger RNA transcripts, acting as an 
auxiliary factor in termination. Upon maturation the association with the transcript 
is lost. A physical association of La with RoRNP complexes has been observed. 
The latter can be isolated with the La protein bound to the 3' oligouridylate tail of the 
hYRNA species (Boire and Craft, 1990). The La protein has also been isolated as 
part of RNPs with 5S rRNA, tRNA, and U6 snRNA (Rinke, J and Steitz, J.A., 1985; 
Rinke, J. and Steitz, J.A., 1982). 
1.3.4.4 	La Autoepitopes 
Fifteen per cent of SLE patients have circulating anti-La autoantibodies, 
compared with over 40% of SS sufferers. However, unlike Ro factor, the pattern of 
La autoepitopes appears to be very similar in both autoimmune conditions. The 
presence of La antibodies in SLE sera is nearly always accompanied by Ro60 
antibodies. More specifically, Dickey, W.D. et al. (1993), have found that anti-La 
SLE sera simultaneously contain autoantibodies directed against the C-terminal 
l3kDa of the Ro60 protein. Since no sequence identities have been observed 
between these peptides, it was concluded that this finding represents two distinct 
autoantibody specificities. 
Deletion mutants of bacterially expressed La fusion proteins have been used 
to identify possible autoepitopes. St.Clair et al. (1988), found at least three distinct 
antigenic regions on the La protein. This was deduced from the reactivities of anti-
La SS/SLE sera with several B-galactosidase-La fusion proteins in ELISA. It was 
concluded that the central region (residues 111-242) contained the majority of 
autoepitopes. They also found that three out of the four epitopes located were 
conserved between the human and bovine forms of this protein. 
Bini, P. et al. (1990), found that a similar region of La (residues 112-226) 
was immunodominant, since it reacted on immunoblots with over 70% of anti-La 
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sera tested. In addition, the epitopes within this region were shown to be largely 
conformational in nature, as heat denaturation abolished this reactivity. In contrast, 
the weaker autoreactive C-terminal epitopes (residues 226-380) were found to be 
linear. 
An immunodominant, discontinuous La epitope has been located in the N-
terminal 1-107 residues (McNeilage, L.J. et at., 1992). This region has been found 
to be the most highly conserved in evolution. In accordance with this, SLE 
autoantibodies directed against this region can bind the N-terminus of another 
mammalian La species (murine). While region 111-226 has also been shown to 
contain an immunodominant epitope (Bini et at., 1990), its reactivity appears to be 
restricted to the human La species. This is surprising since this region contains an 
RNA recognition motif, which is also highly conserved. 
Kohsaka, V. et at. (1990), demonstrated the presence of an additional N-
terminal epitope. Using ELISA, various bacterial 3—galactosidase-La deletion 
mutants were examined. An epitope within amino acids 88-100 was recognised by 
autoantibodies in all anti-La SLE/SS sera tested. It is not clear whether these amino 
acids are part of the discontinuous epitope defined by McNeilage et al. (1992), or 
represent a distinct linear epitope. Interestingly, these 13 amino acids (Table 1.3) 
bear a striking resemblance to a region of a retroviral GAG protein. Two other 
autoantigens, the Ul snRNP 70K and DNA topoisomerase I proteins (autoantigens 
in SLE and scleroderma respectively), also have regions of amino acid identity with 
this viral species. 
In summary, many different regions of Ro and La autoantigen factors are 
autoepitopes in SLE. Their close physical association implies that the entire 
RoRNP-La complex may act as autoantigen. Consistent with this theory, is the 
occurrence of a large number of conformational or discontinuous epitopes, which 
would be expected if the immune system is directed against such a structure. In 
addition, the etiology of SLE and other autoimmune diseases becomes intriguing, as 
homologies between autoantigen and viral protein sequences appear to suggest a role 
for these infectious agents in the pathology of autoimmune disorders. 
1.3.5 Ribosomal Ribonucleoprotein Particles (rRNPs) 
Autoantibodies occasionally occur in SLE sera which are directed against 
specific regions of rRNPs. Three proteins present in the 60S ribosomal complex are 
predominantly targeted in SLE (Elkon, K. et al., 1985). In addition to reacting with 
15 
cytoplasmic compartments, autoantibodies reactive with P0, P1, and P2 proteins 
have been shown to bind nuclei, signifying a possible role for these proteins in early 
assembly of translation complexes. The three proteins are acidic in nature (all are 
phosphoproteins), and have molecular masses of 38 (P0), 19 (P1) and l7kDa (P2) 
respectively. These proteins are presumed to represent the human equivalents of E. 
coli L10 and L7/L12 proteins (Uchiumu, T. et al., 1987) with which they have a 
high degree of primary sequence similarity. Coincidentally, autoantibodies have 
also been found which are directed against 28S rRNA, also a component of the 60S 
ribosomal complex (Uchiumu, T. et al., 1991). The existence of these autoantibody 
specificities has enabled functional analyses of 60S ribosomes and their constituent 
species. 
Elkon et al. (1985), demonstrated that anti-PO, P1 or P2 SLE autoantibodies 
can cross react on immunoblots with any of the other two species, suggesting that at 
least one epitope was shared by these proteins. In addition, anti-P SLE 
autoantibodies cross reacted with all three Artemia sauna P proteins, implying that 
the primary sequences of these species may be highly conserved in evolution. 
Human P0, P1 and P2 amino acid sequences have since been determined, revealing 
highly homologous, hydrophilic, C-terminal regions (Rich, B.E. and Steitz, J.A., 
1987). In particular, the C-terminal 22 amino acids are extremely well conserved. 
Highly similar C-terminal sequences have also been found in yeast (Mitsui, K. and 
Tsurugi, K., 1988; Remacha, M. et al., 1988). 
It is the C-terminal 22 amino acids of all three P proteins which have been 
shown to contain a major SLE epitope (Elkon, K. et al., 1986). This region of the A. 
sauna P2 protein (the sequence of which is identical to its human counterpart except 
for two conservative substitutions) was used to absorb antibodies from an anti-P SLE 
serum. The residual serum lost its ability to bind any of the three human P proteins 
on an immunoblot. However, the same serum still retained the ability to bind 
nondenatured P proteins on native dot blots, suggesting that additional 
autoantibodies exist which recognise at least one conformational epitope. Consistent 
with other findings, which attempt to define properties of SLE autoantigens and their 
epitopes, this region contains highly charged amino acid residues (Brendel et al., 
1991). That this C-terminal region is important functionally is demonstrated by the 
fact that mouse monoclonal antibodies raised against this A. sauna P2 peptide, 
inhibit the interaction of elongation factors with the ribosome and their associated 
GTPase activity. This implies that this C-terminal peptide permits the interaction of 
elongation factors with the ribosome (Uchiumu, T. et al., 1990). Anti-P SLE sera 
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also inhibit these interactions and functions (Stacey, D.W. et at., 1988). However, 
autoantibodies with many different anti-P epitope specificities can exist in an 
autoimmune serum, therefore presenting difficulties in discerning the targeted 
regions with which to associate specific functions. 
SLE sera occasionally contain antibodies which can react with RNA. 
Recently, sera have been identified which react specifically with 28S rRNA. An 
autoepitope has been defined, which corresponds to a highly conserved region of this 
nucleic acid. A stretch of 59-nucleotides was found to be protected from RNAse Ti 
digestion by anti-28S antibodies, localising the epitope to residues 1944-2002 
(Uchiumu et at., 1991). The sequence of this epitope region is 97% and 62% 
identical to the corresponding regions in the yeast (25S) and E. coli (23S) rRNA 
homologues, respectively. In order to define the epitope more specifically, Chu, J-L. 
et at. (1991), carried out immunoprecipitation experiments of mutated, in vitro 
transcribed 28S rRNA using anti-28S antibodies. Both sequence and secondary 
structure were shown to be imperative in permitting antibody recognition, 
particularly in the stem region of residues 1944-1955. A mere four nucleotide 
substitution in this area was sufficient to decrease the efficiency of 
immunoprecipitation by over 75%. Once again, conformation and sequence 
specificity appear to be essential in defining an SLE autoepitope. 
The molecular relationship between the ribosomal P proteins and the 28S 
rRNA species has been examined as a result of the existence of their corresponding 
antibodies. It has been suggested, that the autoepitopes of the P proteins and 28S 
rRNA are distinct, but in close proximity (Uchiumu et at., 1991). A direct 
interaction between the P proteins and in vitro transcribed 28S rRNA has been 
demonstrated by immunoprecipitation with monoclonal anti-P antibodies. Only 
transcripts bearing the 28S rRNA immunoreactive domain (1944-2002) could bind 
these proteins, and accordingly be precipitated. However, the epitopes of both 
antigens must be simultaneously accessible, since anti-28S antibodies can bind 
ribosomes containing P proteins. A close molecular association of these species is 
supported by the occurrence of anti-28S antibodies in 75% of anti-P SLE sera (as 
opposed to 8% of anti-P negative sera; Chu et at., 1991), and implies that the 
production of both antibody specificities may be linked. In addition, anti-P (Stacey 
et at., 1988) and anti-28S antibodies (Uchiumu et al., 1991) block the binding of 
elongation factors EF1-a and EF-2 to ribosomes and their associated GTPase 
activity. The implication with regard to ribosomal RNP autoantigens, is that the 
17 
GTPase functional domain of the 60S ribosomal subunit is targeted by antibodies in 
some SLE patient sera (Uchiumu et al., 1991). 
1.3.6 Small Nuclear Ribonucleoprotein Particles (snRNPs) 
Serum autoantibodies targeting snRNPs occur in 30% of SLE and 32% of 
MCTD sufferers (Table 1.1). In fact, it was the presence of such antibodies in 
autoimmune sera, which led to the discovery of snRNPs (Lerner, M.R. and Steitz, 
J.A., 1979). SLE sera were shown to immunoprecipitate a set of 6 novel, uridine 
rich, small, nuclear, ribonucleic acid molecules (UsnRNAs) and their associated 
proteins. These proteins were initially identified on Coomassie blue stained SDS-
polyacrylamide gels and named alphabetically B, B', D, E, F and G in order of 
descending molecular mass. Three other proteins were also identified in these 
snRNP immunoprecipitates, but are now known to be associated with one specific 
snRNP (Bringmann, P. et at., 1983). The target of the anti-snRNP autoantibodies 
was shown to be protein in nature and subsequent studies have revealed the B, B' and 
D proteins to be the focus of the snRNP-directed SLE autoantibodies. The 
occurrence of these antibodies in some autoimmune sera has been invaluable in 
determining the components and structure of snRNPs. In addition, the role of 
snRNPs in pre-messenger RNA splicing as well as an understanding of the 
mechanism itself have been greatly advanced. 
1.3.6.1 	Functions and Interactions within the Spliceosome 
The four major spliceosomal snRNPs are nucleoplasmic and designated Ui, 
U2, U4/U6 and U5 after their constituent snRNA (the U4/U6 snRNP contains two 
different RNA species). The primary function of snRNPs as essential components of 
eukaryotic spliceosomes is to facilitate pre-messenger RNA splicing. This is an 
ATP-requiring process which results in the removal of an intron from an immature 
pre-mRNA transcript. The spliceosome is a multi-subunit complex which assembles 
on the pre-mRNA and processes the latter in a two-step transesterification reaction. 
Step 1 involves cleavage at the 5' splice site followed by formation of an Intron-
Exon2 lariat structure. This arrangement is achieved by covalent linkage of the 5' 
end of the intron with a G nucleotide in a highly conserved region, termed the branch 
point sequence. The second step results in cleavage at the 3' splice site and ligation 
of the two exons. 
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The Ui snRNP is thought to bind the 5' splice site, via the 5' end of Ui 
snRNA. This may be mediated by the Ui-specific C protein. The U2 snRNP binds 
to the branch point sequence in an ATP-dependant manner. This interaction 
probably involves protein-protein and RNA-RNA interactions. After the U  and U2 
snRNPs have bound to the pre-mRNA, the U4/U6 and U5 snRNPs bind as part of a 
pre-assembled tri-snRNP complex. It is thought that the U2 and U6 snRNAs base 
pair at a region just upstream from the branch point binding region of the former 
snRNA species. 
1.3.6.2 	Structural Organisation 
The constituents and structural organisation of these RNP particles have been 
extensively reviewed by Luhrmann, R. et al. (1990). Mammalian U-rich snRNAs 
vary in length from 106 (U6) to 189 (U2) nucleotides (Table 1.5). Their secondary 
structures are loosely conserved around a single-stranded stretch of ribonucleotides 
termed the 'Sm site'. The Sm site of each snRNA (except U6, which does not 
contain one) follows the consensus A/gAUUUU/gUGG/a (infrequently observed 
nucleotides in lower case). All four snRNAs with an Sm site, have flanking stem-
loop structures and hypermethylated caps of trimethylguanosine (TMG) at their 5' 
ends. A complement of eight proteins; B, B', Dl, D2, D3, E, F and G are present 
within each snRNP and are therefore designated 'common snRNP proteins'. As a 
consequence of their precipitation with SLE (or Sm) sera these proteins are 
alternatively called 'Sm proteins'. When the latter are associated with the 'Sm site' 
of the appropriate snRNA they comprise the 'core snRNP' particle. UV crosslinking 
studies have revealed that it is the 9kDa G protein which associates intimately with 
the AAU stretch in the Sm site of the snRNA (Heinrichs, V. et al., 1992). This 
protein can be isolated cytoplasmically as part of a 6S (Dl, E, F, G) complex. 
Indeed, it is the cytoplasmic association of the 6S complex at the Sm site of the 
snRNA, as well as the addition of the tri-methylguanosine cap at its 5' end, which are 
thought to represent bipartite nuclear localisation signals for this entity (Hamm, J. et 
al., 1990). 
The U4/U6 snRNP is unusual in that it contains two different snRNA 
species. The two small RNAs are proposed to base pair over a region of twenty 
nucleotides, comprising two intermolecular helices, which are separated by a U4-
specific stem-loop structure. 
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SnRNPs also contain proteins specific to individual snRNPs. Some of these 
have been well characterised and their genes have been isolated. However, others 
have only been identified relatively recently as a result of a modification in the 
snRNP purification procedure (LUhrmann et al., 1990). It appears that the core 
snRNP particle represents the scaffolding on which the individual snRNP-specific 
proteins are hung. The latter therefore, may contribute to the functional specificity 
of each snRNP. 
In addition to the major spliceosomal snRNPs mentioned, other U-rich RNA-
containing RNPs do exist. The U3, U8 and U13 snRNAs are contained within 
nucleolar RNPs (termed snoRNPs, small nucleolar ribonucleoprotein particles). 
They are thought to participate in the processing of rRNA transcripts. There are also 
a further six nuclear, minor snRNPs, which contain snRNAs U7, U9, UlO, Ull, U12 
and U14 (Zieve, G.W. and Sauterer, R.A., 1990). All of these U-rich RNA species 
have a trimethylguanosine cap at their 5' ends, and also contain an Sm site (except 
U3). Accordingly, their corresponding RNPs are precipitatible by anti-Sm 
antibodies. 
1.3.6.3 	Common SnRNP Proteins 
The molecular masses and p1 values of the eight Sm proteins have revealed a 
tendency for these species to be small and basic (Table 1.2). The primary sequences 
of six of these proteins (B, B', Dl, D2, D3 and E) have been deduced from their 
corresponding genes/cDNAs. 
Amino acid sequences of the B and B' proteins have been determined 
(Ohosone, Y. et al., 1989; Schmauss, C. and Lerner, M.R., 1990). These species are 
identical, apart from an additional 9 amino acids at the C-terminus of B'. Both 
proteins are extremely proline-rich, and contain a repetitive motif (PPPGMRPP) 
which is represented on two and three occasions in B and B' respectively. Evidence 
indicates that the two different proteins arise from one pre-mRNA transcript which is 
differentially spliced (Van Damm, A. et al., 1989). In addition, a tissue-specific 
variant of the B protein (termed N) has been identified in rodent and human cells 
(Sharpe, N.G. et al., 1989). At an amino acid level, the N protein is 92.5% 
homologous to B' and similarly has three proline-rich motifs. This variant is 
expressed in brain, cardiac and embryonic tissue, the latter perhaps indicative of a 
role in embryonic differentiation (McAllister, G. et al., 1988). 
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Table 1.2 	Properties of the Common and Specific SnRNP Proteins 
Species Molecular Mass 
(kDa)  
Apparent p1 
Core snRNP (or Sm)  
B 28 10.6 
B' 29 10.7 
D3 13.9 10.4 
D2 13.5 9.9 
Dl 13 10.5 
E 12.5 10.3 
F 11 3.3 
G 9 8.8 
Ui snRNP-specific  
70K 54 6.7-8.6 
A 34 10.0 
C 22 10.4 
U2 snRNP-specific 
A' 31 8.3/8.6 
B" 28.5 10.2 
The initial identification of snRNP protein constituents involved analysis of 
immunoprecipitates on Coomassie blue stained SDS-polyacrylamide gels (Lerner 
and Steitz, 1979). The SmD protein was initially identified as a l3kDa, basic 
protein. In 1988, Rokeach, L.A. et al., reported the isolation of the gene for this 
species. However, two years later, Lehmeier, T. et al. (1990), suggested that there 
were actually three distinct D proteins, discernible only in SDS-polyacrylamide gels 
of a certain polymerisation specificity. The three proteins, Dl, D2 and D3 are 
present in each snRNP. The primary sequence of the Dl species is known and is 
identical to the SmD protein sequence identified by Rokeach et al. (1988). This 
species contains an interesting motif (GR)9 in its C-terminal region. The cDNAs 
encoding the D2 and D3 species have been recently isolated, from which primary 
peptide sequences have been deduced. The latter predict molecular masses of 13.5 
and 13.9kDa, and pT's of 9.9 and 10.4 respectively. The D3 protein like Dl, has a 
GR-rich C-terminal region, but containing only 4 such repeats. These two species 
demonstrate 29% identity at an amino acid level (particularly in the C-terminal 
region, where 7/11 residues are identical). The D2 protein is not similar in amino 
acid sequence to Dl or D3, but contains a basic cluster of residues 
(KSGKGKKKSK) in its C-terminal half. North-Western analysis has shown that 
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one of the D proteins has non-specific affinity for RNA (Tazi, J. et al., 1986), despite 
the lack of RRMs in their predicted primary sequences. 
SLE sera occasionally react with Sm proteins other than B, B and D (1, 2 
and 3). Such a serum was used to screen a human cDNA library, from which the 
nucleic acid sequence of the SmE gene was obtained (Wieben, E.D. et al., 1985). 
This basic, 12.5kDa species contains potential N-glycosylation sites and bears 
resemblance to a yeast 38S ribosomal protein. 
Recently a 69kDa protein has been identified, which is loosely associated 
with snRNPs Ui, U2, U4/U6 and U5 (Hacki, W. et al., 1994). It is thought that this 
protein has not been previously detected as a result of the experimental conditions 
generally used in isolating snRNPs. In addition, it has a molecular mass virtually 
identical to that of the Ui snRNP 70K protein, and co-migrates with the latter in 
SDS-polyacrylamide gel electrophoresis. This protein however, cannot be viewed as 
a intrinsic snRNP protein, since it is not always associated with these particles. This 
was demonstrated by the fact that it could not be detected in the U4/U6.U5 tn-
snRNP complex. The 69K protein appears to be immunologically distinct from the 
other common snRNP proteins, since antibodies raised in rabbits against this protein 
fail to react with any of the Sm proteins B-G. A panel of SLE sera has yet to be 
tested on the immunoblotted or purified 69K protein. 
1.3.6.4 	Specific SnRNP Proteins 
Some proteins associate specifically with individual snRNPs. Within this 
group there are two categories of proteins; (1) those which are integral components 
of their cognate snRNPs and are found associated with all forms of these particles, 
(2) those which are loosely associated with snRNPs and are detectable only in the 
larger snRNP entities (as defined by S values obtained from density gradient 
centrifugation). Hence, more than one cellular form of each snRNP exists, 
containing different numbers of snRNP-specific proteins. The concentration of 
cations during snRNP purification has been shown to determine which cellular form 
is isolated (Luhrmann et al., 1990). 
The Ui snRNP is the most abundant major snRNP and contains three 
specific proteins, termed 70K, A and C. It has a constant glycerol gradient 
sedimentation value of 10-12S, regardless of the concentration of mono/divalent 
cations present in the snRNP extraction buffer. This signifies that only these three 
proteins and no other factors are associated with the Ul snRNP core particle. The 
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70K protein migrates aberrantly in SDS-polyacrylamide gel electrophoresis. Its true 
molecular mass approximates to 54kDa, as predicted from its cDNA sequence 
(Theissen, H. et al., 1986). However, its initial identification as a 70kDa protein 
(Lerner and Steitz, 1979), probably reflected its various isoforms (13 in total, with 
isoelectric points ranging from 6.7 to 8.7) and/or any alternatively spliced gene 
products. Differential phosphorylation may explain the majority of isoelectric 
variants, and/or as yet unidentified post-translational modifications. The primary 
sequence of the 70K protein has been deduced from the cloned cDNA, which 
predicts that this species is rich in arginine and glycine residues, and contains a 
hydrophilic region (of mixed charge amino acids) in the C-terminal half. The latter 
also constitutes an RNA recognition motif, which in addition to some flanking 
sequence has been shown to be essential for U1 snRNA binding in vitro. Evidence 
suggests that the 70K protein binds directly the 5' end of U  snRNA at the base of 
stem-loop I and that this interaction can occur independantly of Sm protein binding 
(Query, C.C. et al., 1989). The primary sequence of the Ui A protein has also been 
predicted from its cDNA (Sillekens, P.T.G. et al., 1987). This species contain two 
RRMs, the N-terminal motif essential for binding the loop of U! snRNA hairpin II 
in vitro (Scherly, D. et al., 1989). The Ui C protein contains a zinc finger motif, an 
element which may play a role in protein-protein interactions. This motif is situated 
in the N-terminal 45 amino acids and is the minimal region required for binding to 
C-depleted Ui snRNPs. Substitution of the zinc finger CC-HH amino acids 
abolishes this association, implying that this element is essential for interaction with 
the Ui snRNP (Nelissen, R.L.H. et al., 1991). In addition, crosslinking studies 
suggest that the 70K and A proteins mediate the association of U  C protein with the 
U  snRNP (Hamm, J. et al., 1990). 
The U2 snRNP can be isolated from sedimentation gradients in either of two 
forms, 12S or 17S. The 12S particle contains the common snRNP proteins and a 
further two specific proteins, A' and B". The primary sequences of both of these 
proteins have been determined from their, respective gene sequences (Sillekens, 
P.T.G. et al., 1989; Habets, W.J. et al., 1987). In comparison with other snRNP 
protein sequences a striking similarity was observed between U2 B" and U  A. Both 
are basic proteins (reflected in their isolelectric points of 10.2 and 10.0 respectively), 
and have two regions of extremely high identity; (1) a 78 amino acid C-terminal 
domain which shares 86% identity, (2) a U2 B" N-terminal region of 95 residues, 
which has 77% identity with Ui A. Both U2 A' and U2 B" contain RRMs (the 
former highly similar to that of the Ui 70K) and are thought to associate with stem- 
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loop IV in the 3' half of U2 snRNA. Interestingly, B" cannot associate with its 
cognate RNA unless A' is available. Hence, U2 A' confers specific RNA binding 
ability on U2 B" (Scherly, D. et al., 1990). As with the snRNA-binding region of the 
Ui snRNP 70K and A proteins, loop IV of U2 snRNA is highly conserved in 
evolution (Guthrie, C. and Paterson, B., 1988). 
Low salt concentrations permit isolation of 17S U2 snRNPs. Behrens, S-E. 
et al. (1993), found that this particle contains an additional nine proteins not present 
within the 12S particle. These proteins have estimated molecular masses of 35, 53, 
60, 66, 92, 110, 120, 150 and 160kDa. Electron microscope studies reveal that the 
U2 snRNP has a bipartite structure consisting of two globular domains which are 
centred around the Sm site and 5' half region of U2 snRNA. These domains are 
thought to represent the Sm proteins and the U2 snRNP-specific proteins 
respectively. 
The lOS U4/U6 snRNP is not thought to contain any specific proteins. 
However, such species may associate with this snRNP as part of the 25S U4/U6.U5 
tri-snRNP (see below). 
The US snRNP can be found in three cellular forms, 10-12S, 20S and as part 
of a 25S U4/U6.U5 tri-snRNP complex. The first of these, like the 105 
U4/U6snRNP contains only the eight common snRNP proteins assembled at the Sm 
site of the U4 snRNA. The 20S form contains an extra complement of 7 proteins, 
which have estimated molecular masses of 15, 40, 52, 100, 102, 116 and 200kDa 
(doublet; Bach, M. et al., 1989). The tri-snRNP assembly, however, appears to be 
the additive product of the lOS U4/U6 snRNP and the 20S US snRNP, plus a further 
4 proteins which are presumed to be necessary for the assembly of the complex. 
One of these proteins appears to have phosphokinase activity, since a US specific 
protein becomes phosphorylated in vitro while contained within this assembly 
(Lührmann et al., 1990). 
In summary, alternative purification procedures have led to the discovery of 
many more snRNP-associated proteins than previously observed. As yet, these 
remain to be genetically and biochemically characterised, but it is apparent that 
snRNP constitution is more complex than previously thought. 
1.3.6.5 	SnRNP-Directed Autoimmune Sera 
Antibodies reactive with snRNP constituents often occur in the sera of two 
autoimmune conditions, systemic lupus erythematosus and multiple connective 
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tissue disease (MCTD) (Tan, 1989). MCTD is a condition which retains the clinical 
features of several connective tissue diseases, namely SLE, scleroderma and 
polymyositis. Symptoms from at least two of these diseases, in conjunction with 
high titres of U 1 snRNP-directed antibodies (termed anti-RNP) define this condition. 
As previously stated (Section 1. 1), serum antibodies directed against the Sm proteins 
(B/B', D(l, 2 and 3), E, F and G) are diagnostic for SLE. This antibody specificity 
can be experimentally verified by either; (1) immunoblot analysis of snRNP 
immunoprecipitates, or (2) immunoprecipitation of the five major snRNAs (Ui, U2, 
U4, U5, and U6, the latter precipitated by virtue of its association with U4). In 
addition, an anti-Sm serum may contain antibodies to the U! (as well as U2, U4/U6 
and U5) snRNP-specific constituents. Therefore, any snRNP component previously 
identified as an autoantigen by any autoimmune serum, has been investigated in this 
work, since a given SLE serum may contain autoantibodies against such species. 
Such an analysis may reveal the properties of highly targeted regions and/or shared 
epitopes of snRNP components. Furthermore, the autoreactivities of sera obtained 
from MRL(lpr) mice will be included where relevant. This strain of lupus prone 
(ipr) mouse has a genetic susceptibility for SLE-like symptoms and is therefore 
widely regarded as a murine model for the human condition. Since snRNP 
constituents in mouse and man are highly conserved (Section 1.5), antibodies from 
this strain of mouse are likely to target similar proteins and/or peptide regions. 
Indeed, it has been demonstrated that monoclonal antibodies obtained from mice 
previously immunised with purified human U  snRNPs target the same proteins and 
even recognise similar peptide regions as anti-RNP/Sm sera (Reuter, R. and 
LUhrmann, R., 1986). Therefore, analysis of the human and mouse protein Sm 
epitopes may indicate the sequences of the conserved regions which are strongly 
antigenic in SLE. 
Detailed analysis of the autoepitopes of snRNP constituents has shown that 
many antibody specificities are overlapping. This is often due to the similar protein 
sequences observed in these snRNP species. Alternatively, a specific antibody may 
react with dissimilar peptide regions e.g. the mouse monoclonal antibody, Y12 
(obtained from an MRL(lpr) mouse) which reacts with the Sm B/B', D and E 
proteins, species which demonstrate no primary sequence identity (Section 
1.3.6.5.1). Despite these difficulties, an attempt has been made to clarify the anti-
snRNP autoantibody specificities. 
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1.3.6.5.1 	Anti-Sm Sera 
Immunoblotting analysis has shown that the majority of anti-Sm antibodies 
are directed against the B/B' proteins. This specificity is accompanied by anti-D(l, 2 
or 3) antibodies 70% of the time (van Venrooij, W.J. and Sillekens, P.T.G., 1989). 
However, this cannot be regarded as indicative of the relative antigenicity of these 
species with regard to the other Sm proteins, since only linear epitopes are 
recognised in this detection method. 
In an attempt to map SmB autoepitopes Rokeach, L.A. et at. (1990), assessed 
the reactivity of SLE sera against 12 bacterially expressed TrpE-SmB deletion 
mutants. Immunoblotting of these fusion proteins with various sera suggested the 
existence of 6 epitope regions, 5 of which were thought to be located in the proline-
rich C-terminus. It was also found that certain experimental conditions which 
facilitated the refolding of denatured, blotted proteins resulted in a significant 
increase in sera reactivity, implying that conformational epitopes are prominent in 
this autoantigen. In addition, a serum was obtained which failed to react with the 
TrpE-SmB full length fusion protein on immunoblots, but did react with 5m1B. It is 
possible that the addition of the TrpE moiety changed the antigenic properties of the 
SmB protein in a conformation-dependant manner, resulting in the abolition of 
immunore activity. Alternatively, post-translational modification of the human 
protein, absent in the bacterially expressed fusion protein, may play an important 
role in defining some autoepitopes. 
A similar study was carried out by Elkon, K. et at. (1990). Bacterially 
expressed TrpE-SmB fusion proteins (sequences derived from amplified B cDNAs) 
were analysed for reactivity with sera from 12 SLE patients and 12 MRL(lpr) mice. 
Immunoblotting demonstrated multiple epitopes in the SmB protein recognised by 
SLE sera. The majority of human sera tested bound a short C-terminal peptide 
region of fifteen amino acids (205-231). This region contains a proline-rich motif, 
PPPGMRPP (Section 1.3.6.3). The N-terminal region (residues 8-94) also contains 
a proline-rich sequence, but this failed to react with these same sera on iminunoblots. 
Within this N-terminal region, the proline-rich sequence is flanked by negatively 
charged amino acids, whereas that of the C-terminus is surrounded by neutral or 
positively charged residues (glycine, methionine, alanine and arginine). It was 
suggested that the neighbouring amino acids of the proline-rich sequence determine 
this region's autoreactivity. This implies that negatively charged amino acids such as 
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aspartate (D) and glutamate (E) inhibit selection of a particular autoepitope, whereas 
positive or neutral amino acids enhance it. In addition, ELISA absorption 
experiments indicated that neither conformational nor linear N-terminal epitopes 
existed, and that the majority (two-thirds) of the immunoreactive epitopes were 
located in the C-terminal half (amino acids 94-205). 
A more detailed analysis of the SmB linear autoepitopes was carried out by 
James, J.A. and Harley, J.B. (1992). Overlapping, SmB octapeptides were 
synthesised on polyethylene pins, whereafter reactivity with SLE sera was analysed 
by ELISA. In agreement with previous findings, the proline-rich motif 
(PPPGMRPP) was identified as being the most antigenic sequence. In an attempt to 
determine the antigenic significance of the only positive residue (R) with within this 
motif, the latter was mutated at position six. Only when lysine (another positive 
amino acid) replaced arginine, was 75% of the original reactivity preserved. This 
figure fell to 60% when histidine (also positive) was substituted, whereas negative 
amino acids such as aspartate and glutamate were two of nine which diminished 
reactivity to less than 25% of the original. This suggests that positive amino acids 
may play a role in the definition of this particular epitope, as previously observed by 
Elkon et al. (1990). 
A proline-rich motif is also found in the Ui C (twice) and Ui A proteins. 
These octapeptide sequences were also tested for immunoreactivity. Interestingly, 
one of these motifs, PAPGMRPP which is contained in the Ui C protein was found 
to have 95% of the reactivity of the SmB PPPGMRPP peptide. The other two motif 
sequences, PAPAMIPP and PPPGMIPP (Ul C and A proteins respectively) retain 
less than 25% of this original reactivity. A similar motif, PPPGIRGP is also present 
in the C-terminus of SmB/B'. This peptide demonstrated over 70% of the optimal 
reactivity. These results, and the finding that the deletion of the C-terminal di-
proline repeat barely diminishes antibody binding, led James and Harley (1992) to 
propose a consensus sequence for this epitope: PPPG(I,M)(R,K). 
Two other octapeptides (GTFKAFDK and CDEFRKIK) were found to be 
strongly immunoreactive with SLE sera, both of which reside in the N-terminal 66 
amino acids of SmB/B'. This finding, however seems to contradict the majority of 
epitope mapping studies, which rarely locate any epitopes in this region. 
A septapeptide which is homologous to a region in the EBV nuclear Ag-i 
was also tested for reactivity with SLE sera. Significantly, this peptide (PPPGRRP) 
demonstrated over 50% of the reactivity shown by the SmB PPPGMRPP sequence. 
Autoantibody cross-reactivity with a viral antigen supports the theory of molecular 
27 
mimicry, which is one of the etiological models proposed for this and other 
autoimmune diseases. 
The work of Ohosone, Y. et al. (1992), has helped not only in defining anti-
snRNP autoantibody specificities, but provided insight into the three dimensional 
structure of these particles. Two bacterially expressed SmB/B' fusion proteins were 
used to affinity purify autoantibodies from SLE sera. Immunoprecipitation 
experiments with some of these anti-B antibodies selectively precipitated the U1 
snRNP, despite the presence of the SmB species in each of the major snRNPs. 
However, other purified anti-B antibodies immunoprecipitated all of the major 
snRNPs. Analysis of these results, led to the conclusion that there were three 
distinct epitopes on the SmB/B' proteins and accordingly three separate autoantibody 
specificities. Two of these SmB/B' epitopes were found to be accessible to 
antibodies only in the Ui snRNP, whereas the third (situated in the N-terminal 79 
amino acids) was available for antibody interaction in each snRNP. In an attempt to 
localise these epitopes more precisely, antibodies specific to the U! snRNP SmB/B 
proteins were tested for reactivity against other snRNP proteins. It was found that 
one of these two antibody specificities cross-reacted with the Ui A protein. As 
previously observed, a region of sequence similarity exists between the SmB/B' and 
Ui A proteins, corresponding to the proline-rich motifs PPPGMRPP and 
PPPGMIPP respectively. Despite the finding by James and Harley (1992), that the 
latter was not strongly immunoreactive with SLE sera in ELISA, it is possible that 
this peptide represented in the U 1 A species on an immunoblot or in the U 1 snRNP 
is more antigenic. It was suggested that one of the Ui snRNP SmB/B' specific 
epitopes, was the proline-rich motif PPPGMRPP. It is surprising however, that if 
this is the case, the Ui C protein does not cross-react with these specific antibodies 
on immunoblots, since it has two similar proline-rich motifs, one of which James 
and Harley (1992), found to be highly immunoreactive with sera containing anti-
PPPGMRPP antibodies. Overall, these findings imply that despite containing the 
same complement of common snRNP proteins, the architecture of each of these 
particles and regions of each constituent which are surface-exposed are very 
different. In addition, the identification of an SmB autoepitope which is accessible 
only in the U1 snRNP is significant with regard to the categorisation of autoimmune 
sera. A serum designated anti-Sm (pertaining to a diagnosis of SLE) by immunoblot 
(therefore demonstrating reactivity with a peptide region of 5mB) could be 
simultaneously defined as anti-RNP (pertaining to MCTD diagnosis) by 
immunoprecipitation. 
The most extensive analysis of autoepitopes present in any of the SmD 
proteins, has been carried out by Rokeach, L.A. et al. (1992). Bacterially expressed 
TrpE-D1 deletion mutants were analysed by immunoblotting (under conditions 
facilitating antigen renaturation) with 17 anti-D1 SLE sera. Their results suggest 
that most anti-Di sera react with discontinuous or conformational epitopes, as all 17 
sera reacted positively with the full length TrpE-D 1 fusion protein, but weakly or not 
at all with seven overlapping fusion proteins. The same sera were used in 
immunoprecipitation analysis of native or truncated (containing only the N-terminal 
1-54 amino acids) SmD1. All sera precipitated the full length Dl protein, but only 
one also reacted with the truncated species. These results led to the conclusion that 
the C-terminal half of Dl (especially residues 87-119) contained the requirements 
for the majority of SLE epitopes and that the latter were predominantly 
conformational in nature. The C-terminal 33 amino acids of the Dl protein have two 
noteworthy features: 
(1) 	A motif (RGGPRR) which is similar to that found in protamines 
(nucleic acid binding proteins). 
(2)A (GR)9 repeated motif, which is contained within and preceded by a 
highly charged cluster. This region constitutes a repetitive array, with alternating 
uncharged residues, properties which have previously been suggested as indicative 
of SLE nuclear autoantigens (Brendel et al., 1991). 
Interestingly, the immunoreactive C-terminal 24 amino acids of Di have 
over 60% identity with a viral antigen. Sabbatini, A. et al. (1993), showed that 
affinity-purified anti-DI autoantibodies were able to bind the Epstein-Barr virus 
nuclear antigen-1 (EBNA-1; residues 35-58). In addition, these antibodies also 
recognised the native viral protein in a total cell extract prepared from virally 
infected cell lines. These findings support the theory of molecular mimicry in 
playing a role in the induction and pathology of SLE. 
Rokeach et al. (1992), has demonstrated an association between anti-La and 
anti-DI autoantibody specificities in SLE sera. Anti-La sera were shown to react 
strongly with the SmD1 protein as well as the C-terminal region of La. This 
correlation has previously been observed in MRL(lpr) mice (St.Clair, E.W., 1991), 
but it is unclear whether this signifies (1) a shared autoantibody specificity or, (2) 
two (or more) separate specificities, the simultaneous production of which is 
immunologically linked. 
Lehmeier et al. (1990), have analysed 38 different SLE sera in terms of their 
relative reactivity with Dl, 2 and 3 species as well as other snRNP proteins. Purified 
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snRNP proteins were immunoblotted and probed with anti-Di, D2, D3 or B/B' 
affinity-purified antibodies. The results imply the existence of three different linear 
epitope groupings. Epitope 1 lies on Dl, D3 and the BIB' proteins, epitope 2 is 
situated on all three D and both B species, and epitope 3 is exclusive to D2. Hence, 
the three D species appear to be immunologically distinct. Immunoprecipitation 
experiments with in vitro translated D (1, 2 and 3) species confirms these 
conclusions (Lehmeier, T et al., 1994). Furthermore, the reactivity of the mouse 
monoclonal antibody (Y12) with the Sm proteins was examined. Both immunoblots 
and immunoprecipitation experiments demonstrated that this antibody reacted with 
five Sm proteins, Dl, D3, B/B' and B, but not D2. 
In general, only epitopes and antigens of human SLE autoantibodies are 
considered here. However, an exception is permitted in the case of the mouse 
monoclonal antibody, Y12. This antibody was isolated from an MRL(lpr) 
autoimmune mouse and appears to reflect the observed patterns of immunoreactivity 
of some human SLE autoantibodies. 
Hirakata, M. et al. (1993), showed that Y12 had identical binding 
specificities with respect to the Sm BIB' and Dl proteins as found in over 20% of the 
SLE sera. A panel of fourteen anti-Sm sera and the Y12 monoclonal antibody were 
used in immunoprecipitation experiments of in vitro translated B and D deletion 
mutants. The results suggest that the Y12 antibody recognises two non-overlapping 
regions of the B protein (corresponding to amino acids 1-115 and 120-231) as well 
as the Dl protein. However, reactivity with the latter is only detected when the C-
terminus of this species is present. This finding and primary sequence comparisons, 
led to the conclusion that some form of GRG motif may define the Y12 epitope, 
since (1) the C-terminus of the Dl protein ,contains a nine-fold GR repeat and (2) 
GRG repeats exist in all B polypeptide fragments that bind Y12. Furthermore, the 
D. melanogaster B protein, which similarly binds Y12, shows poor conservation of 
sequence at its C-terminus (compared with human B protein), except for the location 
of three out of four of the GRG motifs. However, the SmE protein, which binds Y12 
on immunoblots (Lehmeier et al., 1990), lacks a GRG motif, but does contain N/C-
terminal interspersed GR repeats. Hirakata et al. (1993), proposed that these 
residues may associate in order to form the Y12 epitope in this Sm protein. 
Interestingly, Y12 fails to be reactive on immunoblots with a murine B 
protein which has been synthesised in E. coli , but does react with the same protein 
when translated in vitro from a rabbit reticulocyte lysate. Therefore, the Y12 
monoclonal antibody distinguishes immunologically between prokaryotically and 
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eukaryotically expressed forms of the SmB protein. This implies that modification-
dependant criteria may be necessary for the interaction of SmB with Y12. This 
suggestion is consistent with previous data, which also demonstrated the failure of 
an SLE serum to recognise the bacterially expressed (but not the eukaryotic) form of 
the SmB protein (Rokeach et al., 1990). 
Hirakata et al. (1993) summised that the Y12 monoclonal antibody 
recognises some kind of GRG motif, in conjunction with a particular protein 
conformation and/or the addition of a specific eukaryotic moiety, such as a post-
translational modification. 
1.3.6.5.2 	Anti-RNP Sera 
Autoantibodies directed against the specific proteins of the U 1 snRNP (70K, 
A and C; termed anti-RNP) are common in MCTD and sometimes occur in SLE. 
However, titres of these autoantibodies are normally much lower in SLE patient sera. 
The immunoreactivity of U1 snRNP-specific proteins may be a consequence of the 
selective targeting of the latter and/or U1 snRNPs by the immune system. 
Alternatively, the observed antigenicity could be attributed to shared amino acid 
sequences between these species and other snRNP proteins (e.g. the proline-rich 
motifs of Ul C and SmB/B'). Hence, the reactivity of a Ui snRNP-specific protein 
on an immunoblot with an autoimmune serum does not necessarily indicate that this 
species is an autoantigen in vivo. Indeed, analysis of the epitopes of the Ui A, C and 
70K proteins have shown that many overlapping antibody specificities occur within 
this group and with other snRNP proteins. 
Habets, W.J. et al. (1989), considered the reactivities of a panel of 
autoimmune sera (from SLE and MCTD patients) against in vitro translated Ui A 
deletion mutants. The immunoprecipitation pattern of the various mutants indicated 
that two linear epitopes exist within the regions of amino acids 165-185 and 232-256 
(epitopes 1 and 2 respectively). Affinity-purified anti-epitope 1/epitope 2 
autoantibodies were obtained and used to probe immunoblots of snRNP proteins. 
Epitope 2 affinity-purified antibodies cross-reacted only with the U2 B" protein. 
This is perhaps not surprising, since the latter contains a region identical to epitope 2 
(except for two amino acids). Epitope 1 contains a proline-rich region (PPPGMIPP), 
which is similar to that found in SmB/B' (PPPGMRPP). Anti-epitope 1 affinity-
purified antibodies demonstrated three different specificities, binding (1) Ul A only, 
(2) Ui A, SmB/B' and a synthetic peptide of protein N, or (3) Ui A, C, SmB/B' and 
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the N peptide in immunoblot analysis. In addition, it was observed that anti-epitope 
1 (Ul A) antibodies (specificity 3) reacted more strongly with SmB/B' than U  A on 
immunoblots. If the cross-reactivity of these antibodies is attributable to the proline-
rich sequence found in both these species, then this is perhaps not surprising. James 
and Harley (1992), found that the Ui A proline-rich octapeptide was not strongly 
immunoreactive (25% of the SmB/B' proline-rich peptide activity) in ELISA. 
Hence, experiments exposing these proline-rich sequences in linear forms (such as 
immunoblotting and octapeptide ELISA) indicate that the SmB/B' sequence is most 
reactive. It is possible that the immune response directed against the proline-rich 
regions present in many snRNP proteins is initially (and perhaps solely) directed 
against the SmB/B' PPPMGRPP motif. However, the proline-rich sequence as part 
of the native Ul A species (individually or as a constituent of the Ul snRNP) may 
demonstrate greater immunoreactivity than its linear counterpart. 
The Ul A epitopes identified by Habets, et al. (1989), were subsequently 
found not to be immunodominant. This was determined by immunoprecipitation 
analysis of Ui A deletion mutants (Habets, W.J. et al., 1990). In addition, two N-
terminal epitopes were located in region 1-142. Overall, it was concluded that 
epitopes of the Ul A species were predominantly conformational, since deletion of 
the N-terminal 1-51 or C-terminal 263-282 amino acids led to the abolition of 
antibody binding in the majority (75%) of sera tested. 
Barakat, S. et al. (1991), used ELISA and immunoblotting in an attempt to 
determine autoepitopes of the Ul A protein. The reactivities of 145 SLE sera with 
thirteen synthetic, overlapping A peptides conjugated to bovine serum albumin were 
assessed. Three regions of Ul A were found to be targeted by SLE sera. Peptides 1-
11, 35-58 and 257-282, demonstrated reactivity with 33.8, 19.3, and 64.5% of SLE 
sera tested respectively. Representative sera were used to probe immunoblotted 
snRNP proteins. Sera targeting regions 35-58 and 257-282 were found to react with 
U  70K and U2 B" proteins on immunoblots. The Ul A peptide regions 1 (1-11) 
and 2 (35-58) are contained within RRMs which are highly similar to those in the Ui 
70K and U2 B!!  species. Hence, this observed cross-reactivity could be explained by 
primary sequence similarities. It is interesting that no reactivity was found with 
peptides spanning the two regions of Ui A (residues 165-185 and 232-256) 
previously proposed to contain epitopes (Habets et al., 1989). However, the Ui A 
species scrutinised in the experiments of the latter were produced from eukaryotic 
sources, whereas Barakat et al. (1991), used synthetic peptides. Therefore, the 
immunoreactivity of U 1 A found in the experiments of the former may be due to a 
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eukaryotic modification, possibly post-translational. This has previously been 
suggested for the Sm antigens (B/B', Dl and E; Hirakata et al., 1993). 
The U! snRNP-specific C protein has recently been the study of B-cell 
epitope analysis (Misaki, Y. et al., 1993). A region of the C protein has been 
defined, which may contain a major autoepitope, since it reacted with all SLE sera 
tested. Immunoblot analysis of various E.coli fusion proteins, combined with 
ELISA of these and other synthetic C protein peptides, suggested that this epitope 
was situated within amino acids 90-125. This region contains the previously 
identified PAPGMRPP motif, which has been shown to be highly immunoreactive 
with autoantibodies in most SLE sera (James and Harley, 1992). Interestingly, 
within this immunodominant region, there is a sequence (amino acids 102-117) 
which shows 50% identity with a region contained within the ICP4 protein of the 
Herpes simplex virus I. This is another example of an epitope of an SLE autoantigen 
sharing sequence identity with a viral protein. 
The autoepitopes of the Ui 70K protein have also been studied. Guidner, 
H.H. et al. (1988), found the immune response in patients with anti-70K sera to be 
polyclonal. Using bacterially expressed partial 70K fusion proteins, one region of 
this Ui snRNP species (containing residues 276-297) was found to react on 
immunoblots with over 90% of sera. This region was suggested to be contained 
within a major immunoreactive domain (residues 276-371) harbouring multiple, 
discontinuous, overlapping epitopes. This inimunodominant region also co-localises 
with the Ui 70K RRM. 
Fine mapping of an epitope outwith this region of the Ui 70K protein has 
been carried out (Netter, H.J. et al., 1991). The sequence ERKRR, which is present 
in the N-terminal domain of 70K has previously been shown to be antigenic 
(Guldner, H.H. et al., 1990). However, a related motif (ERERR) occuring four times 
within the C-terminal half of this protein cross-reacts with anti-ERKRR affinity-
purified autoantibodies. Hence, a substitution of a negative amino acid for a positive 
one in this highly charged motif does not abolish the autoantibody interaction. In 
addition, the dual specificity of these affinity-purified antibodies may explain the 
multiple epitopes observed within this protein, and again illustrates the ability of 
specific antibodies to cross-react with similar epitopes (as observed with the proline-
rich motifs in many snRNP species). However, these anti-ERKRR antibodies failed 
to immunoprecipitate the native U 1 snRNP, implying that this epitope of the 70K 
protein is hidden within these particles. The anti-ERKRR antibodies could be result 
of the mature immune response and only produced by the immune system after 
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antigen processing. Furthermore, the pentapeptide sequences ERKRR and ERERR 
appear frequently in proteins of viral pathogens, such as the matrix protein of 
influenza B and vaccinia viruses, as well as the HHLF6 protein of cytomegalovirus. 
In accordance with the theory of molecular mimicry, it was suggested that antibodies 
to these regions may be early serological markers, indicative of viral invasion. In 
support of this, it was noted that anti-ERKRR antibody titres in sera from one patient 
dropped as anti-Ui 70K autoantibodies of a different specificity appeared. 
Occasionally, autoantibodies in the sera of SLE, MCTD and overlap 
syndrome sufferers are directed against a specific RNA species. Deutscher, S.L. and 
Keene, J.D. (1988), have defined an epitope on the Ui snRNA, which is recognised 
by a patient with lupus overlap syndrome and rheumatoid arthritis. Ui snRNA 
containing deletions were produced by in vitro transcription and subjected to 
immunoprecipitation analysis with this anti-RNP serum. The precise location of this 
epitope (nucleotides 51-90) was determined by RNAse Ti mapping of the antibody-
bound snRNA species and found to encompass stem-loop II. Deletion of any of the 
3' nucleotides which are part of this structure led to the abolition of antibody 
binding. Ui snRNA immunoreactivity was shown to be dependant on 
nondenaturing conditions and therefore epitope conformation. It was suggested that 
these antibodies may have arisen as a result of an idiotype-anti-idiotype network, 
whereby the immune system would have initially recognised a U 1 snRNA binding 
protein. This primary antibody would subsequently serves as target antigen, 
resulting in a second population of antibodies which could interact with the region of 
Ui snRNA implicated in binding the original antigenic protein. 
A more recent study (Hoet, R.M. et al., 1992), demonstrates that two specific 
regions of Ui snRNA contain independant B-cell epitopes, recognisable by some 
autoantibodies in sera from MCTD patients Autoantibodies directed against this 
snRNA species were found in 45% of sera with anti-U1RNP specificity. 
Immunoprecipitation experiments with in vitro transcribed, truncated or mutated Ui 
snRNAs revealed that the stem of stem-loop II and the upper stem and loop of stem-
loop IV (the latter possibly containing two epitopes) were regions targeted by these 
autoantibodies. The sequence and structure of these antigenic regions are highly 
conserved throughout eukaryotes. In agreement with previous findings (Deutscher 
and Keene, 1988) it was found that secondary structure was imperative in permitting 
antibody interaction with the Ui snRNA species. In addition, the molecular 
association of species was proposed to play an important role in defining the targets 
of the immune system in autoimmune diseases, since the Ui A protein (which is a 
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common target of antibodies in MCTD/SLE patient sera) interacts specifically with 
the loop region of stem-loop II. This proposal is also supported by previous 
observations which demonstrate that SLE autoantibodies recognise the P ribosomal 
proteins and 28S rRNA as part of a GTPase activity centre (Section 1.3.5). As with 
the anti-U1RNP sera described here, these anti-ribosome antibody specificities were 
often found simultaneously in such autoreactive sera. 
The properties of some of the snRNP autoepitopes described in this section 
are presented in Table 1.4. 
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Table 1.4 	Autoepitopes of SnRNP Factors 
SnRNP Immunoreactive Comments 
Factor(s) Epitope/Region  
B/B'  
PPPGMRPP Linear epitope, (C-terminal) possibly 
Consensus:PPPG(I,M)(R,K) only accessible in the Ui snRNP. 
Position 6, (R) strongly influences 
immuno-reactivity, in which positive 
residues are preferred. 
GTFKAFDK, CDEFRKIK Linear, N-terminal. 
C-terminus Contains the majority of epitopes 
which may be conformational. 
D 
87-119 Highly charged C-terminal region 
containing (GR) repeats. 	Epitopes 
discontinuous in nature. 
B/B/D lIE 
Discontinuous GRG motif Y12 monoclonal antibody epitope, 
predicted to require dispersed (GR) 
repeats in a particular conformation, 
in 	addition 	to 	post-translational 
modification. 
U1A 
165-185 These linear epitopes are weakly 
(contains PPPGMIPP) immunoreactive. 	The former may 
232-256 share autoantibody specificity with 
B/B' anti-PPPGMRPP antibodies. 
1-282 Predominantly 	conformational 
epitopes. since N-terminal 1-51 and 




90-125 Linear, 	possibly 	shared 	antibody 
(contains PAPGMRPP) specificity with anti-PPPGMRPP, 
B/B 	autoantibodies. 
Ui 70K 
ERKRR/ERERR Linear epitopes frequent throughout 
this species of shared autoantibody 
specificity. 
276-297 Multiple, 	discontinuous 	epitopes, 
276-371 RRM-containing. 
U  snRNA 
51-90nts Stem-loop 	structures 	suggest 	the 
(representing stem-loop II) epitope is highly conformation- 
134-1 65nts dependant. 
(representing the stem and 
loop of stem-loop IV)  
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1.3.6.5.3 	Other Anti-snRNP Sera 
Occasionally, antibodies occur in autoimmune sera which target the U2 
snRNP-specific A' and B" proteins. As a consequence of shared amino acid 
sequences, such antibodies often cross-react with the Ui snRNP-specific A, C and 
70K proteins. Sera of this type are obtained from patients with overlap syndrome, a 
condition which incorporates the clinical features of several different autoimmune 
diseases, e.g. SLE, scleroderma and/or polymyositis. Eight sera of this specificity 
were used to probe immunoblots of snRNP proteins (Craft, J. et al., 1988). Each 
serum bound the U2 B" protein. Furthermore, affinity-purified anti-B" antibodies 
cross-reacted with the Ui A protein, which is perhaps not surprising, since these 
species share 77% identity at an amino acid level. Additionally, anti-B" antibodies 
were always found accompanied by anti-Ui C and anti-70K antibodies, a property 
reflected in the dual precipitation by such sera of the Ui and U2 snRNPs. Sera 
which preferentially precipitated the U2 snRNP over the Ui snRNP, also had an 
added antibody binding specificity (on immunoblots) directed against the U2 A' 
protein. In addition, the majority of sera also contained antibodies to the SmB/B' 
proteins, but could not immunoprecipitate the U4, U5 or U6 snRNA species. This 
finding may indicate the presence of anti-SmB/B'-U1/U2 snRNP-specific antibodies 
(similar to the Ui snRNP-specific SmB/B' antibodies detected by Ohosone et al., 
1992). 
Serum from a patient with systemic sclerosis has recently been shown to 
contain anti-U4/U6 snRNP antibodies (Okano, Y. and Medsger, T.A., 1991). Under 
isotonic conditions (140mN'I salt), this patient serum (MaS) immunoprecipitates only 
this snRNP species. However, under hypertonic conditions this is not the case, since 
the snRNP core particle (containing U4/1J6 snRNAs and the Sm proteins BIB', D(1, 
2 and 3), E, F and G) dissociates from the MaS factor. Immunoblot analysis showed 
that this serum reacts solely with a protein of molecular mass 1 5OkDa, but can 
immunoprecipitate a further four species of 120, 80, 36 and 34kDa. It could be that 
these proteins are also individually antigenic, but require a particular conformation 
in order to interact with anti-MaS antibodies. Alternatively, the quarternary structure 
of this five-protein MaS particle may be required for antibody interaction. It was 
concluded, that two antigenically different forms of the U4IU6 snRNP exist, the 
larger one of which contains the Smlcore snRNP particle and an additional five 
previously unidentified proteins. 
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A patient with Sjorgens syndrome has provided another source of U4/U6 
snRNP-specific sera (Fujii, T. et al., 1992). This serum (TT) reacts with a 120kDa 
protein in immunoblots of HeLa cell extracts. In addition, this serum selectively 
immunoprecipitates the U4 and U6 snRNAs, the 120kDa and the common snRNP 
proteins. This implies a specific association of TT autoantibodies with the U4/U6 
snRNP. Furthermore, an 120kDa protein was found to co-sediment with U4/U6 
snRNPs, implying that this species may be the target of the antibodies in TT serum. 
However, this protein only appears to be associated with a subset of U4/U6 snRNPs, 
since TT serum cannot immunoprecipitate the U4/U6.U5 tri-snRNP assembly. An 
alternative explanation may be that the antigenic determinant is not be accessible in 
this pre-spliceosome particle. A further five species with predicted molecular 
masses of 92, 86, 76, 72 and 36kDa are also immunoprecipitated (the last three 
weakly) by these serum antibodies. The 92 and 86kDa species have tentatively been 
identified as nuclear organiser region proteins, (NOR)-90, since antibodies specific 
for this doublet reacted with these species on immunoblots. The last three (with 
molecular masses of 76, 72 and 36kDa) were not recognised by this serum on 
immunoblots. As with the other putative U4/U6 snRNP proteins, identified by 
Okano and Medsger (1991), the epitopes of these constituents may be 
conformational in nature, and therefore not recognised in this denatured form. It was 
observed that a reference Sm serum also immunoprecipitated a protein of 36kDa, 
supporting the association of this species with the U4/U6 and/or other snRNPs. 
Antibodies can be artificially raised in rabbits against the trimethylguanosine 
cap (TMG) of the major snRNAs and it has recently been discovered that a serum 
from a systemic sclerosis (scleroderma) sufferer may contain autoantibodies of such 
a specificity (Okano, Y. and Medsger, T. A., 1992). Serum antibodies were shown 
to immunoprecipitate snRNAs Ui, U2, U4, U5 and U6 (the latter by association with 
U4 snRNA) from a deproteinised HeLa cell total RNA preparation. Cell 
immunofluorescensce studies and TMG analogue (m7GTP) blocking experiments 
supported the existence of anti-TMG antibodies. Interestingly, the TMG cap of U3 
snRNA appears not to associate with antibodies contained within these sera. In view 
of this, it was suggested that this particular cap structure may be specifically 
inaccessible on this species of snRNA alone. 
1.4 	Saccharomyces Cerevisiae SnRNPs and Splicing Factors 
Higher eukaryotic snRNPs have been extensively studied biochemically. 
However, in the budding yeast, Saccharomyces cerevisiae this has been difficult to 
achieve as a consequence of the low level of pre-mRNA processing occurring in this 
organism (and therefore low abundance of splicing machinery). The general 
approach in attempting to study the constituents, interactions and functions of yeast 
snRNPs has been to harness the genetic capabilities of this lower eukaryote. The 
isolation of a mutant strain or defective gene, which carries a characteristic 
phenotype (e.g. a splicing defect) is usually the starting point from which associated 
molecular species and cellular processes can be analysed. Genes associated with the 
splicing mechanism in yeast are termed PRP (pre-mRNA processing). 
Yeast snRNPs, as do their mammalian counterparts contain U rich snRNA 
species. It is apparent that the main features of the higher eukaryotic snRNAs are 
conserved in yeast (reviewed extensively in Guthrie, C. and Patterson, B., 1988). 
The size, nucleic acid sequences at particular regions (such as the Sm site and stem-
loop sequences) and secondary structures of these species are generally highly 
conserved. However, the yeast U2 snRNA at 1175 nucleotides is considerably 
longer than its mammalian counterpart (as is the U 1 snRNA, but to a lesser extent, 
Table 1.5). In addition, US snRNA in the lower eukaryote has two forms, U5L and 
U5S, both of which are transcribed from the SNR7 gene. The overall secondary 
structure of these species is conserved from man to yeast, except that the 3' stem-
loop II is not present in the shorter form (U5S). Similarly, the 3' stem-loop 
structures of U4 and U6 snRNAs which flank the Sm site in higher eukaryotes, are 
not present in the S. cerevisiae homologues. Additional well conserved features of 
yeast UsnRNAs include the Sm site (consensus sequence A.U4-6.G), the presence of 
5' trimethylguanosine (TMG) caps (on Ui, U2, U4 and US snRNAs), and 
immunoprecipitability by some SLE sera. The latter is an indication of the 
conservation of protein elements within mammalian snRNPs, from man to yeast. 
The protein constituents of yeast snRNPs have recently been studied 
(Fabrizio, P. et al., 1994). SnRNPs were isolated by affinity purification using anti-
TMG antibodies, subjected to glycerol density gradient centrifugation, whereafter 
the protein constituents of the different snRNP forms were assessed by silver 
staining of SDS-polyacrylamide gels. It was found that the Ul and U4/U6.U5 
snRNPs contain six common proteins with molecular masses of 10, 11, 11.5, 12, 15 
and l7kDa. These species are thought to represent the homologues of the 
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mammalian common snRNP proteins G, F, E, Dl, D2 and D3 respectively (Table 
1.2). In addition, it was shown that the llkDa yeast species cross-reacted with anti-
F antibodies, suggesting immunological and perhaps sequence conservation. 
Interestingly, yeast species co-migrating with the human B/if proteins were not 
detected. In view of the variant forms of this protein (B/B' and N) in humans and 
absence of the B' in some Drosophila melanogaster cell lines (Brunet, C et al., 
1993), specific roles for the B class of proteins in organism-specific snRNP 
interactions and/or functions (which by definition are lacking in S. cerevisiae), may 
exist. 







Ui SNR19 572 164 
U2 SNR20 1175 187 
U4 SNR14 160 145 
U5 SNR7 179(S) 
214 (L)  
116 
U6 SNR6 112 106 
A closer inspection of the protein constituents of the yeast Ui snRNP 
revealed a greater number of specific proteins than found in the corresponding 
mammalian particles. Eight Ui snRNP-specific species with molecular weights of 
32, 34, 36, 54, 57, 60, 69 and 77kDa were detected, in addition to a further two (27.5 
and 38kDa) more tentatively identified. The U4/U6.U5 tri-snRNP complex is 
thought to contain six specific proteins, of molecular masses 51, 52, 56, 62, 97 and 
280kDa. Two of these are possibly associated with the U4/U6 snRNP (52 and 
97kDa species), and may represent the previously identified products of the PRP4 
and PRP6 genes (as suggested by immunoblot analysis). Similarly, the 28OkDa 
species most probably represents the U5 snRNP-specific PRP8 protein (see below). 
Electron microscopy of the Ui snRNP and U4/U6.U5 tri-snRNPs revealed that the 
size and architecture of the latter particle is conserved from man to yeast. However, 
as expected from the additional specific proteins present in yeast U  snRNP, the size 
of this entity is considerably larger and its structural appearance clearly different in 
the lower eukaryote. 
Although many proteins have been identified as playing a role in pre-mRNA 
splicing in S. cerevisiae, relatively few of the well characterised mammalian snRNP 
protein homologues have been identified (reviewed by Beggs, J.D., 1993). Only one 
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potential homologue of the higher eukaryotic core snRNP proteins has been 
identified in yeast. The yeast SMDJ gene sequence has been isolated by virtue of its 
incidental location downstream from another splicing gene (PRP38; Rymond, B.C., 
1993). The ySMD1 amino acid sequence shares 40% identity with the human Dl 
core snRNP protein, but significantly, lacks the highly characteristic C-terminal 
(GR)9 repeat motif. Interestingly, a recently identified human cDNA, thought to 
encode the Sm D3 protein, demonstrates 40% identity with a yeast gene, previously 
reported as a 5' flanking gene of pep3 (Lehmeier, T. et al., 1994). The yeast protein 
is predicted to have a molecular mass of 11.2kDA and p1 of 10.0 and has been 
suggested to be the homologue of the mammalian Sm D3 protein. However, the 
(GR)-rich C-terminal domain present in the human Dl (and D3) species was not 
observed in the predicted yeast protein sequence. 
There are only three other yeast proteins which have been identified as 
possible homologues of specific mammalian snRNP proteins. Two of these may be 
the functional and structural homologues of the U  snRNP-specific 70K and A 
proteins. The genes encoding these yeast proteins have been cloned and are 
designated SNPJ and MUD] respectively (Smith, V and Barrell B., 1991; Liao, X.C. 
et al., 1993). The yeast SNP1 and human 70K amino acid sequences share an 
overall identity of 30%. Interestingly, the RNA recognition motif (RRM) and 
glycine rich domains, but not the arginine rich region of the mammalian 70kDa 
species are conserved in the yeast protein. However, the absence of the latter does 
not appear to affect the functional specificity of the putative 70K homologue, as 
demonstrated by the binding of the yeast Ui snRNA to the RRM region of a 
bacterially expressed SNP1-fusion protein (Kao, H-Y. and Siliciano, P.G., 1992). 
The MUD] gene encodes a protein which contains two RRM regions (as does the 
mammalian Ui A protein). The homologous regions of both proteins demonstrate 
24% identity and 47% similarity. An interaction of the yeast protein with Ui 
snRNA has been shown by co-immunoprecipitation of the latter with antibodies 
directed against an epitope-tagged MUD  species (Liao et al., 1992). Furthermore, 
the SNP1 and MUD1 proteins have molecular masses (34 and 38kDa respectively) 
identical to two of the proteins suggested by Fabrizio et al. (1994), to be yeast U  
snRNP-specific constituents Surprisingly, both the SNPJ and MUD] genes have 
been shown to be dispensable for growth under certain conditions, possibly implying 
the presence of alternative gene products which can facilitate the functions of the 
yeast U  snRNP and so access pre-mRNA splicing. 
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PRP8 is a yeast gene which encodes a protein stably associated with the 
yeast U5 snRNP (Lossky, M. et al., 1987). This 280kDa protein, which is also an 
intrinsic component of the U4/U6.U5 tri-snRNP has a mammalian homologue of 
220kDa, identified as such on the basis of immunological data. Immunoprecipitated 
U5 snRNPs from HeLa cell nuclear extracts contain this protein, which can cross 
react with anti-PRP8 antibodies, demonstrating conservation of amino acid 
sequences between these two proteins, in addition to molecular associations 
(Anderson, G.J. et al., 1989). The yeast protein has also been shown to have RNA 
binding ability, as demonstrated by its association with spliceosomal pre-mRNA 
(Whittaker, E. and Beggs, J.D., 1991). 
Other proteins have also been implicated in associations with yeast snRNPs. 
Several yeast species have been isolated which may be specifically, but loosely 
associated with U2 snRNPs. PRP9, PRP11, and PRP21 proteins are believed to 
functionally interact with each other. This interaction may in part be mediated by 
the formation of PRP9 homodimers which are associated via interaction of its zinc 
fingers. This multi-molecular complex, associated with PRP5, is thought to interact 
with U2 snRNA. These associations may be essential in allowing U2 snRNPs to 
interact with spliceosomes. It has been suggested that the three proteins, PRP9, 
PRP1 1 and PRP21 are the yeast equivalents of the 60, 66 and 120kDa proteins found 
in human 17S U2 snRNPs. 
A genetic interaction between PRP3 and PRP4 genes has been demonstrated. 
Both PRP3 and PRP4 proteins may directly associate with the U4/U6 snRNP, the 
latter specifically interacting with the 5' stem-loop of the U4 snRNA (Last, R.L. et 
al., 1987). PRP24 protein is thought to interact functionally with U6 snRNA but not 
U4 snRNA, as demonstrated by immunoprecipitation experiments which imply that 
this protein has a role in facilitating the molecular interaction of these two RNA 
species (Shannon, K.W. and Guthrie, C., 1991). PRP6 protein has been shown to 
associate with the U41U6 snRNP, but this is only detectable as part of the U41U6.U5 
tri-snRNP complex (Galisson, F. and Legrain, P., 1993). The products of the PRP3, 
PRP4 and PRP24 genes have molecular masses of 56, 52 and 5 lkDa respectively. 
In agreement with previous findings (Fabrizio et al., 1994) proteins of this 
description have been identified as specific constituents of the yeast U4/U6.U5 tri-
snRNP. 
The yeast U5 snRNP contains a specific protein (PRP8) which appears to be 
phylogenetically conserved between man and yeast. In addition, this snRNP may 
also contain another specific protein, encoded by the PRP18 gene. A biochemical 
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interaction has been demonstrated between this protein and the U5 snRNP using 
anti-PRP18 antibodies in immunoprecipitation experiments (Horowitz, D.S. and 
Abelson, J.S., 1993). Suppressor genes of synthetic lethal U5 snRNA mutants were 
isolated by Frank et at. (1992). The protein products of these genes, SLU1, SLU2, 
SLU4 and SLU7 have been suggested as having functional and interactive 
associations with the first (SLU1 and SLU2) or second (SLU4 and SLU7) stages of 
splicing, as well as with U5 snRNA. Analysis of the genetic interaction between 
SLU7 and SLU4 confirms an association of the PRP18 protein with U5 snRNA and 
further implicates PRP16, an ATP-dependant RNA helicase in this molecular 
association. 
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1.5 	Other Eukaryotic SnRNPs 
Mouse snRNPs have been purified and analysed by SDS-polyacrylamide gel 
electrophoresis and two dimensional separation (Woppman, A. et al., 1990). The 
similarities between mouse and human snRNP constituents are striking. The 
observed molecular weights and p1 values of each protein are inseparable, except for 
the G protein which appears to be more basic than its human counterpart. 
Potential homologues for the human Sm B and D (1, 2 and 3) species in 
Drosophila melanogaster have been identified by SDS -poly acrylamide gel 
electrophoresis and immunoblotting (Paterson, T. et al., 1991; LUhrmann, R. et al., 
1990). Furthermore, immunological cross-reactivity between the eukaryotic B 
species has been demonstrated by anti-Sm antibodies. A comparison of the primary 
sequences of the B proteins from man, mouse and fruit fly indicate that the N-
terminus is most highly conserved, whereas the C-terminal region (predicted to 
contain the major Sm and Y12 monoclonal antibody epitope) is most evolutionarily 
variable (Brunet, C. et al., 1992). However, the latter region demonstrates similarity 
in terms of predicted secondary structures (Chou and Fasman algorithm) in human 
and Drosophila melanogaster B species, which both contain f3—turns interspersed 
with positive residues. 
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1.6 	Summary and Aims of this Thesis 
Many different components of subcellular particles act as immunogens in the 
autoimmune condition systemic lupus erythematosus. The autoantigens are often 
constituents of nucleic acid-protein complexes or proteins closely associated with 
nucleic acids. SLE autoantibodies directed against such entities can often inhibit the 
cellular function of their associated complexes. In addition, antibody specificities in 
a given serum may reflect the close molecular associations of targeted species. 
Many autoantigens have been observed as containing clusters of highly charged, C-
terminal residues (Brendel et al., 1991). Epitope patterns appear to be unique to 
individuals, although certain regions of autoantigens tend to be more highly targeted 
than others. These immunodominant epitopes are sometimes linear, but mainly C-
terminal, conformational and frequently located in exposed regions in the tertiary 
structure of an autoantigen complex. Often they represent regions interacting with 
nucleic acids (or proteins if the autoantigen is a nucleic acid) which are highly 
conserved in evolution. In addition, a role for post-translational modification has 
been suggested as a factor in defining some SLE autoepitopes. 
An anti-Sm SLE serum was obtained which demonstrated 
immunoprecipitation of yeast snRNAs Ui, U2, U4, U5 and U6 (M. Dalrymple, 
unpublished results; Figure 1.1). A yeast cDNA Xgtll library was screened using 
this serum (M.Dalrymple). The aim of this thesis is to determine the nucleic acid 
sequences of the positive clones isolated in this library screen, in an attempt to 
identify and partially characterise any yeast homologues of mammalian Sm or 
snRNP proteins. In addition, by analysing the targets of the autoantibodies present 
in this particular patient serum, it may be possible to contribute to the understanding 
of the etiology of SLE. 
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Figure 1.1 	Yeast RNA Species Precipitated by Serum Sm24# 
Immunoprecipitation was performed from yeast splicing extract with an SLE 
serum (Sm24#) and anti-TMG antibodies (TMG) (Table 2.4). Precipitated RNA 
species were radioactively labelled, electrophoresed through a denaturing 
polyacrylamide gel (6% acrylamide/7M urea) and autoradiographed (M. Dalrymple, 
unpublished results). SnRNA species (U I, U2, U4, U5L and U5S) and sizes (nts) of 
molecular weight standards (M) are indicated. 
Figure 1.1 




















Methods and Materials 
2.1 General Methods and Equipment 
All procedures were carried out in 1.5m1 microfuge tubes (Treff), at room 
temperature unless otherwise stated. For larger volumes, 15m1 or 30m1 glass tubes 
(Corex) or 50m1 polycarbonate tubes (Falcon) were used. Dispensing solutions, 
aliquoting or general manipulations were performed by glass pipettes or automatic 
pipettors (Gilson pipetman, P-20, P-200, P-bOO), with the appropriate sterile tip. All 
tubes, tips and pipettes were sterile when used (2.1.2). 
2.1.1 Centrifugation 
Samples were centrifuged in a microcentrifuge at 13,800g, at room 
temperature unless otherwise stated. For larger volumes, a bench-top centrifuge with 
a swing-out rotor (Centra-4X) or a centrifuge with fixed angle rotors (Sorvall 
Superspeed RC-5B with an SS-34, G-SA or GS-3 rotor) were used. High speed 
centrifugation was performed in an ultra-centrifuge (Sorvall OTD50B with a Ti50 
rotor). All centrifuge tubes were washed if not sterile (2.1.2) when used. 
2.1.2 Sterilisation of Equipment and Disposables 
Microfuge tubes and pipette tips were sterilised by autoclaving for 20 minutes 
at 120°C and 15 pounds/inch2. Polycarbonate tubes were sterile when obtained and 
used as such. All glassware was baked at 250°C for 16 hours, a dry-sterilisation 
procedure which destroys ribonucleases. 
2.1.3 Preparation, Sterilisation and Storage of Solutions 
All solutions were prepared in dry-sterilised glassware with sterile, distilled 
water and sterilised by filtration, using a disposable filter (0.45 JIm, Acrodisc, Gelman 
sciences) or autoclaving for 20 minutes at 120°C and 15 pounds/inch2. Solutions 
were kept in glass bottles, 20m1 polycarbonate tubes (Greiner) or microfuge tubes, 
wrapped in foil if light sensitive and stored at an appropriate temperature. Solutions 
requiring deionisation and filtration were added to 0.1-0.2 volumes of mixed-bed resin 
(20-50 mesh, Bio-Rad), stirred for half an hour and filtered through filter paper 
(Whatman, No. 1). 
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2.1.4 Autoradiography 
Blots or dried gels containing radiolabelled (32P or 35S) nucleic acids were 
exposed to X-ray film (pre-flashed before exposure) in a light-proof, lead-shielded 
cassette, with an intensifying screen, at -70°C and 25°C respectively. 
2.1.5 Dialysis 
Various lengths of dialysis tubing were boiled in a covering volume of sodium 
bicarbonate/EDTA (2%(w/v)/lmM, pH8.0) for 10 minutes. The tubing was 
thoroughly rinsed in distilled water and boiled in EDTA (1mM, pH8.0) for a further 
10 minutes. After cooling, tubing was stored in 50% ethanol, at 4°C and prior to use 
was rinsed through with distilled water. 
2.2 Materials 
2.2.1 Buffers 
The following buffers and solutions were prepared in advance and stored in 
dark containers at room temperature, unless otherwise stated. 
2.2.1.1 	Electrophoresis/Transfer Buffers 
1OxTAE: Tris-acetate, 0.4M, pH7.5; EDTA, 20mM. 
1OxTB: 	Tris-borate, 0.9M, pH8.3. 
1OxTBE: Tris-borate, 0.9M, pH8.3; EDTA, 20mM. 
1OxPBS: 	Sodium chloride, 137mM; potassium chloride, 2.7mM; disodium 
hydrogen phosphate, 4.3mM; potassium dihydrogen phosphate, 1.4mM, pH7.4. 
20xSSC: 	Sodium chloride, 3M; tn-sodium citrate, 0.3M, pH7.0. 
lOxElectrophoresis Buffer: Tris-base, 25mM; glycine, 192mM; SDS, 1%(w/v); 
pH8.8. 
Resolving Gel Buffer: 	Tris-HC1, 3.OM, pH8.8; filtered and sterilised by 
autoclaving. 
Stacking Gel Buffer: Tris-HC1, 0.5M, pH6.8; filtered and sterilised by autoclaving. 
l0xWestern Blot Transfer Buffer: 	Tnis-base, 20mM; glycine, 150niM. 
1OxMOPS Buffer: 	MOPS, 0.2M; sodium acetate, 0.05M; EDTA, 10mM adjusted 
to pH7.0 with sodium hydroxide, SM. 
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2.2.1.2 	Blot Incubation Buffers 
1OxTBS: Tris-HC1, 0.5M; sodium chloride, 1.5M; pH7.5 (Western blots). 
RNA Binding Buffer: Tris-HC1, 10mM, pH7.5; sodium chloride, 50mM; EDTA, 
1mM; BSA, 0.02%(wlv); polyvinyl pyrrolidine, 0.02%(w/v); Ficoll, 0.02% (w/v); 
filtered and made just prior to use (North-Western blots). 
50xDenhardt's Solution: 	SDS, lO%(w/v); BSA, 1%(w/v); Ficoll, 1%(w/v); 
polyvinylpyrrolidine, l%(wlv); filtered and made just prior to use (Southern blots). 
2.2.1.3 	Enzyme/Cell Resuspension Buffers 
lOxConcatamerisation Buffer: 	Tris-HCI, 500mM, pH7.5; magnesium 
chloride, 100mM; DTT, 100mM; ATP, 10mM; stored in aliquots at -20°C. 
5xOligo Labelling Buffer: 	Tris-HC1, 1.25M, pH8.0; magnesium chloride, 
0.125M; 3-Mercaptoethanol, 1.8%(vlv); 0.5mM each of dATP, dGTP and dTTP; 
stored in aliquots at -20°C. 
1OxTE (pH7.4/ 7.5/ 8.0): 	Tris-HC1, 10mM, pH7.4/ 7.5/ 8.0; EDTA, 1mM, 
pH8.0. 
1OxPBS: 	Sodium chloride, 137mM; potassium chloride, 2.7mM; disodium 
hydrogen phosphate, 4.3mM; potassium dihydrogen phosphate, 1.4mM, pH7.4, 
sterilised by autoclaving (2.1.3). 
1M Sodium Phosphate Buffer: 	1M disodium hydrogen phosphate, titrated to 
pH7.5 with lM sodium dihydrogen phosphate, sterilised by autoclaving (2.1.3). 
1M Potassium Phosphate Buffer: 	IM dipotassium hydrogen phosphate, titrated to 
pH7.5 with 1M potassium dihydrogen phosphate, sterilised by autoclaving (2.1.3). 
Transformation Buffer: 	MOPS, 10mM (adjusted to pH7.0 with potassium 
hydroxide, 1M); calcium chloride, 75mM; rubidium chloride, 10mM, glycerol, 
15%(v/v), sterilised by filtration (2.1.3). 
2.2.1.4 	Gel Loading Buffers 
2xProtein Gel Loading Buffer: 	Tris-110, 125mM, pH6.8; DTT, 200mM; SDS, 
4%(w/v); glycerol, 40%(v/v); bromophenol blue 0.25 %(wlv). 
2xFormamide Loading Buffer: 	Formamide, 95%(v/v); EDTA, 20mM, pH8.0, 
bromophenol blue, 0.05%(w/v); xylene cyanol, 0.05%(w/v). 
5xRNA Gel Loading Buffer: Bromophenol blue, 0.025%(wlv); xylene cyanol, 
0.25%(wlv); Ficoll, 15%(w/v). 
lOxAgarose Gel Loading Buffer: 	Glycerol, 30%(v/v); bromophenol blue, 
0.25%(w/v); xylene cyanol, 0.25%(wlv). 
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2.2.2 Stock Solutions 
30%(w/v) Acrylamide Solution: Acrylamide:N,N'-methylene bisacrylamide, 1: 19 
(deionised, filtered and stored in the dark, at 4°C for up to one month). 
40%(w/v) Acrylamide Solution: Acrylamide:N,N'-methylene bisacrylamide, 1:29 
(stored as above). 
X-gal: 50mg/mi in dimethylformamide, stored in the dark at -20°C. 
IPTG: 100mg/mi, stored at -20°C. 
I.A.A. (Indoleacrylic acid): 	1mg/mi, dissolved in ethanol, stored at -20°C) 
Ethidium Bromide: 10mg/mi, stored in the dark. 
2.2.3 Enzyme/Nucleic Acid Solutions 
DNAse (RNAse free): 	10mg/mi, aliquoted and stored at -20°C. 
RNAse A: 	10mg/mi, boiled for 10 minutes to inactivate DNAses, stored at -20°C. 
E. coli tRNA: 	20mg/mi, extracted with phenol, phenol/chloroform (until the 
interface was clear of debris, 2.4.2), followed by ethanol precipitation(2.4.3). Stored 
at -20°C. 
Salmon sperm DNA: 10mg/mi, boiled for 10 minutes prior to use, otherwise stored 
at -20°C. 
2.2.4 Miscellaneous Materials 
Acid-washed Glass Beads: Glass beads (100 mesh) were boiled for 20 minutes in 
HCI (1M), cooled and washed extensively, before baking at 250°C, for 16 Hours. 
Protein Molecular Weight Markers: lomg/ml, added to 2x Protein Loading Buffer 
(2.2.1), stored at -20°C. 
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2.2.5 Plasmid Vectors and Constructs 
The following plasmids were used for the purposes described in Table 2.1. 
Table 2.1 
Plasmid Description Source/Reference 
pTZl8r E. coli phagemid; multiple cloning Pharmacia 
site in 	the 5' end of lacZ 	gene, 
ampr. F' origin permits synthesis 
of single stranded DNA.  
pBST+ E. coli phagemid; multiple cloning Stratagene 
site in the 5' end of LacZ 	gene, 
ampr.  
pUR288 E. coli plasmid; multiple cloning Lane, D., ICRF, Clare 
site in the 3' end of LacZ gene, Hall / Ruther, 	U. 	and 
amp'. IPTG induces fusion protein Muller-Hill, B. (1983). 
synthesis in strain BMH7 1-18  
pATH3 E. coli plasmid; multiple cloning Finnegan, D., Edinburgh / 
site in 3' end of trpE gene, amp'. Dieckmann, 	C.L. 	and 
IAA induces synthesis of anthrilate Tzagaloff, A. (1985). 
synthase fusion protein.  
pFN-1 pEMBL8+ containing the yeast Anderson, G. (this lab.). 
snR7 gene.  
pTaq-6 pUC118 containing part of the Brow, D. 
yeast snR6 gene.  
pTZ18U4G pTZ18r 	containing 	the 	yeast Dalrymple, M. (this lab.). 
SNR14 gene.  
pBSKS-U1 pBSKS+ containing the yeast Newman, A. (Cambridge). 
SNR19 gene.  
pDF97 pTZl8r containing the SNR20 Field, D. 
gene  
pJD14 pTZ19r containing part of the yeast Brown, J.D. (Edinburgh, 
SNR20 gene. Ph.D. thesis). 
pYA301 pBR322 containing the yeast actin Gallwitz, D. and Sures, I., 
gene. (1980). 
pTZrp28s pSPT19 containing part of the Lossky, M. (this lab.) 
RP28 gene.  
pBM125 E. coli /Yeast shuttle plasmid; Johnson, M. and Davis, 
contains the GALl-JO promoter R.W. (1984). 
(on an 0.81Kb EcoRl-BamHl 
fragment), from which genes can 
be conditionally expressed, ARS, 
CEN, URA3  
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The following plasmids were constructed in this work as described in Table 
2.2. 
Table 2.2 
Plasmid construct Description 
pHMK1-pHMK18 PCR (primers 199 and 200) was performed on clones 1-18. 
Products were cloned into the EcoPJ site of pTZ1 8r. 
pHMK19-pHMK36 PCR (primers 199 and 200) was performed on clones 19- 
36. Products were cloned into the Smal site of pBST+. 
pHK14 PCR (primers 386V and 387V) was perfomed on clone 14. 
The product was cloned into the BamHI and HindIII sites 
of pTZ18r. 
pIPP-SM 14 Inverse PCR (primers 090Y and 091 Y) was performed on 
DraI digested yeast genomic DNA. The product was cloned 
into the Sall site of pTZ 1 8r. 
pATH3-SM14 The BamHI-HindIII fragment from pUR288-SM14 was 
subcloned into pATH3. 
pUR288-SM14 PCR (primers 386V and 387V) was performed from clone 
14. The product was cloned into the BamHI and HindIII 
sites of pUR288. 
pBM125-SM14 PCR (primers C864 and C865) was performed on yeast 
genomic DNA. The product was cloned into the BamHI 
and Sall sites of pBM 125. 
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2.2.6 Synthetic Oligonucleotides 
The oligonucleotides described in Table 2.3 were obtained from OSWEL DNA 
Service, Edinburgh. 
Table 2.3 
Primer Nucleotide sequence Function! 
Comments 
090Y FCT AGA GTC GAC GTA GCG AGA TAA ACC PCR from yeas 
XbaI 	Sail genomic DNA (with  
)91Y). 
091Y GAG CTC GTC GAC CAC GAG TTG TTG ACG PCR from yeas 
Sacl 	Sail genomic DNA (with  
)90Y). 
199 GCC GGC GAC GAC TCC TGG AGC CCG PCR from 1ambd 
clones (with 200). 
200 FAG GTA ATG GTA GCG ACC GGC GC PCR from lambda 
clones (with 199). 
386V  GAG CTC CTG CAG AAG Clii' AGC GAC CGG PCR from lambthFGT
CC clones (with 387V). 
Sacl 	PstI 	HindlII  
387V CTA GAG TCG ACG GAT CCT GGA GCC CG PCR from lambth jCGT 
XbaI 	Sal 	BamHI clones (with 386V). 
P1 CGT CAA CAA CTC GTG C Sequencing of clone 
14 cDNA plasimc 
constructs. 
P2 AGT TTC ACC AGC G Sequencing of clone JCGG 
14 cDNA plasimc 
constructs. 
P3 TGG TGA AAC TCC G Sequencing of clone jCGC 
14 cDNA plasim 
constructs. 
P4 TCA CTC GAT GCC Sequencing of clone JGGT 
14 cDNA plasimc 
constructs. 
A020 ACT CTG AGT T Used 	in 	pIPP JACG 
SM14 sequencing. 
A345 GAG TGG TAG GG Used 	in 	pIPP jCGT 
SM14 sequencing. 
A390 ACG GTG TTG TA rGG 
SM14 sequencing. 
C864 CGC ATA TGG ATC CGA GCG GAA TGT TAA G PCR from yeas 
NdeI 	BamHI genomic DNA 
(with C865). 
C865 GCG GAT CCG TCG ACG AAG TAG AGG AAC C PCR from yeas 
BamHI 	Sall 
Used 	in 	pIPP- 
genomic DNA 
(with C864). 
M13 GTA AAA CGA CGG CCA GT Sequencing 	of 
Universal )BST+ constructs. 
Ml 3 GGA AAC AGC TAT GAC CAT G Sequencing 	of  
Reverse pTZ1 8r constructs. 
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2.2.7 Antisera and Antibodies 
The antisera/antibodies described in Table 2.4 were used in immunological 
procedures. 
Table 2.4 
Antiserum/Antibody Description Source 
PRP8 A crude serum, raised against a 13- Anderson, G. (this lab.) 
galactosidase/PRP8 fusion protein 
(partial species, containing the N- 
terminal 	35 	amino 	acids) 	in 
rabbits.  
TMG A rabbit monoclonal antibody, Luhrmann, R. (Marburg) 
raised against 2,2,7-trimethyl- Lührmann, 	R. 	et al., 
guanosine. (1982) 
5m24# A human autoimmune serum, of Nuki, 	G. 	(Northern 
anti-Sm specificity. General Hospital, 
I Edinburgh) 
2.2.8 Growth Media 
Liquid and solid media were prepared in 300 or SOOml volumes, sterilised by 
autoclaving (2.1.3) and stored for up to four weeks, at room temperature. However, 
ampicillin-containing LBroth-agar plates were kept at 4°C, for up to two weeks. 
Ampicillin and amino acids (filter sterilised, 2.1.3) were added to media after 
autoclaving and cooling (below 50°C). Liquid media containing these supplements 
were used immediately. 
2.2.8.1 	E. coli Media 
Media quantities stated are per litre. 
LBroth: 	Bacto-tryptone, log; bacto-yeast extract, 5g; sodium chloride, log; 
pH7.2. 
LBroth-agar: LBroth + bacto-agar, 20g. 
Minimal-agar: Agar, 13.3g; after autoclaving, 5x Spizizen salts, 267m1s, glucose, 
2.65g; vitamin B1, 0.65g. 
SxSpizizen salts: 	Ammonium sulphate, log; dipotassium hydrogen phosphate, 
70g; potassium dihydrogen phosphate, 30g; tn-sodium citrate, 30g; magnesium 
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sulphate, 1g. 
M2: Disodium hydrogen phosphate, 6g; potassium dihydrogen phosphate, 3g; 
sodium chloride, 0.5g; ammonium chloride, ig; glucose, 2g; thiamine, 10mg; 
magnesium sulphate, 0.25g; calcium chloride, 22mg. 
M9-agar: 	M9 medium + bacto-agar, 20g. 
M9+Cas: M9 medium + Casaminoacids (Difco), 5g. 
M9+Cas+Trp: 	M9 medium + Casaminoacids, 5g + tryptophan, 20mg. 
2xYT: Bacto-tryptone, 16g; bacto-yeast extract, log; sodium chloride, lOg. 
Ampicillin / amino acids were added when required at 50/20mg per litre 
respectively. 
2.2.8.2 	Yeast Media 
Media quantities stated are per litre 
YPDA: 	Bacto-yeast extract, lOg; bacto-peptone, log; glucose, 20g; 
adenine sulphate, 20mg 
YPDA-agar: YPDA + bacto-agar, 20g. 
YMGIu 	Yeast nitrogen base (without amino acids), 6.7g; glucose, 20g; vitamin 
free casamino acids, lOg. 
YMGaI: 	Yeast nitrogen base (without amino acids), 6.7g; galactose, 20g; 
vitamin free casamino acids, lOg. 
Amino acids (if required) were added to liquid media at 20mg per litre and 
spread on solid media at 8p.gIrnL 
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2.2.9 Bacterial Strains 
All strains used were derivatives of E. coli K-12. 
Table 2.5 
Strain Genotype Reference/Origin 
NM522 (z\(lac, pro), hsdz\5, supE, thi- , Gough, J. and Murray, N. 
F'(lacI, IacZAM15, pro) (1983). 
DH5-cx F, recA], endAl, gyrA96, thil, Hanahan, D. (1985). 
hsdRl 7(r-K, rnK), supE44  
HB101 hsds20(rB, rnB), recA13, arg-14, Boyer, 	H. W. 	and 
proA2, lacY], galK, rps, L20(smr), Roulland-Dussoix, D. 
xyl-5, mtl-1, supE44 (1969). 
BMH71-18 (A(lac,pro), thi, supE, F(1acI), Messing, J. et al. (1977). 
ZAM15, pro)  
2.2.10 	Yeast Strains 
Table 2.6 
Strain Genotype Reference/Origin 
BJ2412 a/a, ura3-52/ura3-52, leu2/leu2, trpl/trpl, Jones, E. (Pittsburgh) 
gal2/gal2, prbl -1122/p rbl -1122, prcl -407/p rd - 
407, pep4-3/pep4-3  
DJY84 al a, ura3-52/ura3-52, his3-A200/his3-A1, ade2- Jamieson, 	D. 	(this 
1 Oloc/ADE2, lys2-801am/LYS2, trpAl/trpl- lab) 
289, leu2-3,112/LEU2, Gal+ I _________ 
2.2.11 	Suppliers of Laboratory Reagents 
General laboratory reagents and chemicals: BDH, Bio-Rad, Fisons, Serva, Sigma. 
Restriction enzymes and other DNA/RNA modifying enzymes: Boehringer 
Mannheim, New England Biolabs, Pharmacia, Stratagene. 
Deoxyribonucleotides (lithium salts): Boehringer Mannheim. 
Ribonucleotides: Pharmacia. 
Deoxyribonucleases and ribonucleases: Sigma. 
Acrylamide and N'N-methvlenebisacrylamide: BDH Chemicals (Electran grade). 
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Radionucleotides: Amersham International. 
Agarose: Seakem (Ultra-Pure), Gibco BRL (Low Melting Point Agarose). 
Media reagents: Difco Laboratories, Fisons. 
Sequencing reagents: United States Biochemicals (Sequenase Version 2.0 Sequencing 
Kit). 
2.3 Microbiological Techniques 
2.3.1 Propagation and Maintenance of E.coli Strains 
E. coli strains were maintained on inverted LB-agar or minimal media plates 
(2.2.8.1), with ampicillin when required. Cells from single colonies were picked 
from agar-plates and used to inoculate LBroth (+1-amp) in a flask. Cells were grown 
in a conical flask (five times the culture size) with continuous shaking, at 37°C. 
Growth was monitored by determining the optical density of the culture at 650nm. 
2.3.2 Transformation of E.coli 
This method is based upon that of Hanahan, D. (1985). Cells from a single 
colony were used to inoculate LBroth (5mls). The culture was grown overnight to 
stationary phase (2.3.1). Cells (I ml) were diluted (1:100) in L-Broth and growth 
continued for two hours or until an O.D.650nm of 0.3-0.6. Cells were transferred to 
50m1 polycarbonate tubes and harvested by bench-top centrifugation at 1,600g for 10 
minutes at 4°C. The L-Broth supernatant was removed and the pellet gently 
resuspended in ice-cold calcium chloride (30mls, 75mM) and left on ice for 30 
minutes. The cells were recentrifuged (as before) and resuspended on ice in freshly 
prepared, chilled Transformation Buffer (8mls; 2.2.1). Aliquots (200[d) were snap-
frozen in liquid nitrogen (freeze-thaw limit of 1) or used immediately. Plasmid DNA 
(50-1Ong) or a ligation reaction (2.4. 11) were added to an aliquot of competent cells, 
flick-mixed and incubated on ice for twenty minutes. Cells were heat-shocked at 42°C 
for one and a half minutes, prior to incubation on ice for a further five minutes. 
LBroth (imI) was added to the cells, which were incubated at 37°C for one hour. 
Cells were pelleted by microfugation for 10 minutes and dilution's plated onto LBroth-
agar (+amp) with X-gal (20pJ, SOmg/ml) and IPTG (10pl, 100mg/ml)(2.2.2), if 
required. 
2.3.3 Propagation and Maintenance of Yeast Strains 
Yeast strains were maintained on inverted YPDA-agar or YMG-agar plates 
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spread with the appropriate nutrient amino acid(s) (5Op1, 4mg/mi, 2.2.8.2) at 4°C. 
Cells from a single colony were used to inoculate YPDA, YMG or YMGa1/Raf liquid 
media, with or without nutritional supplements. Cells were cultured in conical flasks 
(a volume five times the culture size) with continuous shaking at 30°C. The growth of 
a culture was monitored by reading its optical density at 600nm. 
2.3.4 Transformation of Yeast 
Yeast cells were transformed according to the method of Ito, H. et al. (1983). 
A 50m1 culture of the appropriate cells was grown in YPDA to stationary phase 
(2.3.3), diluted (2.5mls, 1:40) in the same media and growth continued until an 
O.D.600nm of 0.3 was reached. The cells were harvested by bench-top centrifugation 
at 1,600g for 5 minutes, washed in dH20 (resuspended in lOmis and recentrifuged) 
and resuspended in 1 m of 1xTEL (1xTE, pH7.5 (2.2.1); lithium acetate, 0.1M). The 
cells were pelleted by microfugation for one minute and resuspended in 250tl of TEL. 
An aliquot (50p1) was mixed with 50jtg of salmon sperm DNA (heat-denatured and 
cooled on ice, 2.2.3) and 1tg of plasmid DNA. Freshly prepared PEG solution 
(300j.i1; PEG8000, 40%(w/v); lxTE, pH7.5; lithium acetate, 0.1M) was added to the 
transforming cells, which were vortexed gently and incubated at 30°C with agitation. 
The cells were heat shocked by incubation at 42°C for 15 minutes, microfuged for one 
minute and resuspended in lml of 1xTE (pH7.5). Aliquots were plated onto 
appropriate solid media with supplements (if necessary, 2.2.8.2) and incubated at 
30°C for 24-48 hours. 
2.4 Nucleic Acid Methods 
2.4.1 Storage and Handling of Nucleic Acids 
Nucleic acids were dissolved in dH20 or 1xTE (pH8.0; 2.2.1) and stored as 
deproteinised solutions at -20°C. Tubes containing nucleic acids were kept on ice if 
not in immediate use and handled wearing disposable gloves. 
2.4.2 Quantitation and Deproteinisation of Nucleic Acids 
The concentration of nucleic acid solutions was obtained by 
spectrophotometric analysis. The optical density of a sample at 260nm was 
determined. Nucleic acid concentrations were calculated, on the basis of an 
absorbance of 1.0 representing 50pg/mi of double stranded DNA, 40pg/m1 of single 
stranded DNA and 20tg/m1 of an oligodeoxynucleotide. 
Deproteinisation of DNA or RNA solutions was achieved by extraction with 
organic solvent. An equal volume of phenol was added to a tube containing nucleic 
acids, mixed by brief vortexing and microfuged (or centrifuged at 12,000g) for five 
minutes. The upper, aqueous layer was removed to a fresh tube, ensuring no 
contamination of organic solvent or interface material. Extraction was repeated with 
phenol/chloroform (1 part phenol/i part chloroform) followed by chloroform 
(chloroform:isoamyl alcohol, 24:1) until the organic solvent:aqueous interface was 
free of contaminating debris. 
2.4.3 Ethanol Precipitation of Nucleic Acids 
Following deproteinisation, DNA was precipitated by the addition of 0.1 
volumes of sodium acetate (3M, pH5.2) followed by 2 volumes of ice-cold ethanol. 
However, if the DNA solution contained SDS, 0.05 volumes of sodium chloride (4M) 
were used as the precipitating salt. After vortexing briefly, tubes were put at -20°C for 
at least 20 minutes. DNA was sedimented by centrifugation, in a microfuge (30 
minutes) or at 16,000g (15 minutes) at 4°C. The nucleic acid pellet was washed 
several times with 70%(v/v) ice-cold ethanol (by adding ethanol, dropwise over the 
pellet and removing it), before drying in a vacuum dessicator. 
RNA was precipitated with 0.1 volumes of 3M sodium acetate (pH5.2) or 
0.13 volumes of ammonium acetate (7.5M), followed by 3 volumes of ice-cold 
ethanol. The precipitation of small RNA species (or low concentrations) was 
facilitated by the addition of glycogen (20tg), prior to ethanol, and incubation at 
-70°C for 30 minutes. Hereafter, RNA was sedimented and washed as DNA. 
2.4.4 Small Scale Plasmid DNA Preparation 
Plasmid DNA was prepared according to the method of Birnboim, H.C. and 
Doly, J. (1979). LBroth+amp (5mls) was inoculated from a single cell colony and 
grown for 6 hours (NM522, HB101, BMH71-18) or 16 hours (DH5-(X)(2.3.1). 
Cells (1.5mls) were microfuged for 10 minutes. The supernate was removed and the 
pellet washed by resuspension in imi of STE (sodium chloride, 0. 1M; EDTA, 1mM, 
pH8.0; Tris-HC1, 10mM, pH8.0) and microfugation as previously. After removing 
the supernate, cells were resuspended in 100.il of TEG (Tris-HC1, 25mM, pH8.0; 
EDTA, 10mM, pH8.0; glucose, 50mM) and incubated on ice for 5 minutes. An 
aliquot (20O RI) of SDS/sodium hydroxide (1%(w/v)/0.2M) was added, mixed by brief 
vortexing and the lysed cells returned to ice for a further 5 minutes. Following the 
addition of sodium acetate (150tl, 3M, p115.2), vortexing and incubation on ice for 
10 minutes, the samples were microfuged (10 minutes). The supernate (containing 
plasmid DNA) was decanted to a fresh tube, where it was extracted with an equal 
volume of phenol/chloroform followed by chloroform (2.4.2). Ethanol precipitation 
was carried out (2.4.3) and the resulting plasmid DNA pellet was resuspended in 30p1 
of dH20 with RNAse A (1tl, 10mg/mi, 2.2.3). Plasmid DNA isolated by this method 
was used in restriction endonuclease digestion and/or transformation procedures. A 
typical yield from this procedure was 3-5tg. 
2.4.5 Large Scale Plasmid DNA Preparation 
LBroth+amp (50mIs) was inoculated with cells from a single colony. A 
culture was grown for 16 hours (2.3.1), before cells were pelleted in 50m1 
polypropylene tubes in a bench-top centrifuge (1,600g, 10 minutes). The supernate 
was discarded and TEG (lml, as small scale preparation) was used to resuspend the 
cell pellet. A further imi of TEG, containing lysozyme (4mg) was added, and after 
vortexing, the lysing cells were left on ice for 30 minutes. Sodium hydroxide/SDS 
solution (4mls; 0.2M/0.1%(w/v)) was added to the tube, the contents of which were 
mixed by inversion, and incubated on ice for 5 minutes. By the addition of 3m1 of 
sodium acetate (3M, pH5.2), chromosomal DNA was precipitated on ice for 30 
minutes. The contents of the tube were then transferred to a 30m1 glass tube and 
centrifuged (17,000g, 10 minutes, 4°C). The supernate, containing the renatured 
plasmid DNA was removed to another 30m1 glass tube, whereupon two volumes of 
ice-cold ethanol were added. Ethanol precipitation was carried out at -20°C for 30 
minutes. Precipitated plasmid DNA was recovered by centrifugation (17,000g, 10 
minutes, 4°C). The pellet was air dried and resuspended in 2" of solution B (Tris-
HC1, 40mM, pH8.0; EDTA, 1mM, pH8.0; sodium acetate, 0.1M, pH5.2; SDS, 
0.1%(w/v)). The DNA solution was extracted with phenol/chloroform and chloroform 
(2.4.2) until the interface was clear of any precipitate (bench-top centrifuge, at 1,600g 
for 5 minutes). Plasmid DNA was precipitated with two volumes of ethanol (as 
described above) and resuspended in 1xTE (400il, pH8.0; 2.2.1). This volume was 
transferred to a microfuge tube, whereupon RNAse A (20tl, lOmg/ml; 2.2.3) was 
added, mixed by vortexing and incubated at 37°C for 1 hour. The DNA solution was 
extracted with phenol, phenol/chloroform and chloroform (2.4.2) before precipitation 
with ethanol and sodium chloride (0.05 volumes, 4M; 2.4.3). The pellet was 
resuspended in dH20 (200il) and typically contained 1 00.ig of plasmid DNA. 
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2.4.6 Phagemid DNA Preparation 
E. coli cells (NM522) were transformed with phagemid DNA (2.3.2). Cells 
from a single colony were used to inoculate LBroth+amp (3mls) and grown to 
stationary phase (2.3.1). A 30il aliquot was diluted into 2xYT (1.5m1;2.2.8: l), and 
growth continued for 30 minutes, whereupon helper phage (M13K07, Pharmacia) 
were added at a m.o.i. of 20 (4.5t1). Cells were grown for a further 6 hours, 
transferred to microfuge tubes and centrifuged for 5 minutes. The supernatant (imi) 
was decanted to a fresh tube, where phagemid DNA was precipitated by the addition 
of PEG/sodium chloride (150il; PEG8000, 20%(w/v)/sodium chloride, 4M). The 
contents of the tubes were mixed by inversion and left at room temperature for 20 
minutes (or 16 hours at 4°C). The single stranded DNA was pelleted by microfuging 
for 10 minutes and resuspended in 1xTE (200iJ, pH8.0, 2.2.1). An equal volume of 
phenol was added and following extraction (2.4.2) the DNA was precipitated with 
ethanol (2.4.3). Phagemid DNA was dried in a vacuum dessicator and resuspended in 
dH20 (25il), 7ji1 of which was used in a single sequencing reaction. 
2.4.7 Yeast Genomic DNA Preparation 
Cells from a single colony were used to inoculate YPDA (20mls), grown for 
24 hours (or until stationary phase was reached)(2.3.3), transferred to 50m1 propylene 
tubes and harvested by bench-top centrifugation (1,600g, 5 minutes). The supernate 
was discarded, cells were resuspended in 800 jil of freshly prepared sorbitol solution 
(sorbitol, 0.9M; DTT, 5mM; sodium phosphate, 50mM, pH7.5, (2.2.1); lyticase, 
625U/ml), transferred to a microfuge tube and placed on a rotating wheel at 37°C for 
60 minutes. The cells were microfuged for 1 minute and the pellet resuspended in 1 ml 
of Tris-HC1/EDTA (50mM, pH8.0/20mM, pH8.0), before SDS (100..tJ, 20%(w/v)) 
was added. The contents of the tubes were mixed by inversion and incubation was 
continued at 65°C for 30 minutes. Potassium acetate (400pl, SM) was added, mixed 
by inversion and left on ice for 60 minutes. The cell lysate was microfuged (5 
minutes) and the supernate divided between two tubes. Isopropanol (750jil or 1 
volume) was added to each tube, the contents mixed by inversion and left at room 
temperature. The genomic DNA, which precipitated over a period of 10 minutes, was 
spooled using a blunt pipette tip and resuspended in dH20 (300i1) or TE (300t1, 
pH8.0). The last step was often left at room temperature, overnight in order to 
facilitate complete dissolution. 
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2.4.8 Agarose Gel Electrophoresis 
Agarose gels were prepared by dissolving agarose powder in 1xTAE (0.8-
1.0%(w/v) in lOOmis; 2.2.1). On cooling, ethidium bromide (5p1, 10mg/mi; 2.2.2) 
was added, mixed by swirling, before pouring into a gel forming plate. A 14-well gel 
comb was placed in the molten gel mix, which was left to solidify at room 
temperature. DNA samples were mixed with 0.1 volumes of Agarose Gel Loading 
Buffer (2.2.1), the comb removed and samples loaded into the wells. DNA size 
markers were simultaneously loaded. Horizontal electrophoresis in 1xTAE buffer was 
performed at 100V for 90 minutes, or 15V for 16 hours. Electrophoresed DNA was 
visualised by placing the agarose gel on a short wave ultra-violet light transiliuminator, 
where it was photographed. 
2.4.9 Recovery of DNA Fragments from Agarose Gels 
Purification of specific DNA molecules was achieved by one of two methods: 
An agarose gel (0.8%(w/v); 2.4.8), was prepared with low melting 
point agarose powder. DNA samples were electrophoresed through the gel and 
visualised on a UV transiliuminator (2.4.8). Individual DNA fragments were excised 
from the gel using a sterile razor blade and placed in microfuge tubes. Distilled water 
(3 gel volumes, 100i1 per 100mg of gel), SDS (0.1%(v/v)) and glycogen (1pl, 
20mg/mi) were added to the tubes, which were vortexed and incubated at 65°C until 
the gel slice became molten (usually after 10 to 15 minutes). Phenol extraction was 
carried out 3 or 4 times, followed by phenol/chloroform and chloroform extraction 
(2.4.2), until no debris remained at the interface. The aqueous phase was removed to 
a fresh tube and the DNA was precipitated with ethanol and sodium chloride (0.05 
volumes, 4M; 2.4.3). The DNA pellet was resuspended in a volume of dH20 
appropriate to its next application. 
DNA samples were electrophoresed through an agarose gel (0.8%(w/v); 
2.4.8). Fragments were excised (as described above) and purified using a gel 
extraction kit (Qiaex, supplied by Qiagen). The DNA gel slice was incubated for 10 
minutes, at 50°C with QX1 sodium perchlorate buffer (3 gel volumes, calculated as 
above; this buffer solubilises the gel slice and dissociates proteins from DNA 
molecules) and 10tl of a silicagel matrix, which in the presence of large anions (e.g. 
perchlorate) binds DNA fragments. Tubes were briefly vortexed at two minute 
intervals. The DNA-silicagel matrix was pelleted by microfugation for 30 seconds and 
washed by resuspension in high salt buffer (QX2; this removes agarose and 
contaminants) and recentrifugation. This was repeated with an ethanol based buffer 
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(QX3), which removes any remaining salt. The DNA-silica gel matrix was 
resuspended in dH20 (10tl) and incubated at 50°C for 10 minutes, with intermittent 
brief vortexing. 
Both methods of DNA purification resulted in a recovery of 60-80%. 
	
2.4.10 	Restriction Endonuclease Digestion of DNA 
Up to 1 p quantities of DNA were digested in a total reaction volume of 20tl, 
which contained 2tl of the appropriate lOx buffer and 1 Unit of restriction enzyme(s) 
(both supplied by Boehringer Mannheim). Digests of yeast genomic DNA, typically 
contained 30t1 of DNA (2jig) in a 45t1 reaction volume. Generally, digests were 
performed at 37°C for at least one hour, however genomic DNA digests were 
incubated for 16 hours with agitation at the appropriate temperature for the enzyme. 
Double enzyme digests of yeast genomic DNA, were performed separately. 
Following the first digest, DNA was extracted with phenol/chloroform and chloroform 
(2.4.2), before ethanol precipitation (2.4.3), whereafter the second digest was carried 
out. 
2.4.11 	Ligation of DNA Fragments 
Fragments of DNA were recovered from agarose gels (2.4.8). In a total 
reaction volume of 2091, T4 DNA ligase (0.8jil, lU4tl), ligation buffer (2.il, lOx) 
(both supplied by Boehringer Mannheim) and purified DNA fragments were mixed 
(plasmid:insert DNA in the ratio 1:2) in a microfuge tube, and incubated at 16°C for 16 
hours. 
2.4.12 	Sequencing of Phagemid DNA 
Phagemid DNA was prepared (2.4.6). Chain termination sequencing was 
performed according to "United States Biochemicals, step-by-step protocols for DNA 
sequencing" using the Sequenase Version 2.0 enzyme (a genetic variant of T7 DNA 
polymerase) and kit. An annealing reaction was set up in a microfuge tube, containing 
phagemid DNA (7pJ), synthetic primer (10, 25pM/jil) and 2t1 of reaction buffer 
(Tris-HC1, 200mM, pH7.5; magnesium chloride, 100mM; sodium chloride, 250mM). 
The tube was heated (65°C, 2 minutes) and allowed to cool slowly to 35°C. To the 
annealing reaction, the following were added; ijil of DTT (0.1M), 2il of diluted 
labelling mix (containing dGTP, dCTP and dTTP, each 0.5jiM), liil  of [a-35S]dATP 
(specific activity 10.tCi/tl) and Sequenase enzyme (2jil, 1:8 in dilution buffer). The 
contents of the tube were vortexed and microfuged briefly, prior to incubation at 23°C 
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for 5 minutes. This step extends the DNA from the primer, while incorporating the 
radiolabelled nucleotide. The extension mixture was aliquoted (4jil) into 4 pre-
warmed (37°C), labelled tubes containing 2.5 p1 of each of one of the four different 
termination mixes ddTTP, ddGTP, ddCTP, ddATP (dNTPs, 80jiM; sodium chloride, 
50mM; one of the four ddNTPs, 8jiM). After vortexing and microfuging (as before), 
the four tubes were incubated at 37°C for 5 minutes. This step terminates any further 
extension of the DNA by incorporating one of the four DNA synthesis blocking 
dideoxynucleotidetriphosphates. Formamide loading dye (50; 2.2. 1) was added to 
each tube, mixed and contents were heated to 75°C for 2 minutes, before loading onto 
a 6% acrylamide/7M urea gel (2.4.13) or stored at -20°C for up to one week. 
2.4.13 	Denaturing Polyacrylamide Gel Electrophoresis 
Polyacrylamide/urea gels (6%(w/v)/7M) were used in analysing RNA species 
from immunoprecipitation experiments and sequenced DNA samples, according to the 
method described in Sambrook, J. et al., (1989). An acrylamide/ureaJTBE stock was 
prepared by dissolving 235g of urea in 75m1s of 40% acrylamide solution (2.2.2) and 
25m1s of 1OxTBE (2.2.1). The stock solution was brought to SOOmls with dH20, 
deionised and filtered (2.1.3) and stored in the dark, at 4°C for up to one month. To 
50mls of the acrylamide/ureaJTBE mix, freshly prepared ammonium persuiphate 
(400jil, 10%(w/v)) and TEMED (40p1) were added and mixed by swirling. The 
mixture was immediately poured into pre-assembled sealed gel plates (60x45x2 1.5cm, 
0.4mm spacers). The straight edge of a sequencing gel comb or a 12-well comb were 
inserted at the top of the gel, for sequencing or RNA gels respectively. The gel mix 
was allowed to polymerise for a minimum of 2 hours (or overnight at 4°C, ensuring 
the gel comb area is kept damp). Samples were added to an equal volume of 
Forman-fide Loading Buffer (2.2.1), heated to 90°C for three minutes, before loading 
onto the gel. Electrophoresis was carried out in 1xTBE Buffer at 45W (60cm plates) 
or 33W (45cm plates) until the loading buffer dyes had migrated appropriately 
(indicative of DNA or RNA size separation). The gel plates were carefully prised 
apart, and gels were Northern blotted (2.4.23) or transferred to sequencing gel fix 
solution (10%(v/v) methanol/ l0%(v/v) acetic acid). The gel was carefully transferred to 
a sheet of blotting paper and dried under vacuum, at 80°C for 2 hours on a gel drier. 
The gel was autoradiographed (2.1.4) and the sequence of phagemid DNA 
determined. 
ME 
2.4.14 	Polymerase Chain Reaction (PCR) 
PCR was performed using a Hybaid Thermal Cycler. Reactions (100tl, final 
volume) were assembled on ice, in 250g1 microfuge tubes, according to Table 2.7. 
The reaction was mixed by brief vortexing and microfuging, before overlaying with 
mineral oil (lOOjil). The tube cap was punctured before PCR initiated. PCR products 
(1/10th of the reaction) were assessed by agarose gel electrophoresis (2.4.8). 
Table 2.7 
Reagents Final Concentration/Volume/Mass 
dNTPs 200mM 
l0xThermalase Buffer lx(Tris-HC1, 100mM, pH8.3; potassium chloride, 
500mM; magnesium chloride, 5mM; Tween-20, 
0.1 %(v/v); gelatin, 0. 1 %(w/v); NP40, 0.1 %(v/v). 
Primers 0.5pM 
Template DNA plasmid; 25-50ng 
yeast genomic DNA; 2-4 jig 
?gt11 DNA; 100-500ng 
dH20 brought to 99ji1 
Thermalase 0.5 Units 
In general, there were four stages to all PCR programmes: 
DNA denaturation stage (slightly longer for genomic DNA). 
Primer:template annealing stage (at least 5°C lower than the melting 
temperature of the DNA hybrid). 
Bridging or holding stage (overcomes premature melting of 
primer: template) 
Primer extension stage (one minute per kilobase of expected PCR product). 
A general PCR programme for a one kilobase DNA product is outlined here 
(25 cycles; Table 2.8). A low stringency PCR programme was preceded by an 
additional four cycles (prior to the general PCR programme) and was performed when 











 1 95 - 1-2 95 - 1 
 35 - 0.75 - 	35-65 0.5 
 50 - 0.5 50 - 0.5 
 70 - 1.0 70 - 1 	1.0 
CYCLES - 	 x4 - 	 x25 
PCR programmes were adjusted according to several factors: the nature of 
template DNA, the expected size of the PCR product and the degree of homology 
between primers and DNA template sequence. 
	
2.4.15 	Inverse PCR from Circularised Yeast Genomic DNA 
Genomic DNA (60t1, 12.tg; 2.4.7) was digested with an appropriate enzyme 
(2.4.10) and the volume brought to 150jtl with dH20. This was extracted with 
phenol/chloroform and chloroform (2.4.2), before ethanol precipitation (2.4.3). The 
DNA was circularised by high dilution ligation. This was performed essentially as 
described in (2.4.11), except that the reaction volume was 100-1 50tl and 50 Units of 
T4 DNA ligase (supplied in high concentration) were used. DNA was extracted with 
phenol, phenol/chloroform and chloroform, and ethanol precipitated. The pellet was 
resuspended in a volume permitting a 100.tl PCR reaction. Inverse PCR was carried 
out using the appropriate primers and according to section (2.4.14). 
2.4.16 	Molecular Cloning of PCR Products 
PCR products were transferred into vector DNA, by cohesive or blunt end 
ligation (2.4.11). The generation of cohesive ends was achieved by digestion of 
restriction enzyme sites (2.4. 10) present in the DNA prior to PCR (e.g. EcoRl in the 
2gt1 1 positive clones), or provided by the restriction tails of PCR primers. 
To facilitate digestion of restriction sites located near the termini of a PCR 
product (less than 10 base pairs) and to create blunt ended DNA fragments, DNA 
concatamerisation was performed. DNA fragment PCR products were recovered from 
agarose gels (2.4.9) and resuspended in dH20 (30p1). The following reagents were 
added to the tube containing the DNA solution: 3.5p1 of lOxConcatamerisation Buffer 
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(2.2. 1) and T4 polynucleotide kinase (1 Unit). The tube was briefly vortexed and 
microfuged, before incubation at 37°C for 1 hour. The addition of Klenow enzyme (1 
Unit) and dNTPs (1 .5p1, 2mM) permitted the filling in of overhanging DNA ends. 
The tube was vortexed, microfuged and incubated at 23°C for 1 hour. The Kienow 
enzyme was inactivated by heating to 65°C for 10 minutes. Samples were cooled on 
ice and an aliquot removed for use in blunt-ended ligation (2.4.11) or 
concatamerisation proceeded by the addition of DTT (4ji1, 100mM), ATP (40, 10 
mM) and T4 DNA ligase (1 Unit). Tubes were incubated at 23°C for at least 16 
hours. The concatamerised DNA was extracted with chloroform (2.4.2) and ethanol 
precipitated (2.4.3), before digestion with the appropriate enzyme (2.4.10). 
	
2.4.17 	Radiolabelling of DNA Fragments 
DNA was labelled radioactively with [a-32P]dCTP, using the technique of 
random priming, adapted from a method by Feinberg and Vogelstein (1984). The 
DNA fragment to be labelled was gel-purified (2.4.9), resuspended in dH20 (35p1) 
and heated to 100°C for 10 minutes (to denature the DNA). After brief cooling on ice, 
l0il of oligo labelling solution (Oligo Labelling Buffer (2.2. 1):HEPES (2M, adjusted 
to pH6.6 with SM sodium hydroxide): Random Hexanucleotides (90 O.D.260nm 
Units/ml), in the ratio 1:2.5:1.5) and BSA (2il, 20mg/mi) were added. The tube was 
vortexed and microfuged briefly, before incubation at 37°C for 10 minutes. This step 
permits annealing of the random hexamers to the single stranded DNA. The labelling 
reaction was initiated by the addition of [a-32P]dCTP (30pCi, 3,000Ci/M) and 
Kienow enzyme (2tl, lU/p 1). Following brief vortexing and microfuging, the tube 
was incubated at 23°C for 16 hours. The volume of the reaction was brought to 500t1 
with sodium phosphate buffer (10mM, pH7.5; 2.2.1). In order to remove 
unincorporated radionucleotides the labelled solution was applied to a sephadex 
column (NAP-5, Pharmacia) previously equilibrated with sodium phosphate buffer 
(10mM, pH7.5). Once the probe mix had permeated the column, the radiolabelled 
DNA was eluted with l.Oml of buffer and collected in a microfuge tube. 
Radiolabelled probes were stored in lead containers at -20°C, for up to one week. 
2.4.18 	Capillary (Southern) Blotting of DNA Fragments 
This method of transferring DNA from an agarose gel to nitrocellulose was 
essentially performed according to Southern, E.M., (1975). Plasmid or genomic 
DNA was digested with the appropriate enzyme(s) (2.4.10) and electrophoresed 
through an 0.8%(w/v) agarose gel (2.4.8) at iSV for 16 hours. A ruler was placed 
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alongside the gel, while photographed on a transilluminator. This was done so that 
the distance of migration, and therefore size of any fragment which subsequently 
appeared on the autoradiograph could be calculated. In order to depurinate the DNA, 
the gel was immersed in a covering volume of HCl (0.2M) for 10 minutes, with 
shaking. The gel was similarly immersed twice in denaturation solution (sodium 
chloride, 1.5M; sodium hydroxide, 0.5M) followed by neutralisation solution (Tris-
HC1, 1M, pH8.0; sodium chloride, 1.5M), but for 20 minutes. The capillary blotting 
structure was assembled as follows; a wick was made by placing a double thickness 
sheet of blotting paper over a glass plate so that the ends were immersed in a tray of 
1OxSSC (2.2.1). The gel was placed in the centre of the saturated wick. Bubbles 
present between gel and blotting paper were released by rolling a glass pipette firmly 
over the gel. Cling film was then placed on all four sides of the gel so that the 
assembly above the gel would not be in contact with the wick. A nitrocellulose sheet, 
roughly 2mm larger than the gel area, was briefly immersed in 2xSSC, and placed 
directly on top of the gel. As described, bubbles were eliminated before 15-20 sheets 
of blotting paper (of nitrocellulose size) were laid directly on top of the transfer 
membrane, ensuring a bubble free contact throughout the 'sandwich'. Finally, a stack 
(3-4 inches) of paper towels, a glass plate and heavy weights were placed evenly on 
top of the described assembly. DNA fragments were left to transfer to the membrane 
by capillary action, overnight. The blot was removed from the assembly and marked 
for orientation, before incubation at 80°C for 2 hours. Nitrocellulose membranes were 
then hybridised (2.4.19) with the appropriate radiolabelled probe (2.4.17). 
2.4.19 	Hybridisation of Capillary Blots 
Blotted membranes were briefly immersed in 2xSSC (2.2.1) and placed 
between two sheets of nylon mesh in a shallow tray of buffer. This 'sandwich' was 
rolled up (while taking care to exclude bubbles) and placed in a hybridisation bottle 
with 30mls of warmed (37°C) pre-hybridisation solution (5xDenhardt's solution 
(2.2.2); 6xSSC; SDS, 0.5%(w/v)). Salmon sperm DNA solution (ling per ml of pre-
hybridisation solution; 2.2.4) was heated to 100°C for 10 minutes and immediately 
added to the hybridisation bottle. Pre-hybridisation was carried out in a rotisserie 
oven, at 65°C, for 1 hour. DNA fragments were radiolabelled (2.4.17) and denatured 
by boiling for 10 minutes. Pre-hybridisation solution was discarded and replaced with 
hybridisation solution (as pre-hybridisation solution, but containing the denatured 
probe(s)) and salmon sperm DNA (prepared as previously described). Hybridisation 
was carried out as for pre-hybridisation, but for at least 16 hours. Hybridisation 
solution was discarded and blots were washed twice at 65°C for 10 minutes in each of 
the following; (1) 2xSSC/SDS, 0.5%(w/v); (2) 1xSSC/SDS, 0.1%(w/v); (3) 
0. 1xSSC/SDS, 0.1%(w/v). The membrane was removed from the hybridisation bottle 
and air-dried, whereupon it was wrapped in cling film and autoradiographed (2.1.4). 
	
2.4.20 	Yeast RNA Preparation 
YPDA (200mls) was inoculated with cells from a single yeast colony. Cells 
were grown to an O.D.600nm of 0.6 (2.3.3) and harvested by centrifugation (3,000g, 
10 minutes at 4°C). Hereafter, cells were maintained on ice, unless otherwise stated. 
The pellet was washed by resuspension in TNE (lOml; Tris-HC1, 0.2mM, pH7.5; 
sodium chloride, 0.5M; EDTA, 10mM, pH8.0) and centrifugation (as before) in 30m1 
glass tubes. The cells were resuspended in 3mls of TNE, and aliquoted (300tl) into 
microfuge tubes containing acid-washed glass beads (200il, approx. volume; 2.2.4). 
The addition of phenol/chloroform (300Rl)  and vortexing of the capped tubes (2 
minutes) resulted in the rupturing of the cells, liberating RNA. The tubes were 
microfuged (1 minute) and the aqueous layer removed to a fresh tube. Extraction with 
phenol/chloroform (2.4.2) was repeated until no material remained visible at the 
interface. The aqueous phase was extracted with chloroform and the RNA precipitated 
with ice-cold ethanol (3 volumes; 2.4.3). Tubes were microfuged (15 minutes, 4°C), 
the RNA pellet was washed with 70% ethanol and resuspended in 50pi of ddH20. 
2.4.21 	Denaturing Agarose Gel Electrophoresis of RNA 
Yeast RNA (30tg; 2.4.20) was electrophoresed through an agarose gel 
(1.4%(w/v)), prepared as follows; agarose powder (2.1g) was dissolved by boiling in 
dH20 (130.5m1) and 1OxMOPS buffer (15m1; 2.2.1). The mixture was allowed to 
cool below 65°C, whereupon formaldehyde (7.65m1 of a 37% solution) was added 
and mixed by swirling. The gel mix was poured into a gel former, an 8-well comb 
inserted and the gel left to solidify. Yeast mRNA (30ig per gel lane), was diluted 1:1 
with Formamide Sample Buffer (FSB) (5:10:6; 1OxMOPS buffer:deionised 
formamide:formaldehyde, 37% solution(v/v)), heated to 65°C for 5 minutes and cooled 
on ice. This was added to FDE gel loading buffer (0.25 volumes; 2.2.1), mixed and 
loaded into the wells of the gel. Electrophoresis (with a buffer circulation pump) was 
performed at 1OV/cm of gel, in 1xMOPS buffer. 
M. 
2.4.22 	Northern Blotting of RNA from Agarose Gels 
RNA was electrophoresed through a denaturing agarose gel (2.4.22). A 
portion of the gel was removed and stained for reference by incubation in ethidium 
bromide (10mg/mi; 2.2.2)/1xMOPS buffer (2.2.1). The remainder of the gel was 
placed in a container with a covering volume of 1OxSSC (2.2. 1) and incubated with 
shaking for 20 minutes (this step removes formaldehyde). RNA was transferred from 
gel to transfer membrane using a capillary blot (as described in section 2.4. 18) except 
that Hybond-N (Amersham) (pre-wetted in 2xSSC), was used as the blotting 
membrane. Transfer was carried out for a minimum of 16 hours, after which the blot 
was carefully removed, marked for orientation and baked at 80°C for 2 hours. 
	
2.4.23 	Northern Blotting of RNA from Polyacrylamide/Urea gels 
RNA samples were electrophoresed through a 6%(w/v) acrylamide/7M urea gel 
(2.4.13). The gel plates were prised apart and the gel transferred to blotting paper. 
The area of the gel containing the 5 different snRNAs was estimated and cut away 
from the remainder. The gel was divided in two (containing the larger U  and U2 or 
smaller U4, U5 and U6 snRNA species) and each part transferred to double thickness 
blotting paper. The following were assembled in order, on one half of a transfer 
cassette; a scouring pad (soaked in 0.5xTBE; 2.2.1), two sheets of blotting paper (cut 
to pad size), the gel, a transfer membrane (gel size, briefly immersed in buffer; 
Hybond-N, supplied by Amersham International), a further two sheets of blotting 
paper and scouring pad (soaked as previously). Care was taken to ensure that no air 
pockets formed between blotting paper, gel and transfer membrane, by rolling a glass 
pipette over each surface, so that even transfer could be achieved. The cassette was 
tightly closed and placed in an electroblotter (Trans-Blot Electroblotting cell, Bio-
Rad). Transfer was performed at 60V for 30 minutes in 0.5xTBE Buffer. The 
cassette was dismantled, the membrane carefully removed from the gel, marked for 
orientation and air dried. RNA species were irreversibly fixed to the membrane by 
UV crosslinking (UV Stratalinker 1800, Stratagene). 
2.4.24 	In Vitro Transcription from a linearised DNA Template 
This technique was performed essentially as described by Davanloo, P.(1984). 
DNA template (2tg) was linearised (2.4. 10) and T7/T3 directed in vitro transcription 
performed, in the presence of radiolabelied [a-32P]UTP. The following reagents 
were assembled in a microfuge tube, in the order given: linearised plasmid DNA 
(0.2tg), 1i1 of T7/T3 buffer (400mM Tris-HC1, pH8.0; magnesium chloride, 
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100mM; DTT, 100mM; sodium chloride, 100mM), lil of RNAsin (40U/iI), 1 g each 
of ATP, CTP, GTP, (5mM), 0.75 jil of [c-32P]UTP (specific activity 30j.iCi/ml), liJ 
of 250mM UTP and ltl of T7/T3 RNA polymerase (20U/pJ). The contents of the 
tube were vortexed and microfuged briefly, before incubation at 37°C for 30 minutes. 
2.5 Protein and Immunological Methods 
2.5.1 Quantitation of Protein 
To assess protein concentration in a given sample, protein assay dye (Bio-Rad) 
was used, in accordance with the method of Bradford, M. M. (1976). The stock 
reagent was diluted with dH20 (1:5). Aliquots of 3mls were added to known protein 
quantities (0. ltg-1Ogg of BSA, 20mg/ml) and experimental samples. The tubes were 
vortexed and the O.D.595nm of lml aliquots determined. A standard curve of 
absorbance against protein concentration was plotted. From this figure, the 
concentration of protein in the sample was calculated. 
2.5.2 Induction of Fusion Protein Synthesis in E.coli 
The pUR vector system 
A starter culture (5m1) of E. coli BMH71-18 cells, carrying the appropriate 
pUR based plasmid, was grown in LBroth (+amp) to stationary phase (2.3.1). The 
cells (2m1) were diluted 1:100 into fresh medium and grown to an O.D.650nm of 0.4. 
Synthesis of the 3-galactosidase fusion protein was induced by the addition of IPTG 
(400pJ, 25mg/mi; 2.2.2). Cells were grown for a further hour, before protein extracts 
were prepared (2.5.3). 
The pATH vector system 
A starter culture (5m1) of E. coli BIB 101 cells, carrying the appropriate pATH 
based plasmid was grown in M9+CA+W+amp to stationary phase (2.3.1). Synthesis 
of TrpE fusion protein was induced by diluting the 5m1 culture 1:10 into M9+CA+amp 
(2.2.8.2). Cells were grown for one hour, whereupon Indoleacrylic acid (250pJ, 
1mg/nil; 2.2.2) was added to the culture. Protein extracts were prepared after a further 
two hours of growth (2.5.3). 
2.5.3 E. coli Protein Extract Preparation 
A 200m1 cell culture was induced to synthesise fusion protein (as described in 
section 2.5.2). The cells were pelleted by bench-top centrifugation at 1,600g for 5 
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minutes at 4°C before resuspension in 4mls of TES (Tris-HC1, 50mM, pH8.0; EDTA, 
50mM, pH8.0; sucrose, 15%(w/v)). The cell suspension was transferred to a 
polycarbonate tube on ice, whereupon lysozyme (0.4m1, 10mg/mi) was added and 
mixed by swirling. The tube was incubated on ice for 40 minutes (with occasional 
inversion), before 5.6mls of Triton X-100 (0.2%(v/v))/1xTE (pH8.0; 2.2.1) were 
added. The contents of the tube were mixed by swirling and incubation on ice 
continued for a further 5 minutes. Centrifugation (39,000g. 4°C, 10 minutes) was 
carried out, the supernatant and pellet representing the soluble and insoluble protein 
fractions respectively. The supernatant was removed and added to an equal volume of 
2xProtein Loading Buffer (2.2.1), before aliquoting into microfuge tubes and snap-
freezing in liquid nitrogen. The pellet (containing the insoluble protein fraction) was 
resuspended in lxProtein Loading Buffer and thereafter treated as above. To assess 
expression of fusion protein, small aliquots of 40/50.il were subjected to SDS-PAGE 
(2.5.6). 
2.5.4 Yeast Protein Extract Preparation 
Yeast cells (DJY84), containing pBM125-SM14 were grown in 10mls of 
YMG1u+W (2.2.8.2) to stationary phase (2.3.3). Cells were harvested by bench-top 
centrifugation in 50ml polypropylene tubes at 1,600g for 5 minutes, resuspended in 
lOmls of YMGa1+W or YMG1u +W (2.2.8.2), transferred to a flask and grown to an 
O.D.600nm of 0.4. The cells were pelleted (as above), resuspended in lx PBS (2.2. 1) 
and recentrifuged. The pellet was resuspended in 0.4m1 of Extraction Buffer (1xPBS; 
NP40, 0.1%(v/v); PMSF, 1mM (dissolved in ethanol); DTT, 1mM; pepstatin A, 
5pg/m1; leupeptin, 5.tg/ml) and transferred to a lOmi glass beaker on ice. Cells were 
sonicated by three bursts of 30 seconds each (maximum amplitude; M.S.E. 100W 
Ultrasonic Disintegrator). The sonicated extract was microfuged for 30 seconds, the 
supernatant removed and recentrifuged at 4°C for 10 minutes. The supernatant was 
removed, aliquoted and snap-frozen in liquid nitrogen. 
2.5.5 Yeast Splicing Extract Preparation 
This method is modified from that of Lin, R-J. et al. (1985). YPDA (1 litre; 
2.2.8.2) was inoculated with cells from a single colony of yeast strain BJ2412. Cells 
were grown to an O.D.600nm of 0.5-0.6 (2.3.3), harvested by centrifugation (4,200g) 
for 5 minutes at 4°C and the pellet resuspended in 50mls of potassium phosphate 
buffer (50mM, pH7.5; 2.2.1). The cell suspension was transferred to a 50m1 
polycarbonate tube and bench-top centrifuged at 1,600g for 5 minutes. Cells were 
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resuspended in 50mls of Lyticase Buffer (sorbitol, 1.2M; potassium phosphate, 
50mM, pH7.5; DTT, 30mM) and transferred to a conical flask. After the addition of 
lyticase (2500 units), the culture incubated at 30°C with gentle shaking for one hour to 
induce sphaeroplast formation. The cells were pelleted by bench-top centrifugation 
(1,600g for 5 minutes at 4°C) and resuspended in sorbitol (40mls, 1.2M) twice. The 
suspension was bench-top centrifuged once more (1,600g for 5 minutes at 4°C), the 
pellet gently resuspended in 50m1 of YPDAS (as YPDA, but containing sorbitol, 
1.2M) and transferred to a 500ml flask with a further 200mls of media. The cells 
were incubated with gentle agitation at 30°C for one hour. The sphaeroplasts were 
pelleted by centrifugation (4,200g for 5 minutes at 4°C) and washed by resuspension 
in 40mls of ice-cold SB-3 buffer (Tris-HC1, 50mM, pH7.5; sorbitol, 1.2M; 
magnesium chloride, 10mM; DTT, 3mM), followed by slow centrifugation (as 
before). Hereafter, procedures were carried out at 4°C. The sphaeroplast pellet was 
weighed and resuspended in chilled Buffer A (imi per gram of pellet; HEPES-KOH, 
10mM, pH7.5; magnesium chloride, 1.5mM; potassium chloride, 10mM; DTT, 
0.5mM). The suspension was transferred to a chilled homogeniser and left on ice for 
5 minutes before homogenisation. After 10-13 slow strokes, the mixture was placed 
in a glass beaker on ice, over a magnetic stirrer. Carefully, potassium chloride (0.11 
volumes, 2M) was added dropwise, whereafter the cell extract was left stirring for 30 
minutes before transfer to a polycarbonate tube and centrifugation at 35,000g for 30 
minutes. The supernatant was removed (avoiding the very top lipid layer) to a 
polycarbonate ultracentrifugation tube, and centrifuged at high speed (95,000g) in a 
pre-cooled rotor (Ti50) for one hour, at 4°C. The supernatant was removed (avoiding 
the lipid layer, as before) and dialysed against 3 changes of one litre each of freshly 
made Buffer D (HEPES-KOH, 20mM, pH7.5; EDTA, 0.2mM, pH8.0; DTT, 0.5mM; 
potassium chloride, 50mM; glycerol, 20%(vlv)) at 4°C. The extract was aliquoted, 
snap-frozen in liquid nitrogen (freeze-thaw limit of 3) and stored at -70°C. 
2.5.6 Denaturing Polyacrylamide Gel Electrophoresis (SDS-PAGE) of 
Proteins 
SDS-discontinuous polyacrylamide gel electrophoresis (SDS-PAGE) was used 
to separate proteins of a given sample, on the basis of molecular weight (Laemmli, 
U.K., 1970). SDS-polyacrylamide gels (8.0%-12.5%(w/v)) were prepared. To 
assemble the gel forming apparatus, two 16cm x 16cm glass plates (one notched, one 
with 1.5mm. or 2mm side spacers) were clamped together, with a piece of rubber 
tubing sealing the bottom and sides. Resolving gel solutions according to Table 2.9 
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were prepared (APS and TEMED were added immediately before pouring), mixed by 
swirling and poured between the two glass plates, leaving a 5cm gap from the top. 
This was overlaid with butan-1-ol (lml), covered with cling film and left to set at 
room temperature for at least 1 hour. The butan- 1 -ol was washed away with dH20 
and the space between the plates dried with blotting paper. Stacking gel solution was 
prepared, mixed by swirling and poured on top of the resolving gel up to the level of 
the notch. A slot-forming comb (14 wells of 0.5cm, 10 wells of 0.75cm, or 2 wells 
of 0.5cm combined with 1 well of 10cm) was immediately inserted into the stacking 
gel mix, which was left to set for a minimum of 45 minutes. The comb, clamps and 
rubber tubing were carefully removed and the gel was placed in an electrophoresis 
tank (ATTO), which was filled with lxElectrophoresis Buffer (2.2.1). An equal 
volume of 2xProtein Loading Buffer (2.2.1) was added to protein samples which 
were to be electrophoresed. The microfuge tubes were punctured and samples boiled 
in a water bath for 10 minutes. Following this, tubes were microfuged for 1 minute 
before the supernatant was loaded into the wells of the gel. Protein molecular weight 
markers (2.2.4) were similarly loaded and simultaneously electrophoresed. 
Electrophoresis was carried out at 150V for 3 hours or at 25V overnight. The gel 
plates were removed from the apparatus, prised apart and the gel carefully removed. 
Table 2.9 




Volume in Resolving Gel (ml) 
Final Acrylamide % 
8.5 	10 	12.5 
30%(w/v) Acrylamide (2.2.2) 2.5 8.5 10 12.5 
Stacking Gel Buffer (2.2. 1) 5.0  
Resolving Gel Buffer (2.2. 1)  3.75 3.75 3.75 
SDS, lO%(wtv) 0.2% 0.3 0.3 0.3 
Ammonium 	Persulphate, 
1 .5%(w/v)  
1.0 1.5 1.5 1.5 
TEv1ED 0.015 0.015 0.015 1 	0.015 
dH20 11.3 15.95 14.45 1 	11.95 
2.5.7 Visualising Proteins on Denaturing Polyacrylamide Gels 
Proteins present on SDS-gels were visualised by placing the gel in a sealed 
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container with 50mls of Coomassie Blue staining solution (propan-2-ol, 30%(vlv); 
acetic acid, 10%(v/v); Coomassie Brilliant Blue, 0.05 %(wlv)) and incubated at 37°C, 
overnight, with agitation. The stain was discarded and the gel washed with destain 
solution (methanol, 25%(v/v); acetic acid, 10%(v/v)) (5x, 30 minutes, lOOmis), before 
incubation with shaking in 200mls of this solution at 37°C, overnight. Once 
sufficiently destained, the gel was placed on blotting paper, covered with clingfilm and 
dried at 80°C for 2 hours on a vacuum gel drier. 
2.5.8 Western Blotting 
Western blotting was performed according to the method described by 
Towbin, H. et al. (1979). Protein samples were electrophoresed through an SDS-
polyacrylamide gel (2.5.6), which was immersed in transfer buffer (2.2. 1) for 10 
minutes. The following were assembled in order; on one half of a transfer cassette a 
scouring pad (soaked in transfer buffer), two sheets of blotting paper (cut to pad size), 
the gel, a sheet of nitrocellulose (gel size, briefly immersed in buffer), a further two 
sheets of blotting paper and scouring pad (soaked as previously). Care was taken to 
ensure that no air pockets formed between blotting paper, gel and transfer membrane, 
by rolling a glass pipette over each surface, so that even transfer could be achieved. 
The cassette was tightly closed and placed in an electroblotter (Trans-Blot 
Electroblotting Cell, Bio-Rad), in the orientation cathode: gel: nitrocellulose: anode. The 
cell was filled with transfer buffer and blotting occurred at 100V for one hour. The 
cassette was removed, disassembled and the nitrocellulose sheet marked for 
orientation. The membrane was placed in a solution of Ponceau S (Sigma) for 5 
minutes, before washing with 1xTBS (2.2.1). This step reveals the pattern of the 
transferred proteins. The blot was immersed in a tray with BSA (5%(w/v))/1XTBS 
(20mls), with shaking for 2 hours at 37°C, in order to block non-specific binding 
sites. Incubation with primary antibody (125p1 of affinity purified antibodies or 1-
20il of the various crude sera in Smls of BSA (1%(w/v))/1XTBS) was carried out 
overnight at 4°C with gentle shaking. The antibody solution was discarded and non-
specifically bound antibodies were removed by washing 5 times with 50mls of NP40 
(0.1% (v/v))/1XTBS (5 minutes each) while shaking at room temperature. Blots were 
developed with Promega, Protoblot System. The secondary antibody (goat, anti-
rabbit/human), conjugated to an alkaline phosphatase enzyme was diluted (1:7500) in 
BSA (1%(w/v))/1XTBS. The blot was incubated in this solution (lml per 10cm2) at 
room temperature, with shaking, for 1 hour. The blot was washed (as described 
previously) and incubated with freshly prepared development solution (lOmis; Tris- 
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HC1, 0.1M, pH9.5; sodium chloride, 0.15M; magnesium chloride, 5mM; 
nitrobluetetrazolium (NBT), 0.3 3mg/ml; 5-bromo-4-chloro-3-indoyl phosphate 
(BCIP), 0.1 65mg/mI) until the bands had developed sufficiently. The membrane was 
rinsed with 1xTBS, blotted dry, covered in clingfilm and stored in the dark. 
2.5.9 North-Western Blotting 
Protein samples were electrophoresed by SDS-PAGE (2.5.6) and Western 
blotted (2.5.8). The immunoblotted proteins were visualised using Ponceau S, the 
membrane rinsed with 1xTBS (2.2.1), prior to washing (5 changes of 50mls, 5 
minutes each, with shaking) with RNA Binding Buffer (2.2.1). In vitro transcription 
from a linearised DNA template was carried out (2.4.24). The blot was immersed in 
RNA binding buffer (2mls per 10cm3 of membrane), 1/20th of the in vitro 
transcription reaction and 10ig/m1 of E. coli tRNA (2.2.3). This was incubated in a 
sealed container on a shaking platform, for one hour, at room temperature . The 
radioactive solution was discarded and the membrane washed (as described 
previously) with RNA Binding Buffer. The blot was air-dried, wrapped in clingfilm 
and autoradiographed (2.1.4). 
2.5.10 	Purification of Fusion Protein from Denaturing 
Polyacrylamide Gels 
E. coli insoluble/soluble protein extracts were prepared (2.5.3). An-
polyacrylamide gel (8.5%(w/v); 2.5.6) was prepared using a gel comb with one large 
well (10cm) and two small wells (each 0.5cm). Protein extract (500-1000il) and 
reference markers (2.2.4) were electrophoresed through the gel. The gel plates were 
prised apart and the edges of the gel (0.5-1.0cm) were cut from the body of the gel 
(using a sterile razor blade) and marked for orientation. The proteins on the edges of 
the gel were visualised with Coomassie Brilliant Blue stain (2.5.7). This enabled the 
location of the electrophoresed fusion protein to be determined. The main body of the 
gel (stored at 4°C in clingfilm) was re-aligned with the stained edges, so that the 
position of the fusion protein could be predicted. A narrow horizontal strip, 
representing this region was cut from the gel, placed longitudinally in 2cm wide 
dialysis tubing, with 0.66m1s of SDS-PAGE Electrophoresis Buffer (2.2.1), and 
clipped at the ends. This was placed horizontally across an electrophoresis tank (filled 
with buffer), weighted down with glass tubes and a voltage of 100V applied for 16 
hours. The current was reversed for 2 minutes (so that the protein could detach itself 
from the dialysis tubing membrane), the dialysis bag removed and the buffer 
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containing the purified protein transferred to centrifugation tubes (Centricon-30) in 
which concentration of the solution to a smaller volume was possible. Tubes were 
centrifuged (5,000rpm, 4°C) for 30-90 minutes, depending on the initial volume. A 
final volume of 250il was achieved, an aliquot (25pJl) of which was removed and 
assessed by SDS-PAGE (2.5.6). The remaining volume was snap-frozen in liquid 
nitrogen and used in immunisation procedures (2.5.11). 
	
2.5.11 	Immunisation of Rabbits 
Two rabbits were immunised against gel-purified 3-galactosidase-SM14 
fusion protein according to the 1986 Cruelty to Animals Act under license number 
63181. Female rabbits of the half lop variety were obtained from Froxfield rabbits, 
Hampshire. Gel-purified 3-ga1actosidase-SM14 fusion protein (50tg; 2.5.10) was 
used for the first and all subsequent injections. The volume of fusion protein was 
brought to 500jil with 1xPBS (2.2.1) and then imi by the addition of Freunds 
complete adjuvant (1st immune injection) or Freunds incomplete adjuvant (all 
subsequent injections). The mixture was vortexed until a stable emulsion formed, of 
which each rabbit received 4 subcutaneous injections of 250[i1 (a total of 50pg of 
fusion protein/ml per injection). Injection was performed at monthly intervals, and 
blood collected 14 days after this. After the first and second injections, 20mls were 
collected and 50mls after the subsequent ones. A pre-immune bleed (20mls) was 
taken from the ear vein, 14 days prior to the first injection. At the final bleed, rabbits 
were injected with Sagatal, and blood (lOOmis) was taken from the heart, before a 
final lethal dose was administered. 
2.5.12 	Preparation, Handling and Storage of Sera 
Bleeds were stored in polycarbonate tubes overnight at 4°C, thereby allowing 
a clot to form. The clot was freed from the sides of its container by taking a glass 
pipette around its edges, before transferring the contents to a centrifuge tube. Bench-
top centrifugation at 1,600g for 5 minutes was carried out in order to pellet the red 
cells. The supernatant was removed and recentrifuged if necessary, otherwise aliquots 
were immediately snap-frozen in liquid nitrogen (freeze-thaw limit of 6). 
2.5.13 	Affinity Purification of SM14 Antibodies from Rabbit 
Antisera 
Antibodies were affinity purified from rabbit antisera by a method adapted 
from Robinson, P.A. et al. (1992). E. coli SM14 fusion protein extracts were 
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electrophoresed through an SDS-polyacrylamide gel (8.5%; 2.5.6), using a large well 
comb. The gel was Western blotted (2.5.8) and the pattern of proteins visualised with 
Ponceau S stain. A horizontal strip containing the fusion protein was excised from the 
nitrocellulose blot and incubated with blocking solution and a serum dilution (1:100) 
as described in section 2.5.8. After washing with NP40 
(0.l%(v/v))/1xTBS(2.2.1)(5x, with shaking at 25°C, 50mls each wash), purified 
antibodies were eluted from the strip by incubation with agitation in glycine-HC1 (2m1, 
pH2.5)/ovalbumin (0.1 %(w/v)) for 5 minutes. The antibody eluant was immediately 
neutralised with 0.5mls of Tris-HC1 (pH7.5) and this elution step repeated. Antibody 
solutions were pooled, dialysed against 1xTBS (3 changes of one litre, over 16-20 
hours) and stored at 4°C, with the addition of sodium azide (0. 1%(w/v)). 
	
2.5.14 	Covalent Coupling of Antibodies to Protein A-Sepharose 
Beads 
Protein A-Sepharose (PAS) beads were covalently coupled to antibodies 
according to the method of Harlow, E., and Lane, D. (1988). Antibodies were 
immobilised on PAS beads (2.5.15) and washed (by microfuging for one minute and 
resuspending) in sodium borate (0.2M, pH9.0) 3 times. The beads were resuspended 
in dimethylpimelimidate/sodium borate (200tl; 20mM/0.2M) and mixed by rotation 
for 30 minutes. The beads were washed once with ethanolamine (0.2M, pH8.0)(as 
described previously) and incubated in this solution for two hours on a rotating wheel. 
Three more washes with NTN (2.5.15), an incubation with glycine (0.1M, pH3.0) (5 
minutes with rotation) and 3 final washes with NTN, removed noncovalently bound 
antibodies. The antibody-coupled beads were resuspended in NTN, with sodium 
azide (0.05%, (w/v)) and stored at 4°C. 
2.5.15 	Immunoprecipitation of Protein and RNA Species from 
Yeast Extracts 
This method was performed as described by Lossky, M. et al. (1987). Antibodies 
were immobilised on protein A-sepharose (PAS) beads and used to immunoprecipitate 
snRNPs, snRNAs or specific proteins. The PAS beads (lomgs per 
immunoprecipitation) were swollen in 500il of NTN (Tris-HC1, 50mM, pH7.5; 
sodium chloride, 0.15M; NP40, 0.1%(v/v)) on a rotating wheel for half an hour. The 
beads were washed 5 times by pelleting in a microfuge (1 minute) and resuspension in 
NTN (500pd). After the last wash, the beads were added to crude serum (5-15jil) or 
TMG antibodies (15jig) and the final volume brought to 150j.il with NTN. The 
antibodies were allowed to bind the PAS beads on a rotating wheel, at room 
temperature, for one hour. The beads were washed (as previously described), 4 times 
with NTN and once with NT (Tris-HC1, 50mM, pH7.5; sodium chloride, 0.15M). 
Yeast splicing extract (20-50.tl for immunoprecipitation of snRNAs, 100p1 for 
protein) was added to the PAS pellet and the total volume brought to 150il, so that 
final conditions were: 
(i) Na/K (sodium/potassium chloride), 150mM; HEPES-KOH, 10mM, pH7.5; 
magnesium chloride, 2.5mM; NP40, 0.1%(v/v). 
or 
K (potassium phosphate, pH7.5; 2.2.1), 105mM; PEG, 3%(wlv); 
magnesium chloride, 10mM. 
Alternatively, beads were added to 100tl of an SM14 over-expressing 
extract (2.5.4), previously diluted 1:1 with NTN (for subsequent protein analysis 
only). Immunoprecipitation was carried out on a rotating wheel for 2 hours, at 4°C. 
The immunoprecipitate was washed (as previously described), 4 times with NTN and 
once with NT, at 4°C. Hereafter, the immunoprecipitate was analysed for protein or 
RNA species content. Proteins present in the immunoprecipitate were assessed by 
SDS-PAGE and Western blot. The beads were added to ixProtein Loading Buffer 
(2.2. 1) briefly vortexed and boiled for 10 minutes. Samples were microfuged (10 
seconds) and the supernatant loaded onto an SDS-polyacrylamide gel (2.5.6). After 
electrophoresis, the proteins were transferred to nitrocellulose by Western blotting 
(2.5.8). RNA species present in the immunoprecipitate were analysed as follows. 
The beads were incubated with 50p1 of proteinase K solution (Tris-HC1, 50mM, 
pH7.5; sodium chloride, 0.3M; EDTA, 5mM; SDS, 1.5%(wlv); proteinase K, 2mg/nil; 
stored at -70°C) on a rotating wheel for 30 minutes at 37°C. Distilled water (100p1) 
was then added to the tube and bead complexes were extracted with an equal volume 
of phenol/chloroform (2.4.2), while avoiding the bead-containing interface. 
Following microfuging (3 minutes), the aqueous phase was removed to a new tube, 
while the organic phase was extracted further, by the addition of dH20 (1 50il) and an 
equal volume of phenol/chloroform. The two aqueous phases were pooled and 
extracted with phenol/chloroform once more, ensuring that there were no beads 
present in the final extraction. The RNA species were precipitated by the addition of 
ammonium acetate, glycogen and ice-cold ethanol (2.4.3). The dried RNA pellet was 
then subjected to polyacrylamide-urea gel electrophoresis (2.4.13) followed by 
Northern Blotting (2.4.23). 
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CHAPTER 3 
Analysis of cDNA Sequences Encoding SLE-reactive Species 
	
3.1 	Introduction 
The aim of the experiments described in this chapter was to identify the 
immunoreactive yeast species isolated by the screening of a cDNA-expressing 
library with an SLE serum. 
An S. cerevisiae cDNA 2gtl 1 library (provided by Trachsel, H., Bern) was 
screened (Young, R.A. and Davis R.W., 1983) with an SLE serum (Sm 24#) 
previously shown to precipitate yeast snRNAs Ui, U2, U4, U5, and U6 (M. 
Dalrymple, unpublished results). Positive clones were selected and screened twice 
more, from which 36 cDNA clone isolates (1-14 strongly and 15-36 weakly 
immumoreactive) were obtained (M.Dalrymple, unpublished results). 
cDNA sequences were amplified by PCR, followed by transfer into one of 
two phagemid vectors. DNA sequencing was performed on single-stranded 
phagemid DNA. The nucleic acid sequences of the cDNAs were determined, from 
which primary peptide sequences were predicted. Both nucleotide and peptide 
sequences were subjected to database searches. The occurence and properties of 
these immunoreactive factors were examined with respect to known SLE 
autoantigens, and the etiology of this disease. In addition, the primary sequences of 
the immunoreactive proteins were analysed for the presence of immunodominant 
epitopes (defined in Tables 1.3 and 1.4) which may occur in SLE autoantigens. 
3.2 	Construction of Vectors Containing Amplified cDNA Sequences 
Bacteriophage 2gt1 1 contains the E. coli LacZ gene with a unique EcoRI site 
into which the yeast cDNAs were cloned during library construction. This enabled 
the expression of the peptide encoded by the cDNA as a 3-ga1actosidase fusion 
protein, when viral particles are propagated and the LacZ gene induced in 
appropriate cells. cDNA sequences were amplified by PCR and transferred into 
vectors which facilitated sequence determination (Figure 3.1). 
Figure 3.1 	Construction of Vectors Containing Amplified cDNA Sequences 
PCR was performed from 2gt1 1 clone isolates with primers 199 and 200. 
Products were (1) digested with EcoRI (E) and transferred to pTZ 1 8r, or (2) end-
filled, prior to blunt-end ligation into Smal(S)-digested pBST+, yielding plasmids 
pHMK1-18 or pHMK19-36 respectively. Plasmid multiple cloning sites (MCS), 
lambda DNA (?DNA) and EcoRI sites (EX) are indicated. 
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Figure 3.1 
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PCR (2.4.14) was performed on each of 36 positive Xgtll isolates using 
primers 199 and 200. The sizes of the PCR products generated were assessed by 
agarose gel electrophoresis (2.4.8), prior to and following digestion with EcoRI 
(2.4.10). This enabled the number of cDNA inserts present in individual lambda 
clones to be estimated. Clones 8 and 10 were found to generate two products 
following EcoRI digestion, indicating that each lambda isolate may have contained 
two fused cDNAs. Some PCR reactions did not yield any product (clones 9, 11, 12, 
16, 29 and 36), whereas some produced two DNA fragments of unrelated sequence 
(clones 5, 24, 25 and 28). The latter could be a result of contaminating lambda DNA 
in the initial positive clone isolate, which may have led to the amplification of an 
additional product. 
The products of each PCR reaction were transferred into sequencing vectors 
by one of two methods (Section 2.4.16): 
PCR DNA from isolates 1-18 was concatamerised, prior to digestion 
with EcoRI. Fragments were transferred into appropriately digested pTZ 1 8r by 
cohesive end ligation. 
PCR DNA from isolates 19-36 was end-filled, prior to blunt end 
ligation into Smal-digested pBST+. 
E. coli cells (NM522) were transformed with ligation reactions (2.3.2). Cells 
containing potential constructs were isolated, from which small scale plasmid DNA 
preparations were obtained (2.4.4). These were assessed by restriction analysis with 
EcoRI (2.4.10). 
3.3 	Nucleotide Sequences of cDNAs were Obtained, from which Primary 
Peptide Sequences were Predicted 
3.3.1 Nucleotide Sequencing of Phagemid Constructs 
Single-stranded phagemid DNA was prepared (2.4.6) from E. coli cells 
(strain NM522) bearing the correct cDNA construct and sequenced (2.4.12) with one 






3.3.2 Identification of the Nucleotide Sequences Encoding Immunoreactive 
Yeast Species 
The nucleotide sequences of amplified cDNAs were determined (3.3.1), from 
which peptide sequences were predicted. The amino acid sequences of peptides 
encoded by cDNAs 1-18 were predicted by analysing all six possible reading frames. 
As a result of the cloning technique used for the amplified cDNAs of clone isolates 
19-36, the flanking sequences of the EcoRI site within the Agt11 LacZ gene were 
obtained. This enabled the expressed reading frame of the cDNA to be determined. 
These were submitted to the TFASTA and FASTA programmes (using the UWGCG 
facility of the SERC SEQNET) which search the Genembl and Swissprot databases 
(December, 1994), respectively. The results suggested that three categories of yeast 
species were obtained, which can be represented as: 
Identified Species (Category 1), where cDNAs encode peptide/RNA 
sequences pertaining to reported genes/proteins. 
Hypothetical Species (Category 2), where cDNAs were identical to 
reported DNA sequences, from which potential open reading frames have been 
suggested (speculated as such on the basis of possible gene-defining elements). 
Novel Species (Category 3), where cDNAs (or predicted peptides) bear 
no identity with any reported nucleotide (or protein) sequences. The full nucleotide 
sequence of these cDNAs was obtained from clone isolates 1-14 (those strongly 
immunoreactive), whereas partial cDNA sequences only were determined from the 
remaining, weakly immunoreactive isolates (clones 15-36). 
The results of the database searches are presented in Table 3.1. This includes 
gene identities, Genembl/Swissprot accession numbers and the category of the 
species isolated. 
Where more than one cDNA was contained within a single 7gt1 1 clone, or 
PCR amplification yielded two different fragments, the corresponding species have 
been designated X(l) and X(2). Furthermore, it was not determined which cDNA 
yielded an immunoreactive species. Consequently, some factors identified here may 
have been isolated not as a result of their reactivity with Sm24# autoantibodies, but 
fortuitously. However, all isolated species were considered as potentially 
immunoreactive and therefore analysed accordingly. 
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Table 3.1 	Description of Isolated Species 
Clone Gene/Protein Category Accession No.s 
GenembL/Swissprot 
1 Unidentified 3 
2 Unidentified 3 
3 ILV5/Acetohydroxy Reductoisomerase 1 X04969/P06 168 








6 CRYlIRibosomal Protein 59 1 M16126/P06367 





ORF YBL0501 (Chr. II)! 











13 Unidentified 3 
14 Unidentified/As clone 2 3 
15 YEF3A/Elongation Factor 3 1 J05197/P16521 
17 MIF4/Heat Shock Protein 60 1 M33301/P19882 
18 ORF Sc4554/Hypothetical protein 2 Z38113 
19/20/34 TEFJ/Elongation Factor I—oc 1 X01638//P02994 
21 25S rRNA 1 J01355 
22 ORF YBR0715 (Chr. II)/ 
Hypothetical protein  
2 X76294 
23 GL03 1 X79514 
24(1) 
24(2) 















26 EN02/Enolase 2 or HSP48 1 J01323/P00925 
27 As clone 3 1 
28(1) 
2 8(2) 






30 Unidentified 3 
31 Unidentified 3 
32 Unidentified/As clone 1 3 
33 ENAJ/Enal 1 X67136/Q01896 
35 ABPJ/Actin Binding Protein I 	1 X51780/ P1589 1 
3.4 	Analysis of Identified Species (Category 1) 
These species have been considered in terms of their cellular location, 
complex association and function (Table 3.2 summarises these properties). The 
largest group of immunoreactive yeast species was found to be those associated with 
the translation apparatus. Other species isolated, included transmembrane, heat 
shock, cytoskeleton-associated, glycolytic and amino acid biosynthesis factors. 
Table 3.2 	Properties of Category 1 Species 
GENE Complex Association! Cellular Function of 
(Clone No.) Subcellular Location Species/Complex 
ILV5 Mitochondrial Amino acid 
(3/27)  biosynthesis 
18S rRNA 40S Ribosomal subunit/Cytoplasmic Translation 
 
YL14 A 60S Ribosomal subunit/Cytoplasmic Translation 
 
CRY1 40S Ribosomal subunit/Cytoplasmic Translation 
 
ITR2 Integral membrane protein Myo-inositol transport 
 
TFPJ Species (1):Vacuolar membrane H+ transport,  Ca2+ 
(8(1)) protein/Cytoplasmic homeostasis 
Species (2): Endonuclease/Nuclear 
YEF3 Translation apparatus/Cytoplasmic Elongation Factor, 
(15)  Translation-associated 
MIF4 Mitochondrial matrix HSP, Mitochondrial, 
(17) protein assembly and 
transport 
TEF] Translation apparatus/Cytoplasmic Translation-associated 
(19/20/34)  
25S rRNA 60S Ribosomal subunit/Cytoplasmic Translation 
(21)  
GL03 Unknown Unknown, possibly 
(5(2)/23)  DNA-binding ATPase 
SHMT2 Cytoplasmic Amino acid 
(25(1))  biosynthesis 
PDC] Homotetramer/Cytosolic Glycolysis 
(25(2))  
EN02 Homodimer/Cytosolic Glycolysis and Heat 
(26)  Shock Protein 
SSBJ Translation apparatus/Cytoplasmic Heat Shock Protein 
(28(1)) and possibly 
translation-associated 
ENA] Integral membrane protein Na+/Li2+ transport, 
(33)  ATPase 
ABPJ Cortical cytoskeleton Actin binding 
(35)  
3.4.1 Factors Associated with Yeast Ribosomes 
Several translation-associated species have been identified as 
immunoreactive yeast factors. Six different species (representing 8 isolates) 
involved in this cytosolic/cytoplasmic process have been isolated. These include 
two ribosomal proteins, rp59 (clone 6) and YL14 (clone 5) as well as the 18S (clone 
4) and 25S rRNAs (clone 21). The former and latter of each species are present in 
the 40S and 60S ribosomal particles respectively. Rp59 protein (rp59p) is small, 
extremely basic (it has a predicted p1 of 11.39) and rich in arginine residues (11.7%), 
with 7 out of 11 of the C-terminal residues positively charged. This species is highly 
conserved in evolution, demonstrating 88% and 45% amino acid identity with its 
human (S 14) and E. coli (S 11) respective hornologues. The yeast ribosomal factor is 
encoded by two genes, CRY] and CRY2, the latter of which is expressed at a low 
level. The two gene products differ in only five of their amino acid residues, two of 
which are conservative substitutions. The rp59 protein in yeast is required for the 
stable accumulation of the 40S ribosomal subunit (reviewed by Woolford, J.L., 
1991). 
YL14 (also known as L23) is a 22.7kDa species, encoded by the YL14A gene 
and is a component of the yeast 60S ribosomal subunit (Guthrie, C. and Fink, G.R., 
1991). The yeast YL14 species is extremely rich in lysine (12.2%) and arginine 
(14.8%) residues, a property reflected in its predicted p1 of 11.93. A rat species, L19 
has been identified as a higher eukaryotic form of this protein. The latter has been 
shown to bind 5S and 5.8S rRNA in vitro and may bind these small rRNAs in the 
large ribosomal complex (Chan, Y-L. et al., 1987). 
Two rRNAs have been identified in this work as potentially immunoreactive. 
The 18S (clone 4) and 25S rRNAs (clone 21) are 2000 and 3391 nucleotides 
respectively. It has previously been shown that human 28S rRNA can react with 
autoantibodies in some SLE sera (Uchiumu, T et al., 1991) and that the 
immunoreactive region is located between nucleotides 1944-2002. The yeast 
homologue of this species (25S rRNA) has been identified in this work as 
immunoreactive. However, the human homologue of the 18S rRNA has not 
previously been suggested to be an SLE autoantigen. 
The nucleotide sequences of the elongation factors YEF3 (clone 15) and 
EF1—c (clones 19, 20 and 34) were isolated. The former protein, encoded by the 
TEF3 gene is a member of the ATP-binding transport family (with similarity to 
hydrophilic membrane-associated ATPases; Qin, S. et al., 1990). Although this 
species is acidic, the 36 C-terminal amino acids are highly charged and contain three 
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basic polylysine blocks, regions which have been implicated in interactions with 
RNA (Clarck, R.J. and Felsenfeld, G., 1971). The function of this acetylated, 
phosphorylated protein is thought to be in providing energy for translocation, 
stimulating EF1-u dependent binding of the aninoacyl-tRNA to the ribosome (Qin. 
et al., 1990). 
The identification of the protein encoded by the yeast TEFJ gene on three 
occasions in this library screen may imply a strong autoantibody-protein interaction 
and/or an abundantly expressed yeast species. Indeed, this basic protein represents 
3-10% of the total cellular protein and is one of four subunits, which constitute the 
EF1-c43y6 complex. EF1-a binds the aminoacyl-tRNA in a GTP-dependent manner, 
positioning the latter at the ribosomal A-site. As EF1-c-GDP is released, peptide 
bond formation occurs between the peptidyl tRNA and the ribosomal P-site. The 
yeast EF1-a protein is lysine-rich (10.7%, compared with 6.6% for the 'average 
protein'; Dayhoff, M.O. et al., 1982), particularly in its C-terminus (7/18 residues) 
and is post-translationally modified by methylation at some of these residues (as is 
the higher eukaryotic species). It is postulated that this modification is not required 
for EF1-(x function as only two of the positions of methylation are conserved in 
evolution between yeast and man (Cavallius, J. et al., 1993). Additional cellular 
interactions for the EF1-a protein have also been suggested. These include (1) a 
direct association with mRNA (as demonstrated by UV cross-linking studies; 
Greenberg, J. and Slobin, L., 1987), (2) an association with the Endoplasmic 
Reticulum by phosphatidyl inositol anchoring (Hayashi, Y. et al., 1989), and (3) an 
interaction with the actin cytoskeleton, in which Yang, F. et al. (1990) initially 
identified EF1-cc as an abundant actin-bundling protein in Dictyostelium discoideum. 
Previous analyses of human ribosomal factors which are reactive with SLE 
sera, reveal that the mainly targeted species are the P proteins (P0, P1 and P2), and 
28S rRNA (Section 1.3.5). In higher eukaryotes, the P proteins and 28S rRNA 
constitute a GTPase functional domain. Elongation factors (such as EF1-a) have 
been shown to interact with ribosomes, resulting in GTP hydrolysis. Consequently, 
the entire complex has been suggested to constitute a GTPase functional centre. 
Surprisingly, the yeast P protein homologues have not been identified as 
immunoreactive species in this study. In addition, the finding that the human P 
proteins largely contain linear epitopes (represented predominantly in the C-terminal 
22 amino acids, Table 1.3) suggests that the yeast homologues (in which these 
immunoreactive regions have been shown to be highly conserved) would be readily 
accessible to antibodies of this specificity in a cDNA library screen. Therefore, the 
higher eukaryotic ribosomal P proteins may not be targeted by autoantibodies in this 
particular SLE patient serum. 
However, serum Sm24# does react with four yeast translation-associated 
proteins, two of which reside in the 40S and 60S ribosomes. The two 
immunoreactive yeast elongation factors are both associated with the hydrolysis of 
GTP, in that YEF3 stimulates EF1—a, which in turn stimulates the GTP-dependent 
binding of aminoacyl-tRNA to the A-site of yeast ribosomes. The human 
homologues of rp59 and EF1—cx (YEF3 and YL14 human homologues have not yet 
been identified) have not previously been specified as autoantigens in SLE. Hence, 
autoantibodies present in serum Sm24# may target novel autoantigens within the 
GTPase functional centre of higher eukaryotes (other than those previously defined; 
the P proteins and 28S rRNA) possibly as a result of their functional and molecular 
association. 
It is interesting, that the region of the human 28S rRNA species (nucleotides 
1944-2002), which has been previously defined as predominantly immunogenic does 
not correspond to that identified as reactive in the yeast homologue (25S rRNA; 
nucleotides 3010-3242). This could signify that the 28S rRNA immunoreactive 
domain is (1) not targeted by antibodies in this particular serum, or (2) not conserved 
in the homologous yeast species. 
3.4.2 Heat Shock Proteins 
cDNAs contained within clone isolates 17 and 28(1) were found to encode 
heat shock proteins, HSP60 and HSP70 respectively. Heat shock proteins are 
extremely well conserved in evolution and have been categorised into three families, 
termed HSP60, HSP70 and HSP90. These species are involved in protein folding, 
transport and targeting as well as assembly of oligomeric structures (extensively 
reviewed by Gething, M.J. and Sambrook, J., 1992). HSPs were initially identified 
as a result of an increase in their cellular synthesis following heat shock. However, 
identical species exist, which are constitutively expressed. These have various 
cellular functions which are readily adapted during the heat shock response in order 
to protect the cell from damage. 
Yeast HSP60 is a constitutively expressed ATPase located in the 
mitochondrial matrix, which is essential for the assembly of proteins and 
macromolecular structures in these organelles (Cheng, M. et al., 1989). In addition, 
this factor may be involved in DNA replication or repair, since it has been 
demonstrated to be part of a tri-partite complex, termed SF1 (Stimulatory Factor I; 
Smiley, J.K., et at., 1992). This complex stimulates and controls the activity of 
DNA polymerase E. Interestingly, another factor which stimulates this enzyme is 
PCNA, the human homologue of which is occasionally targeted by SLE 
autoantibodies (Tan, E.M., 1989). Hence, two different species associated with 
DNA polymerase E (one in yeast, one in humans) are targeted by the SLE immune 
system. Furthermore, HSP60 may have a cytoplasmic function, since it has been 
shown to be chemically cross-linked to p21RAS  in vivo (Ikawa, S. and Weinberg, 
S.A., 1992). 
The HSP60 protein is extremely rich in lysine (9.4%), a property of many of 
the presently defined serum Sm24#-reactive species. Interestingly, the E. coli 
equivalent of HSP60 (GroEL) has demonstrated that the charge of such a residue 
(Lys-28) is critical in permitting subunit interaction, highlighting the functional 
importance of this amino acid in this species (Horovitz, A. et at., 1993). In view of 
the fact that SLE autoantibodies often target important functional domains of 
proteins/complexes, and the occurrence of many lysine-rich species identified here, 
both these HSP60 properties may be responsible for the isolation of this factor as 
immunoreactive. 
Proteins of the HSP70 family localise to different subcellular compartments, 
such as mitochondria, the lumen of the Endoplasmic Reticulum and the cytosol. 
HSP70 proteins bind short amino acid sequences and transiently impose a local 
conformation, while initiating constraints on target proteins and preventing 
interactions with aberrant proteins. 
The immunoreactive HSP70 protein identified here is encoded by the former 
of two highly similar genes, (SSB] and SSB2, 99% identical) and is cold-inducible. 
Nelson, R.J. et at. (1992), have isolated an ssbl mutant strain which is defective in 
translation elongation. Accordingly, it has been suggested that this species is 
associated with translating ribosomes and may bind the nascent polypeptide, 
facilitating its passage through the ribosome channel into the cytosol. However, 
upon activation of a dosage suppressor gene HBS], the defect of this ssbl mutant is 
reduced. The protein encoded by this gene, Hbslp is highly similar to EF1-U., 
particularly around the GTP binding and hydrolysis centres. This finding could 
imply a molecular interaction between SSB1 and EFl-oc proteins, both of which 
have been identified in this work. 
Higher eukaryotic HSP70 and HSP60 proteins have no apparent sequence 
similarity. Despite this, both species bind ATP, but have weak ATPase activity. 
Hydrophobic cluster analysis has predicted that there are certain structural 
similarities between these factors. If these similarities are conserved between yeast 
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and human members of each family, then the simultaneous isolation of the yeast 
HSP60 and HSP70 proteins could signify a shared structural epitope, which is 
responsible for their joint isolation. 
Some of the autoepitopes of the human HSP90 protein have been defined 
(Al-Dugayhm, A.M. et al., 1994, Table 1.3). The peptide sequences of serum 
Sm24#-reactive HSP species were studied for the presence of these epitopes. No 
such similar regions were found, possibly indicating that human/yeast HSP90 and 
yeast HSP60/70 species do not share epitopes. 
Autoantibodies in 50% of SLE sera have previously been documented as 
HSP90-reactive (Tan E.M., 1989; Table 1.1). HSP90 is an intracytoplasmic, actin-
binding species, which is responsible for holding intracellular steroid receptors in a 
conformation that prevents the latter from binding to nuclear DNA until the 
hormone/receptor action has occured. The levels of HSP90 and HSP70 (HSP72kDa 
precisely) have been shown to be elevated in SLE sera, specifically in peripheral 
blood mononuclear cells. However, the constitutively expressed HSP73kDa and 
HSP60 cellular levels were not found to be significantly altered (Dhillon, V.B. et al., 
1993). It has been established that some bacterial, viral or parasitic infections result 
in the release of certain HSPs (e.g. Mesocestoides corti, a parasite which is thought 
to release HSPs60/70 upon infection; Ernani, F.P. and Teala, J.M., 1993). 
Therefore, it is possible that the raised level of serum HSPs coincides with a higher 
autoantibody titre of this specificity, which may be a consequence of pathogenic 
infection. This sequence of events would comply with the theory of molecular 
mimicry. 
Heat shock proteins are extremely well conserved species from yeast to man. 
If the reactivity of serum Sm24# autoantibodies with these yeast factors reflects that 
with their human homologues, then (as with ribosomal factors) the immunoreactive 
HSP species identified here, differ from those previously specified as SLE 
autoantigens (HSP90). 
3.4.3 Membrane-Bound Species 
Several membrane-bound yeast proteins have been identified as 
immunoreactive species in this library screen. Clone 8(1)  cDNA encodes a protein of 
1 l9kDa, which undergoes self-splicing, yielding 69kDa and 50kDa species. The 
largest product (VMA1), is a vacuolar ATPase synthase, predicted to be involved in 
H+ ion transport and cytoplasmic Ca2+ homeostasis. The second species (VDE1), is 
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a site specific endonuclease which cleaves the TFP1L\VDE allele (reviewed by 
Grivell, L. A., 1992). 
Clone 7 cDNA yielded a sequence derived from the ITR2 gene. Two highly 
similar genes, ITRJ and ITR2 encode myo-inositol transporters in yeast, the latter 
expressed at a low level. The ITR2 gene product is a 67kDa integral membrane 
protein which belongs to the sugar transport family (Nikawa, J. I. et al., 1991). 
The product of the ENA] gene is an 120kDa Na transporting ATPase which 
has been identified as encoded by clone 13 cDNA. As with the ITR2 and SSB 1 
proteins, this immunoreactive species is a product of two highly similar genes 
(ENA] and ENA2), one of which (the latter) is expressed at a low level. The 
function of this membrane-spanning protein is thought to be magnesium-dependent 
hydrolysis of ATP coupled with the transport of sodium and lithium ions. The 
ENA1 protein also shows sequence similarity with plasma membrane, Ca2+ 
transporting ATPases (Garciadeblas, B. et al., 1993). 
3.4.4 Amino Acid Biosynthesis Enzymes 
Two enzymes involved in the cellular synthesis of amino acids, have been 
identified in this work as immunoreactive. Acetohydroxy reductoisomerase (AHRI) 
and serine hydroxy methyl transferase (SHMT2) were represented by the cDNAs in 
clone isolates 3/27 and 25(1), respectively. The former is a highly expressed, 
mitochondrial enzyme encoded by the ILV5 gene. This 44kDa hydrophilic species is 
involved in the biosynthesis of valine from isoleucine and contains arginine/lysine-
rich domains. In particular, the C-terminal 33 amino acids are extremely 
hydrophilic, containing 17 charged residues (Petersen, J.G.L. and Holmberg, S., 
1986). 
The SHM2 gene encodes the SHMT2 protein. This species is cytoplasmic 
and facilitates the interconversion of serine to glycine. As with other 
immunoreactive species identified here, there are two genes (SHMJ and SHM2) 
encoding highly similar products (McNeil, B.J. et al., 1994) 
3.4.5 Enzymes Involved in Glycolysis 
Two enzymes involved in the glycolytic pathway, have been identified in this 
library screen as immunoreactive yeast species. Clone 25(2) cDNA encodes part of 
the pyruvate decarboxylase enzyme which is the product of two yeast genes, PDCJ 
and PDC5. This enzyme controls the conversion of the end product of glycolysis 
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(pyruvate) to carbon dioxide and acetaldehyde. The PDC1 protein is highly 
expressed and forms a cytoplasmic homotetramer of 230-25OkDa (Kellermann, E. et 
al., 1986) 
Yeast enolase enzyme is a 47kDa species, encoded by two genes ENO] and 
EN02 (the products of which are 95% identical). Clone 26 cDNA was found to be 
derived from the latter gene. The function of enolase is to dehydrate 2-
phosphoglycerate to phosphoenolpyruvate in glycolysis. This enzyme is 
constitutively expressed and exists cytoplasmically as a homodimer (Franklyn, K.M. 
and Warmington, J.R., 1994). However, this species has also been identified as a 
heat shock protein, HSP48 (lida, H and Yahara, I., 1985). Two forms of this protein 
exist, one basic and one acidic. A mutation in the HSRJ gene was found to cause 
elevated expression of these two HSP48 forms (as well as four other protein species) 
resulting in a 1000 fold increase in resistance to lethal heat shock. On the basis of 
this information it has been postulated that yeast enolase (or HSP48) has an 
additional cellular role, other than that associated with glycolysis. It was also 
proposed that the differential expression of the two enolase genes (depending on 
nutritional supplements) and processing of their products may have biological 
significance. In addition, a limited identity at an amino acid level of HSP48 with the 
HSP70 proteins was found to exist, suggesting that these two species may be 
evolutionarily related. Hence, the isolation of the yeast enolase protein (HSP48) in 
this study may be a result of similarities with the HSP70 family, and attributed to the 
existence of a shared epitope. 
3.4.6 Miscellaneous Species 
Clone 23 cDNA encodes the product of the GL03 gene, which has recently 
been identified as a member of a novel zinc binding finger family. This species is 
highly similar to the Gcsl protein, which is thought to play a novel role in the 
resumption of yeast cell proliferation from stationary phase at 15°C. The latter is 
dispensable for continuous proliferation of actively growing cells at either the 
restrictive or non-restrictive temperature. Ireland, L.S. et al. (1994), propose that the 
Gcslp (and therefore possibly the Glo3p) may function in the progression from a 
starved stationary phase state, in a process which is inherently inefficient in the cold. 
A cDNA encoding Actin Binding Protein (ABP1p), was isolated as an 
immunoreactive yeast species (clone 35). This 66kDa protein is associated with the 
cortical actin cytoskeleton, a submembraneous protein network which is important 
for cell regulation, adherence and movement. ABP1p is an extremely hydrophilic, 
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acidic protein (p1 4.6) with a high proline content (11.2%). The C-terminal 50 
amino acids contain an SH3 domain, which is a motif present in many apparently 
unrelated protein species such as tyrosine kinases, phospholipase Cg, and a—
spectrin. Drubin, D.G., et al. (1990), have identified a related motif in myosin I and 
suggest that the SH3 domain may signify proteins which partake in the bringing 
together of signal transduction proteins, their targets and/or regulators to the 
membrane cytoskeleton. 
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3.5 	Analysis of Hypothetical Species (Category 2) 
Several cDNA sequences isolated in this library screen were identified in 
database searches as potential yeast open reading frames, encoding 'hypothetical 
proteins'. The isolation of these species as cDNA sequences acknowledges their 
existence as expressed genes, thereby verifying their identification as ORFs. Some 
of these proteins contain recognisable sequence motifs, associated with particular 
cellular functions. However, since their existence and properties remain speculative 
they are not considered as Identified Species (Section 3.4). These peptide sequences 
were analysed for snRNP protein characteristics, SLE epitopes (defined in Tables 1.3 
and 1.4) and identities with other species (Swissprot accession numbers are given 
where appropriate). In addition, these hypothetical proteins are discussed with 
respect to Category 1 species and SLE autoantigens. 
3.5.1 Properties of Hypothetical Proteins 
Clone isolates 8(2),  18, 24(1) and 22, yielded cDNA nucleotide sequences 
previously reported in the Genembl database. The predicted properties of the 
corresponding proteins have been summarised in Table 3.3. 
Table 3.3 	Predicted Properties of Category 2 Species 
Clone No. Predicted Properties 
Mass 
(kDa) 
p1 Primary sequence similarity with other 
 species 
8(2) 151 4.44 Yeast Uso 1 protein 
18 81 7.86 Disulphide isomerases 
22 108 1 	9.95 1 Helicases of the SNF2IRAD54 family 
24(1) 51 1 6.89 1 Structural proteins, ATPases, e.g.Dynein 
Clone 8(2)  cDNA is derived from an ORF encoding an 150kDa species, 
which is highly acidic (p1 of 4.44) and has similarity to the yeast Usol protein 
(14.9% identity over 669 amino acids; P25386). Genetic analysis of the USO] gene 
suggests that the corresponding protein is a cytoskeletal component, which has an 
essential role in protein transport from the Endoplasmic Reticulum to the Golgi, i.e. 
the yeast secretory pathway (Nakajima, H et al., 1991). 
Usoip is 206kDa and has a hyper-hydrophilic region at residues 469-487 
which also contains a Ca2+ binding loop consensus sequence (DxDxDGxxxxxE) of 
the EF hand (Davis, T.N. et al, 1986), implying that its function may be calcium 
regulated. However, the clone 8(2)  protein does not contain such a motif. The C-
terminal 1,100 amino acids of Usoip, and the species encoded by cDNA 8(2), 
identify strongly with cytoskeleton-related proteins, such as myosin (13.9% over 
residues 615-1110; heavy chain, P12882), neurofilaments and laminin (14.4% 
identity over 418 amino acids; beta—i chain, P07942). Therefore, the 
immunoreactive protein encoded by the clone 8(2)  cDNA may be associated with the 
cytoskeleton, but also involved protein transport. If the clone 8(2)  species is 
correctly described here, then it may represent the third cytoskeleton-related 
component identified in this work. 
There are three major cytoskeleton components in eukaryotic cells, actin 
filaments, microtubules and intermediate filaments. In secretory pathways, 
stabilisation of microtubules is required for transport of newly synthesised proteins 
from the trans-Golgi network to specific secretory vesicles (Kreis, T.E. et at., 1989) 
and for fusion of endocytotic transport vesicles with prelysosornal compartments 
(Gruenberg, J. et al., 1989). It has also been suggested that actin plays a role in 
secretion, especially the exocytotic step. Therefore, species associated with the 
cytoskeleton and those involved in protein biosynthesis may physically interact. 
Hence, the identification of both groups of factors in this work could be due to their 
functional interaction. 
The hypothetical protein encoded by the cDNA of clone isolate 18 has a 
molecular mass of approximately 81kDa and bears similarity to sequences of known 
disulphide isomerases, such as the ERP72 protein (22.5% over 120 amino acids; 
P13667). The latter may help other proteins to obtain their correctly folded 
conformation, a role similar to that of Heat Shock Proteins. Therefore, a property 
peculiar to HSPs and this immunoreactive species may be responsible for the 
identification of these factors in this work. 
Clone 22 cDNA yields a potential nuclear DNA helicase of 108kDa with 
predicted ATP/ssDNA binding abilities. This hypothetical protein has similarities 
with the RAD54/SNF2 family. The RAD54 protein (P32863) is involved in DNA 
repair and recombination and demonstrates 37.1% identity, over 551 amino acids 
with the clone 22 encoded species. The SNF2 protein (P22082) is a nuclear factor 
which shares an identity of 28.8% over 514 amino acids with the latter. SNF2p is 
one of ten subunits in the SWI/SNF complex, required for enhancement of 
transcription by many transcriptional activators in yeast. This species has a highly 
charged C-terminus, as does the clone 22 protein, in which one third of its C-
terminal 150 residues are polar. 
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Clone 24(1) cDNA encodes a species of 51kDa with a p1 of 6.89. As with 
many species identified here, the predicted amino acid sequence has a highly 
charged C-terminus, containing 11/27 polar residues. Database searches reveal that 
this protein has highest identities with (1) dynein f-chain (21.4% over 173 amino 
acids; Tripneustes gratilla, ciliary, P23098), a structural protein and an ATPase, and 
(2) a sodium ion channel of (21.9% over 114 amino acids; human skeletal muscle, 
(x-subunit, P35499). The clone 24(1) encoded protein may therefore have been 
isolated as a result of similarities with other species identified in this work, such as 
the Enal or Abpl proteins (Na+ transporting, ATPase and cytoskeleton- associated 
species, respectively). 
M. 
3.6 	Analysis of Novel Species (Category 3) 
Eleven cDNA isolates were found to be novel in their nucleotide sequences 
(four of which were derived from one cDNA sequence). The predicted peptide 
sequences were examined for defined epitopes (Table 1.3 and 1.4), snRNP protein 
properties/sequence characteristics and highly charged regions (underlined; Table 
3.4). No identities with snRNP proteins or SLE/snRNP autoepitopes were found. 
However, the protein predicted from clone 13 cDNA, showed a remarkable identity 
with a rat ribosomal protein, S5 (Section 3.6.1). 
Table 3.4 Predicted Primary Peptide Sequences of Category 
3 Species 
Clone Predicted Primary sequence 
10(j) KHEVEYDDHG . NKVLKKFENL. PDLISFKGYL. PELTVQLESQ. 
IETDMLLGMQ . MCFALISSIK. ERCEQWYSEQ . LNKLEKQYEL. 
EAOEREKKEO . AKFHGTKVTR. ESYLEWRSKF . ROELKLDERD. 
QVRRNKAHHG . KLTGKQMFEQ . GVVGTGDEYM. EEDDASVDDV. 
AKGLAKTEIA. NQ 
10(2) QDDIKYYAEN.NDDPDFIEYD.TIYEDMGCEI .QPSSSNNEAP. 
KEGNNQTSLJS . SIRSSKKOER. SPKKKAPRRD .VSISDRATTP. 
IAPGVESASQ. SISSTPTPVS . TDTPLHTVKD . DSIK 
13 TPVVLATPIP. EEVQQAQTEI . KLFNKWSFEE . VEVKDASLVD. 
YVQVRQPIFI . AHTAGRYANK. RFRKAQCPII . ERLTNSLNMN 
GRNNGKKLK7 . VRIIKHTLDI . INVLHDQNPI . QVVVDAITNT. 
QVV\JDAITNT . GPREDTTRVG. GGGAARRQAV. DVSPLRRVNQ. 
AIALLTIGAR. EAAFRNIKTI . AETLAEELIN . AAKGSSTSYA. 
IKKKDELERV. AKSNR 
2 and 14 , EF1NELTRKGF.LILEKYKNRI.WFISLPSYST.LSKIPFNAVK. 
(i) SSTINNNENW.VDCFFRARQL. LEEKQILDKI . SNVSFDSKAS. 
SEPSSPPPIS . RKERPLSIGN. NVTTLSYTAK . NGSQNNAPQN. 
1 and 32, DNVGEEKPFP. IPSSTKDRPG.ANSTPSSRHP.RVLSSNNAGE. 
(1-2) TPKKMNGRLP . NSAPSTNTYT . NGSVPAFNHR. PSTNVGNNKH. 
NILTSKKQGS. SVFSPSSCTT . KPQIKTTGYR. QPTPSPPLPQ. 
NEF2PTTREKY. SAPSNNVISS. SRYEVLHTLN . NSQTNFDREI. 
ASRGASAAFR.SLQKSKK KK 
24(2) VFGSCRNLNV.WPVGAVSKIT .VCKVSPSPCS . CLLMCFMTSM. 
KDKASSIPGM. EPVKSARAPP 
28(2) PPGKAKAVAE . OEKEAKAKEK. IAEPEPEPVP . TLQAKKEDIV. 
SNINESKDAN.SSDEEFAQSL . EAE 




3.6.1 Possible Identification of a Novel Ribosomal Protein 
Clone 13 cDNA (712bp) contains an open reading frame of 615 nucleotides, 
encoding a species of 205 amino acids. It is unclear whether this represents the 
entire transcript, as two potential methionine start codons reside 78 and 79 amino 
acids from the clone 13 cDNA-encoded N-terminus. Database searches indicated a 
striking homology with the rat ribosomal protein, S5 (X58465/P24050). An 
alignment of the clone 13 predicted primary sequence with the latter demonstrates 
69% identity (83% similarity), most prominent in the C-terminal region. If the 
homology of these two species is maintained at the N-terminus, then the initiation 
codon of the full length yeast species may lie only a few residues upstream of the 
cDNA sequence obtained (since the full length S5 species is 204 residues, whereas 
clone 13 encoded peptide is 205). The open reading frame of this (possibly 
incomplete) cDNA predicts a highly basic protein with an estimated p1 of 11.05. 
The rat S5 protein is a basic, phosphorylated, 40S ribosomal factor, which 
corresponds to the E. coli S7 protein (Kuwano, Y. et al., 1992). The bacterial 
species interacts with the 3' end of prokaryotic 16S rRNA. The joint identification 
of the yeast potential S5 homologue and 18S rRNA species in this work may signify 
that serum Sm24# has autoantibodies directed against the human homologues, 
indicating that these species (human S5 and 18S rRNA) may functionally or 
physically interact. If the clone 13 cDNA does encode a species which is a 
component of the 40S ribosomal subunit, then, as with those ribosomal species also 
identified here (rp59 and YL14) it is basic in nature and highly charged (27.7% of all 
residues are polar, including 10/14 C-terminal). 
3.6.2 Clone 14 cDNA Analysis 
The most frequently observed cDNA sequence in all categories of species, 
was that represented by clones 1, 2, 14 and 32. The corresponding nucleotide 
sequences were compared, revealing that clones 2 and 14 were identical in length 
and composition, except for a difference in polyA tail length (30 and 40 nucleotides 
respectively), thereby indicating independent origins. Clones 1 and 32 were found to 
contain the 5' 700bp of the clone 14 cDNA up to the internal in-frame EcoRI site. 
These 3' truncated cDNAs are probably the result of incomplete methylation of 
EcoRI sites during library construction (since the majority of cDNAs identified in 
this work were truncated at such sites). 
In order to confirm that the clone 14 cDNA did not contain any further 5' 
nucleotide sequence (which would have been eliminated as a result of the cloning 
technique used for this species), PCR (2.4.14) was performed using primers 386V 
and 387V (2.2.6). The product was digested with BamHI and Hindill, prior to 
ligation into pTZl8r (2.4.16). E. coli cells (NM522) were transformed with potential 
plasmid-containing constructs (pHK14) and selected by virtue of ampicillin 
resistance (2.3.2). Small scale plasmid preparations were made and assessed by 
diagnostic restriction analysis (2.4.4; 2.4.10). Phagemid DNA was prepared (2.4.6) 
and sequenced with M13 reverse and clone 14 cDNA-specific primers (2.4.12). 
Sequencing of plasmid pHK14 revealed that the 5' EcoRl site was indeed the 
position of clone 14 cDNA termination. 
The predicted peptide and nucleotide sequences of the clone 14 associated 
cDNAs are represented in Table 3.4 and Figure 4.4. Primary protein sequence 
predictions deduced from clones 2 and 14 suggested that this cDNA may be 
incomplete at its 5' end, since only one open reading frame was found, which 
contained its first methionine initiation codon 493 nucleotides from the 5' end 
(position 598 in Figure 4.4). This peptide (possibly incomplete) demonstrated no 
significant identities with nucleic or amino acid sequences in the Genembl or 
Swissprot databases, respectively. 
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3.7 Summary 
Thirty-six yeast peptide sequences, derived from amplified cDNA sequences 
were isolated in a screen of a yeast cDNA ?gtl 1 library with an SLE serum 
(Sm24#). Twenty-one species were found to be encoded by previously reported 
yeast genes (Category 1), whereas four cDNAs corresponded to identified DNA 
sequences, from which potential ORFs had been suggested to exist (Category 2). 
The isolation of these cDNAs therefore verifies the existence and expression of the 
corresponding yeast genes. The remaining 11 cDNAs failed to identify with any 
reported DNA or protein sequences. Therefore, these cDNAs may encode novel 
yeast species (Category 3). 
Eight of the identifiable yeast species are known to be associated with the 
translation apparatus. Previous analyses of higher eukaryotic SLE-reactive 
ribosomal factors, have revealed that the P proteins and 28S rRNA are 
predominantly targeted by serum autoantibodies (Elkon, K. et al., 1985; Uchiumu, 
T. et al., 1991). The specificity of autoantibodies in serum Sm24# towards 
ribosome-associated components appears to differ from that previously observed, as 
the 25S rRNA (the yeast homologue of 28S rRNA) is the only factor commonly 
isolated. 
Two SLE-reactive heat shock proteins have been isolated, HSP60 and HSP70 
(the latter possibly associated with translating ribosomes). Another candidate for 
such a species is the product of the ENO] gene, which has been jointly identified as 
the glycolytic enzyme enolase and HSP48. The latter demonstrates an amino acid 
similarity with the HSP70 proteins, suggesting that a shared epitope may be 
responsible for the isolation of these factors in this work. Furthermore, the clone 18 
encoded species has similarity to disulphide isomerases, which could signify that the 
cellular role of the former is similar to that of heat shock proteins, since both 
facilitate the correct conformation of newly synthesised proteins. 
On the basis of extensive amino acid identities with Usoip, myosin and 
laminin, the clone 8(2)  encoded species may be associated with the cytoskeleton. It 
has been postulated that cytoskeleton components may play a role in transport of 
newly synthesised proteins through the secretory network and therefore it is possible 
that the former may physically interact with translating ribosomes and/or species 
involved in facilitating protein conformation (HSPs). Therefore, the isolation of 
HSPs, cytoskeleton and translation-associated elements (such as ABP1p and EF1-U) 
in this work, may reflect the molecular or functional interaction of these species as 
protein biosynthesis factors in humans. 
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It is interesting that many of the yeast species isolated are highly conserved 
and encoded by more than one gene, one of which is usually more highly expressed 
than the other. In addition, some species are synthesised only under certain cellular 
conditions, e.g. heat shock, low temperatures or nutritional starvation. It is tempting 
to speculate that a factor peculiar to conditionally expressed species, perhaps a novel 
post-translational modification (or some other collective specificity) has contributed 
to their isolation. The frequent observation that a prokaryotically (or synthetically) 
expressed protein will not react with SLE sera, whereas an eukaryotically expressed 
species will, supports this suggestion. Indeed, a post-translational modification has 
been propsed to be a partial requirement for the reactivity of some Sm protein 
autoepitopes (Hirakata, M. et al., 1993; Section 1.3.6.5.1). 
Many of the yeast species identified here are lysine-rich. It is possible that a 
modification particular to some lysine residues is related to gene expression. An 
example of one such relationship in yeast is provided by the histone H4 protein. A 
deletion mutant removing amino acids 4-19 has been shown to be viable, while 
dramatically affecting the expression levels of the HML gene (Mullen, J.R.et al., 
1989). The N-terminal region of this histone species (an SLE autoantigen in humans 
containing autoepitopes within this region, Section 1.3.1) contains four acetylated 
lysine residues. When these are substituted for glutamine, HML becomes 
derepressed (Megee, P.C. et al., 1990). Furthermore, the sole replacement of the 
fourth lysine residue with alanine results in the derepression of HMLo (Park, E. -C. 
and Szostak, J.W., 1990). Hence, the substitution of this lysine residue and/or an 
associated modification influences the expression of another gene. In view of the 
variably expressed, lysine-rich, highly conserved nature of many species identified 
in this work, it could be suggested that an aberrant post-translational modification on 
such residues may specifly some targets of SLE and play a role in the etiology of this 
autoimmune disease. 
In summary, cytoplasmic yeast species appear to be the main targets of 
serum Sm24# antibodies, particularly components of the translation apparatus. 
Species involved in the ensuing cellular processes of protein transport and complex 
assembly may also be targeted, as heat shock protein and cytoskeleton-associated 
factors were also isolated. Many of the species identified are especially rich in 
lysine and/or have highly charged C-terminal regions. This may signify that the 
charge of residues and not exact amino acid sequences are critical requirements for 
reactivity with SLE autoantibodies. 
The hypothetical and novel yeast species isolated did not display obvious 
primary sequence or autoepitope identities with mammalian snRNP proteins. 
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Therefore, further analyses were centred on the most frequently occurring and 
therefore possibly most antigenic peptide sequence, that encoded by clone 14. 
102 
CHAPTER 4 
The Identification of a Novel Yeast Gene (SM14) 
4.1 	Introduction 
An attempt has been made to verify the existence of the SM14 gene on the 
yeast genome by Southern blot analysis. In addition, inverse PCR was employed in 
generating a product containing the genomic flanking sequences of SM14. This PCR 
product was cloned into a phagemid vector, from which flanking SM14 sequences 
were obtained. In conjunction with information previously obtained from lambda 
clone isolates, the flanking sequences were used in predicting the complete 
nucleotide sequence of the SM14 gene and the corresponding amino acid sequence 
of the SM14 protein. Northern blot analysis was performed in order to identify the 
SM14 gene transcript. The nucleotide sequences at the SM14 locus and predicted 
primary sequence of the SM14 protein have been analysed. 
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4.2 	The SM14 Gene is Single Copy 
Southern blot analysis was performed. Figure 4. 1(A) represents a restriction 
map of the yeast SM14 locus, as predicted from the Southern blots shown in Figure 
4.2(A)l and (A)2. Yeast genomic DNA was digested with Dral (2.4.10) and 
subjected to Southern blot analysis (2.4.8)(2.4.18) with Probe 1 (Figure 4.2(A)2). 
The presence of a single band suggests that the entire clone 14 cDNA sequence is 
contained within a genomic fragment of approximately 1.9kb. Subsequent analysis 
(also with Probe 1) of EcoRI digested genomic DNA, revealed two radiolabelled 
fragments, one of which approximated to 0.72kb, the other greater than 6kb (Figure 
4.2(A)1). The former species is similar in size to the fragment derived from an 
EcoRI digest of the clone 14 cDNA sequence (0.723kb). In view of the frequent 
occurence of cDNA sequences isolated in the library screen, which terminate at their 
5' ends at genomic EcoRI sites, it is possible that the EcoRI site labelled E1 in 
Figure 4.1(B) represents such a genomic DNA site at the SM14 locus. An alternative 
explanation is that an EcoRI site lies upstream and very close to the 5' end of the 
SMI4 cDNA. 
Double digests of yeast genomic DNA with EcoRI and DraI, followed by 
Southern blot analysis with Probe 1, demonstrate two species of approximately 
0.72kb and 0.92kb (Figure 4.2(A)1). The latter represents an EcoRI-D raT fragment 
(since an EcoRI digest yields a 0.72kb fragment) which contains the 3' end of the 
SMI4 cDNA. A digest with restriction enzymes EcoRI and XbaI, yields a band of 
approximately 0.72kb, which actually represents two species (since complete 
digestion with EcoRI has been shown to generate 0.72kb and >6kb fragments), a 
0.72kb EcoRI and a 0.72kb EcoRI-XbaI fragment (Figure 4.2(A)1). The second 
fragment contains the 3' end of the SM14 gene, the XbaI site of which is predicted to 
be located 0.38kb (0.72-0.34kb) downstream from the SM14 gene transcription 
termination site. 
As the entire clone 14 cDNA sequence is located within a 1.9kb DraI DNA 
fragment, the upstream EcoRI-Dral region is predicted to be approximately 0.26kb 
in length (1.9kb-(0.72+0.92)) as calculated from EcoRIIDraI digests. The 
approximate restriction site locations (within 0.2kb) at the SM14 locus have since 
been confirmed by sequencing of a genomic inverse PCR product (Section 4.3). 
These results suggest that SM14 is a single copy gene. 
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Figure 4.1 Physical Map of the SM14 Locus, Lambda Clone 14 and 
Associated PCR Products 
A restriction map of the yeast SM14 locus, predicted from Southern 
blot analysis. Relevant restriction enzyme sites EcoRI (E), DraI (D) and XbaI (X) 
and approximate distances (kb) are indicated. 
A restriction map of the clone 14 isolate, showing fragments 
generated by PCR and EcoRI (E) digestion, which were used to probe Southern and 
Northern blots (Probes 1 and 2 respectively). Primers (199/200 or 386v/387v) used 
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Figure 4.2(A)1 	Southern Blot 
Genomic DNA was prepared from yeast cells (strain DJY84). DNA was 
digested with restriction endonucleases EcoRI (E), EcoRI/XbaI (EIX), EcoRJIDraI 
(E/D) or EcoRJIBg1I (E/B) and electrophoresed through an agarose gel (0.8%(wlv)), 
before Southern blotting was performed. The blot was probed with Probe 1 (Figure 
4.1(B)). DNA size markers (kb) are indicated. 
Figure 4.2(A)2 	Southern Blot 
Genomic DNA was prepared from yeast cells (strain DJY84). DNA was 
digested with restriction endonuclease Dral (D), and electrophoresed through an 
agarose gel (0.8%(w/v)), prior to Southern blotting. The blot was probed with Probe 
1 (Figure 4.1(B)). DNA size markers (kb) are indicated. 
Figure 4.2(B) 	Northern Blot 
Total RNA was prepared from yeast cells (strain DJY84) and subjected to 
agarose gel electrophoresis and Northern blotting. The blot was probed with Probe 2 
(Figure 4.1(B)) or a pYA301 (Actin gene) fragment (BamII-BglII). The sizes of the 
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4.3 	Inverse PCR Yielded the SM14 Flanking Sequences 
Southern blot analysis (Section 4.2) predicted that a 1.9kb Dral genomic 
fragment contained the SM14 cDNA as well as 0.26kb and 0.38kb of 5' and 3' 
flanking sequence respectively. In an attempt to determine the upstream sequences 
of this gene and therefore the complete SM14 protein primary sequence, inverse 
PCR was employed in generating a product which contained these flanking regions. 
The strategy for inverse PCR is outlined in Figure 4.3. Yeast genomic DNA 
was digested with Dral (2.4.10), prior to circularisation (ligation at high 
dilution)(2.4.15). Primers homologous to regions close to the SM14 cDNA termini 
were synthesised. These primers (090Y and 091Y) contained Sail restriction tails, 
which facilitated cloning of the inverse PCR product. This restriction enzyme was 
chosen since sequencing and restriction analysis of the SM14 cDNA had indicated 
no such site present in this species. PCR was performed using these primers, 
generating a linear species of 1.0kb (2.4.14). This product, IPP-SM14 (Inverse PCR 
Product-SM14) was digested with Sail and ligated into appropriately digested 
pTZl8r (2.4.16). E. coli cells (NM522) were transformed (2.3.2) with this phagemid 
construct (pIPP-SM14), from which small scale plasmid preparations were made 
(2.4.4) and assessed by diagnostic restriction analysis (2.4.10). Single-stranded 
DNA was prepared from pIPP-SM14 bearing cells (2.4.6), which was sequenced 
using primers 090Y, A020, A345 and A390 (2.4.12). Analysis of the sequences 
obtained, confirmed part of the previously identified SM14 cDNA sequence as well 
as providing novel upstream and downstream flanking nucleotide sequences. This 
additional information enabled the sequence of the entire 1.936kb Dral fragment to 
be determined. Analysis of the SM14 gene locus is discussed in Section 4.4. 
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Figure 4.3 	Inverse PCR Strategy 
Yeast genomic DNA was digested with Dral (D) and circularised. Inverse 
PCR was carried out on the total ligation reaction using primers 090Y and 091Y. 
This generated a 1kb Inverse PCR Product (IPPSM14). Relevant restriction sites, 
EcoRI (E), Sail (S), and DraI (D), primers (090Y, 091Y, A020, A345, A390) and 
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4.4 	The SM14 Gene Locus 
The nucleotide and primary peptide sequences pertaining to the 1.936kb Dra 
I fragment were analysed as described below. 
4.4.1 Analysis of the Nucleotide Sequence 
The 1.936kb sequence illustrated in Figure 4.4 contains one open reading 
frame of 1005 nucleotides, with 5' and 3' flanking regions of 179 and 757 
nucleotides respectively. A putative 'TATA' box element has been identified at 
nucleotide position -85 and a possible transcription start site at -51 (Hahn, S. et al., 
1985; Guarente, L. 1987. The 5' flanking sequence of the SM14 cDNA contains 
four possible in-frame translation initiation codons, all of which differ markedly 
from the accepted consensus sequence 5'-AIYAA/TAAATGTCT-3' (Cigan, A.M. 
and Donahue, T.F., 1987; Table 4.1). The most 5 of these (assumed as the authentic 
initiation codon) is downstream of nonsense codons at positions -60, -90, -93, -102, 
-141 and -177. 
Table 4.1 
Nucleotide Position 
(A of ATG; Figure 4.4) 






Consensus Sequence A/YAA/TAAATGTCT 
The translation termination codon of the designated SM14 ORF resides at 
nucleotide position +1003 (TAA). As deduced from SM14 eDNA analysis, the 3' 
untranslated region of the transcript corresponds to 167 nucleotides. In comparison 
with the consensus for yeast transcription termination signals, as reported by Zaret, 
K.S. and Sherman, F. (1982), this region of the SM14 gene complies with the 
majority of these requirements (Table 4.2). 
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Figure 4.4 The Sequence of the SM14 Locus 
The sequence of the 1.936 kb Dral fragment was obtained from the cDNAs 
of clones 1, 2, 14 and 32, in addition to that provided by plasmid pIPP-SM14. The 
predicted primary sequence of the SM14 protein is shown below the corresponding 
nucleotide sequence. A potential TATA?  box element (TAATTA), translation 
initiation/termination codons (ATG/TAA), transcription start (AATTAAA) and 






Net Leu Ser Tyr Lys Asn Thr Val Met Glu Gly Asn Asp Asp Gin Glu Asn 17 
1 ATG TTA AGT TAC AAA AAC ACA GTT ATG GAG GGA AAT GAT GAT CAA GAA AAC 
Lys Glu His Gin Met Ala Asn lie Glu Asp Thr Asp Leu Ser Met Tyr Asp 34 
52 AAA GAA CAC CAG ATG GCT MT ATA GAA GAT ACA GAC TTG TCC ATG TAC GAT 
Phe Glu Phe Asn Glu Leu Thr Arg Lys Gly Phe Leu lie Leu Glu Lys Tyr 51 
103 TTT GAA TTC AAT GAG TTG ACA AGG AAG GGT TTT TTA ATC CTG GAA AAA TAT 
Lye Asn Arg lie Trp Phe lie Ser Leu Pro Ser Tyr Ser Thr Leu Ser Lys 68 
154 AAG AAT AGA ATA TGG TTT ATC TCG CTA CCT TCA TAT TCA ACG TTA TCC AAA 
Ile Pro Phe Asn Ala Val Lye Ser Ser Thr lie Asn Asn Asn Glu Asn Trp 85 
205 ATA CCA TTC AAT GCC GTG AAG TCT TCG ACA ATA AAT AAC AAT GAA AAT TGG 
Val Asp Cys Phe Phe Arg Ala Arg Gin Leu Leu Glu Glu Lys Gin lie Leu 102 
256 GTC GAT TGC TTT TTC AGA GCA AGA CAA CTA CTA GAA GAA AAG CAA ATT CTT 
Asp Lys lie Ser Asn Val Ser Phe Asp Ser Lys Ala Ser Ser Glu Pro Ser 119 
307 GAT AAA ATC AGT AAC GTT TCC TTT GAT AGT AAG GCA TCG AGT GAA CCA TCA 
Ser Pro Pro Pro lie Ser Arg Lys Glu Arg Pro Leu Ser lie Gly Asn Asn 136 
358 TCA CCT CCG CCT ATT TCA AGA AAA GAG CGG CCT CTG AGT ATA GGA AAT AAT 
Val Thr Thr Leu Ser Tyr Thr Ala Lye Asn Gly Ser Gin Asn Asn Ala Leu 153 
409 GTA ACA ACA CTC AGC TAT ACT GCA AAA AAT GGA AGC CAG AAC AAT GCA CTA 
Gin Asn Asp Asn Val Gly Glu Glu Lys Pro Phe Pro lie Pro Ser Ser Thr 170 
460 CAA AAC GAT AAT GTT GGA GAP GAA AAA CCT TTT CCC ATA CCT AGT AGT ACC 
Lys Asp Arg Pro Gly Ala Asn Ser Thr Pro Ser Ser Arg His Pro Arg Val 187 
511 AAG GAT AGG CCC GGT GCA AAT TCC ACT CCT TCT TCA AGA CAT CCT AGG GTT 
Leu Ser Ser Asn Asn Ala Gly Glu Thr Pro Lys Lys Met Asn Gly Arg Leu 204 
562 TTG TCA AGC AAT AAC GCT GGT GAA ACT CCG AAA AAA ATG AAT GGA AGA TTA 
Pro Asn Ser Ala Pro Ser Thr Asn Thr Tyr Thr Asn Gly Ser Val Pro Ala 221 
613 CCA AAT AGT GCA CCT TCT ACC AAT ACA TAT ACC AAC GGT TCG GTC CCA GCT 
Phe Asn His Arg Pro Ser Thr Asn Val Gly Asn Asn Lys His Asn lie Leu 238 
664 TTT AAT CAT AGG CCT TCT ACT AAT GTA GGG AAC AT AAG CAT AAT ATT TTA 
Thr Ser Lye Lys Gin Gly Ser Ser Val Phe Ser Pro Ser Ser Cys Thr Thr 255 
715 ACT TCG AAG AAG CAG GGA TCA TCC GTA TTT TCT CCT TCA TCT TGT ACG ACC 
Lye Pro Gin lie Lys Thr Thr Gly Tyr Arg Gin Pro Thr Pro Ser Pro Pro 272 
766 AAG CCT CAA ATC AAA ACA ACA GGA TAT CGA CAG CCG ACA CCT TCA CCT CCA 
Leu Pro Gin Met Glu Phe Pro Thr Thr Arg Glu Lye Tyr Ser Ala Pro Ser 289 
817 CTT CCG CAA ATG GAA TTC CCA ACT ACG AGA GAA AAG TAT TCT GCT CCT TCT 
Asn Met Val lie Ser Ser Ser Arg Tyr Glu Val Leu His Thr Leu Asn Asn 306 
868 AAC ATG GTG ATC AGT AGC AGC AGA TAC GAG GTC TTA CAT ACC CTT AAT AAC 
Ser Gin Thr Asn Phe Asp Arg Glu lie Ala Ser Arg Gly Ala Ser Ala Ala 323 
919 AGC CAA ACA AAC TTT GAT AGG GAA ATT GCT AGT AGG GGT GCC TCA GCA GCA 
Phe Arg Ser Leu Gin Lye Ser Lys Lye Lye Lye Stop 334 
970 TTT AGA AGT TTA CAG AAG AGT AAG AAA AAA AAA TAA CACGCTTTAATAATATTTG 
1025 TGGTTCCTCTACTTCGAA.ACAAAAAATATGCACGAGTTGTTGACGATCCAGAAAAACCAACATATAA  
1092 ATCATATCCAACCCTTGCATTAATATCCGTATCACTTTATTCAGA1TGCATGTATTTTAT 
11 59 ATATGCCCAGTATATCTTCGATTGAAGCTCTTCGGCATTAGTGCATTGTATTCAAGCAATGAAT 
1226 GCCAAACTAATAAAACTATCAAGACGACAATAAGAGTCCTATACAACAATCGTCGTATTTTTCTT 
1293 TATTTTTTTCGTAGACCCATTCCAATTGCCTACGACCTCTAGCCAGTTATTTACCACCGTCCATA 


















Nucleotide 1003 1011-1023 1110 1131 1151 1209 
Postition 1 (TAA) 1 	(8/13 nts.) I  
In view of the predominance of ribosomal factors identified in the library 
screen, ribosomal protein gene characteristics were studied. A consensus sequence 
for a transcriptional control element has been identified, ACACCCATACATTT 
(Planta, R.J. and Raue, H.A., 1988), and is often located upstream of such genes. 
This sequence is not present in this region of the SM14 gene, however a similar 
sequence is found at +629 (5CTACCAATACATAT3), indicating that such a gene 
may lie downstream of the SM14 locus. 
4.4.2 Codon Usage within the SM14 ORF 
It is possible to estimate the level of expression of any given gene from the 
codon bias of a particular open reading frame (Sharp, P.M. et al., 1986). The index 
of codon bias has been calculated for the predicted SM14 sequence and suggests an 
extremely low level of expression for this gene (Table 4.3). This finding implies that 
the isolation of the 5M14 cDNA on four occasions in the Sm24# library screen is 
due to a strong autoantibody-SM14 interaction and not an abundance of the SM14 
transcript (reflecting a high level of gene expression). 
4.4.3 Analysis of the Predicted SM14 Amino Acid Sequence 
The predicted primary sequence of the SM14 protein is illustrated in Figure 
4.4. The putative protein contains 334 amino acids and has a calculated molecular 
mass of 37.3kDa. This species is extremely basic, a fact reflected in its estimated p1 
value of 10.46. In addition, the protein is extremely rich in serine residues (47/334; 
14%). 
Using the UWGCG facility of SERC SEQNET, the nucleotide and protein 
sequences were submitted to TFASTA and FASTA programmes, which search the 
Genembl and Swissprot databases respectively. No significant identity with any 
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known nucleotide or protein sequence was found. In addition, the SM14 protein 
sequence was compared with all known eukaryotic snRNP-associated proteins using 
the programmes GAP and BESTFIT, in an attempt to locate any regions of similarity 
or identity, perhaps not detected by the database searches. The SM14 protein does 
not contain any of the defined epitopes (Table 1.3 and 1.4), characteristic of Sm 
proteins or long stretches of highly charged amino acids, which are incidental in 
many SLE autoantigens or common/specific.snRNP proteins. 
4.5 	Northern Blot Analysis 
Total RNA was prepared from yeast cells (DJY84)(2.4.20) and 
electrophoresed through a denaturing agarose gel (2.4.21). Northern blot analysis 
(2.4.22) with Probe 2 indicates a major SM14 transcript of 1.3kb, and a minor 
transcript of 1.6kb (Figure 4.2(13)). The predicted size of SM14 transcript, as 
deduced from cDNA and genomic DNA (derived from inverse PCR) sequences 
suggest a species of 1.285kb. The additional minor transcript is not a product of a 
second SM14 gene, since Southern blot analysis clearly defines the SM14 gene as 
single copy (Section 4.2). The presence of the second transcript can be explained in 
one of two ways; (1) the SM14 gene has an additional associated transcript, which is 
expressed at a low level (hence the weak signal), or (2) there exists an adjacent gene, 
the transcript of which overlaps that of the SM14 gene. In the latter case, the 
strength of signal may not be indicative of the level of expression of this gene, but 
the degree of overlap with the probe. 
Nucleotide sequence analysis of the 1.9kb fragment (Section 4.4.1), reveals 
no other significant open reading frame overlapping that of the SM14 transcript, in 
either direction. However, it remains plausible that a transcript is spliced into the 
SM14 gene, in which case it would be expected that certain splice site signals (5' 
splice site; GTATGT, or branch point sequence; TACTAAC) would occur within the 
1.9kb fragment. The SM14 locus contains no such signals, however the downstream 
complementary region (representing a converging gene), has a 5' splice site signal 
(nucleotide position +1509, ACATAC in Figure 4.4). This region is considered in 
more detail in Section 4.6. 
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Gly 1/4 13 3.25 5 
Phe 1/2 14 7 4 
Leu 1/6 19 3.16 3 
Ile 2/3 15 10 9 
Val 2/4 12 6 7 
Ser 2/6 47 15.6 13 
Pro 1/4 28 7 7 
Thr 2/4 25 12.5 11 
Tyr 1/2 9 4.5 3 
His 1/2 5 2.5 1 
Gin 1/2 12 6 7 
Asn 1/2 35 17.5 12 
Lys 1/2 27 13.5 13 
Glu 1/2 19 9.5 15 
Cys 1/2 2 1 1 
Arg 1/6 17 2.83 9 
Ala 2/4 15 7.5 7 
TOTAL  314 1 	129.34 127 
Codon Bias Index (C.B.I.) = C-B, where A=Total codon number 
A-B 
B=Expected codon preference number 
C=Observed codon preference number 
	




4.6 	Analysis of the Regions Flanking SM14 
In order to explain the occurence of two SM14 associated transcripts, an 
analysis of the flanking regions of the SM14 gene was undertaken. The 5' region is 
too small to examine any yeast gene transcription/translation signals. However, the 
3' region appears to contain a short open reading frame of 267 nucleotides (on the 
opposite strand), encoding a putative protein of 89 amino acids, which is flanked by 
such yeast signals. The nucleotide and amino acid sequences of this potential gene 
(DSTR) and possible gene-defining elements are presented in Figure 4.5. The 
predicted translation start and stop signals of this ORF reside at positions +222 and 
+489 in Figure 4.5, respectively (+1535 and +1266 in Figure 4.4). The ORF of this 
gene has a calculated Codon Bias Index of 0.133, indicating a gene which is not 
highly expressed. The putative DSTR protein has a predicted molecular mass of 
lOkDa, an estimated p1 of 4.36 and is highly charged. Database searches fail to 
identify this sequence with those previously reported. 
The transcript of this putative gene, (1) would be predicted not to overlap that 
of the SM14 gene and (2) would not be detected by Northern blot analysis with 
Probe 2. Therefore, the potential DSTR transcript would not explain the presence of 
a second (minor) SM14 transcript. 
IMM 
Figure 4.5 The Sequence of the putative DSTR Locus 
The nucleotide and predicted primary peptide sequences pertaining to the 
putative DSTR gene are illustrated. Possible gene-defining elements (as for Figure 
4.4) have been highlighted and underlined. 
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Figure 4.5 




Net Ala Glu Asn Asn Asp Gly Gly Met Ser Asn Pro Phe Gin Glu Gin Met 17 
222 ATG GCT GAG AAC AAT GAT GGT GGT ATG TCC AAT CCG TTT CAG GAA CAA ATG 
Leu Arg Glu Gin Asp Val His Leu Asp Gly lie His Lys Thr Met Gin Asn 34 
273 TPA AGA GAA CAA GAT GTT CAT TTA GAT GGT ATT CAC AAG ACA ATG CAA AAT 
Leu His lie Gin Ala Gin Thr Met Gly Asp Glu Leu Glu Asn Gin Gly Gin 51 
324 TTG CAT ATT CAA GCT CAA ACA ATG GGG GAT GAA TTA GAG AAC CAG GGA CAA 
Leu Leu Asp Asn Met Asp Glu Gly Met Asp Gly Val Val Asn Asn Trp Leu 68 
375 TTG TTG GAT AAT ATG GAC GAG GGT ATG GAC GGT GTT GTA AAT AAC TGG CTA 
Glu Val Val Gly Asn Trp Asn Gly Ser Thr Lys Lys lie Lys Lys Asn Thr 85 
426 GAG GTC GTA GGC AAT TGG AAT GGG TCT ACG AAA AAA ATA AAG AAA AAT ACG 
Thr lie Val Val Stop 	 89 






The experiments described in this chapter confirm by Southern blot analysis 
the existence of a single copy SM14 gene on the yeast genome. Northern blot 
analysis suggests a major SM14 transcript of 1.3kb (compatible with the size 
predicted from the calculated ORF and cDNA), with an additional minor species of 
1.6kb. The entire sequence of the SM14 gene has been compiled from the cDNAs 
isolated in the library screen and information supplied by a genomic inverse PCR 
product. This has enabled the prediction of the primary sequence of the SM14 
protein, which has been analysed for snRNP protein characteristics (by comparison 
of primary sequences) and properties of eukaryotic snRNP proteins. No significant 
similarities were found with these or indeed any other proteins. 
Coincidentally, sequence analysis of the downstream region of SM14 gene 
may have led to the discovery of a novel gene (DSTR), on the basis of an ORF 
flanked by transcription and translation initiation/termination signals. 
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CHAPTER 5 
Raising Antisera to the SM14 Protein; Characterisation of this and Serum 
Sm24# 
5.1 	Introduction 
This chapter describes the generation of two SM 14 fusion proteins in E. coli. 
Purified -ga1actosidase-SM14(33) fusion protein was used in the immunisation of 
rabbits, from which anti-SM14 sera were obtained. A TrpE-SM14(33) fusion protein 
enabled affinity purification of SM 14(33) antibodies from these sera. The full length 
SM14 protein (SM14(37)) was conditionally expressed in yeast. In addition, a 
candidate for the endogenously expressed SM14 protein has been identified by 
immunoblotting. The reactivities of anti-SM14 rabbit sera and human serum Sm24# 
with yeast and E. coli protein extracts containing various SM14 species were 
examined by immunoblot and immunoprecipitation analysis. 
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5.2.1 Construction of Plasmids which Express SM14 Fusion Proteins in E. coli 
The clone 14 cDNA sequence was amplified by PCR and used to generate 
the plasmid constructs described in Figure 5.1(A). Plasmids pUR288-SM14 and 
pATH3-SM14 express 897 nucleotides of the SM14 sequence in E.coli as - 
galactosidase-SM 14(33) and TrpE-SM14(33) fusion proteins respectively. The fusion 
proteins contain the C-terminal 299 amino acids (33kDa) of the SM14 protein. For 
this reason, they are designated SM14(33). 
The pUR vectors contain the E. coli LacZ gene with frame shift multiple 
cloning sites at the 3 end. This enables the fusion of any open reading frame with 
that of the LacZ gene, facilitating the production of a 3-galactosidase fusion protein. 
The incomplete SM14 coding region was amplified by PCR from lambda clone 14, 
using primers 386V/387V (2.4.14). The PCR product was digested with BamHI and 
HindIII and ligated into appropriately digested vector pUR288 (2.4.16). E. coli 
clones (BMH71-18) containing the SM14-construct were isolated (2.3.2), from 
which small scale plasmid preparations were made (2.4.4) and checked by diagnostic 
restriction analysis (2.4.10). 
The pATH series of vectors contain the E. coli TrpE gene with frame shift 
multiple cloning sites at the 3 ends. The BamHI-HindIII fragment from the 
pUR288-SM14 construct was cloned in pATH3 (2.4.10; 2.4.11), a vector which 
permits expression of the SM14 ORF in the same frame as that of TrpE. Cells 
(HB 10 1) containing this pATH3-SM14 construct were obtained (2.3.2), from which 
small scale plasmid preparations were made (2.4.4) and analysed by restriction 
digestion (2.4.10). 
E. coli cells containing pUR288-SM14, pATH3-SM14 or pATH3 were 
induced for 3-gal-SM14(33), TrpE-SM14(33) or TrpE synthesis respectively (2.5.2; 
2.5.3). Aliquots were subjected to SDS -poly acrylamide gel electrophoresis 
(8.5%(wlv) acrylamide; 2.5.6), before visualisation with Coomassie blue stain (2.5.7) 
which confirmed expression of the fusions as 149kDa (3-gal-SM14(33)) and 70kDa 
(TrpE-SM14(33)) species. 
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Figure 5.1 	Construction of Plasmids which Facilitate Expression of: 
3-galactosidase/TrpE-SM14 fusion proteins 
PCR was performed on lambda clone 14 using primers 386V and 387V. The 
SM14 cDNA-containing product was digested with BamHI (B) and HindIII (H), and 
transferred into appropriately digested pUR288 or pATH3, using the multiple 
cloning sites (MCS) present in the LacZ and TrpE genes respectively. The SM14 
cDNA-associated EcoRI sites (El, E2, EX) are shown. 
The SM14-plasmid constructs (pUR288-SM14 and pATH-SM14) and 
predicted molecular masses of their corresponding fusion proteins (149 and 70kDa, 
respectively) are also indicated. 
SM14(37) Protein 
PCR was performed on yeast genomic DNA with primers C864 and C864. 
The position of these primers with respect to the predicted SM14 ORF is illustrated. 
The PCR product was digested with BamHI (B) and Sail (S), prior to ligation into 
appropriately digested pBM 125. The GAL] gene and SM14 cDNA sequence present 
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5.2.2 Raising Antisera to the 3 -galactosidase-SM14(33) Fusion Protein and 
Production of SM14(33) Affinity-Purified Antibodies 
E. coli cells (strain BMH71-18) were transformed (2.3.2) with the pUR288-
SM14 construct (5.2.1). Soluble protein extracts were prepared (2.5.3) from cells 
which had been induced or uninduced for 3-gal-SM14(33) expression (2.5.2). 
Synthesis of SM14 fusion protein was assessed by SDS-polyacrylamide gel 
electrophoresis (8.5%(w/v) acrylamide; 2.5.8) prior to large scale gel purification of 
this species (2.5.10). Following quantitation (2.5.1), purified f3-gal-SM14(33) fusion 
protein was used in the immunisation of two rabbits (2.5.11). Pre-immune and 
immune (anti-5M14) sera were prepared from each rabbit bleed (702/703PIm and 
702/7031m respectively; 2.5.12). 
E. coli cells (strain HB1O1) were transformed (2.5.3) with plasmids pATH3-
SM14 or pATH3 (5.2.1) and induced for TrpE-SM14(33) fusion or TrpE protein 
synthesis respectively (2.5.2). Soluble protein extracts were prepared from these 
cells (2.5.3), aliquots of which were assessed by immunoblot analysis (2.5.8) with 
anti-SM14 and pre-immune sera. Figure 5.2(A) clearly shows the expression of 
TrpE-SM14(33) fusion protein (70kDa) only in the extract derived from induced cells 
which carry the pATH-5M14 construct. 
Affinity-purified SM14(33) antibodies were prepared from anti-SM14 serum 
(7031m) using the TrpE-SM14(33) fusion protein (2.5.13). These antibodies were 
used in probing immunoblots (Chapter 6). 
5.2.3 Reactivity of Anti-SM14 Rabbit Sera with E. coli Protein Extracts 
Anti-SM14 serum (7031m) reacted on immunoblots with j3-gal-SM14(33) and 
TrpE-SM14(33) fusion proteins (139kDa and 70kDa respectively; Figure 5.2(A)). 
However, this immune serum also reacted with a species of approximately 139kDa 
in the TrpE-SM14(33) and TrpE-containing extracts. This could imply that a protein 
of this mass may be similarly expressed in the -gal-SM14(33)-containing extract and 
also recognised by anti-SM 14 antibodies. However, plasmid-containing E. coli cells 
HB 101 and BMH7 1-18 are grown and induced in different media and therefore 
express different proteins. Furthermore, anti- SM 14 sera react with the TrpE-
SM14(33) and SM14(37) (yeast-expressed) species (Figure 5.2(C)), indicating that 
rabbits were indeed immmunised against the 3-gal-SM14(33) fusion. Surprisingly, 
pre-immune serum (703PIm) also reacted weakly with the 3-gal-SM14(33) fusion. 
Since the same serum, failed to react with the TrpE-SM14(33) species (and the 
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SM14(37) protein; Figure 5.2(C)) it can be deduced that the 3-galactosidase portion 
of the fusion protein is the immunreactive component. 
5.3.1 Construction of a Plasmid which Expresses SM14(37) in Yeast 
PCR was carried out on yeast genomic DNA using primers C864 and C865 
(2.4.14; Figure 5.1(B)). The PCR product contained the predicted SM14 open 
reading frame (ORF), plus 7 and 38 nucleotides of the 5' and 3' untranslated regions 
respectively. The product was digested with restriction endonucleases BamHI and 
Sail (2.4.16) and transferred into pBM125, such that the GAL] promoter of this 
vector was upstream of the predicted SM14 ORF. E. coli cells (NM522) containing 
potential pBM125-SM14 constructs were obtained (2.3.2), from which small scale 
plasmid preparations were made (2.4.4) and analysed by restriction digestion 
(2.4.10). Yeast cells (strain DJY84) were transformed with pBM125-SM14 plasmid 
DNA, from which individual colonies were isolated by virtue of their ability to grow 
on Ura medium (2.3.4). Small scale plasmid preparations were made from such 
cells (2.4.4) and checked by diagnostic restriction endonuclease digestion analysis 
(2.4.10). Protein extracts were prepared from cells bearing this plasmid construct 
and grown in inducing (galactose) or non-inducing (glucose) media (2.5.4). SDS-
polyacrylamide gel electrophoresis (10.5%(wlv) acrylamide; 2.5.6), followed by 
immunoblot analysis with anti-SM14 and pre-immune sera (7031ni/703PIm; 2.5.8) 
confirmed the conditional expression of the SM14(37) protein in these extracts 
(Figure 5.2(C)). 
5.3.2 Reactivity of Rabbit Antisera with Yeast Extracts 
A splicing extract was prepared from yeast cells (BJ2412; 2.5.5), aliquots of 
which were subjected to SDS-polyacrylamide gel electrophoresis (8.5%(w/v) 
acrylamide; 2.5.6) and immunoblotting (2.5.8). The anti-SM14 serum (7031m) 
identified a yeast protein of approximately 37kDa on immunoblots, which was not 
recognised by the corresponding pre-immune serum (703PIm; Figure 5.2(B)). 
Therefore, the endogenously expressed yeast protein has been preliminarily 
identified as a 37kDa protein. 
Yeast cells (DJY84) containing the pBM125-SM14 construct were grown in 
inducing (galactose) or non-inducing (glucose) medium, from which protein extracts 
were prepared (2.5.4). Aliquots were electrophoresed through denaturing poly-
acrylamide gels (2.5.6) and immunoblotted (2.5.8) with anti-SM14 or pre-immune 
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sera. Figure 5.2(C) shows that a protein of approximately 37kDa is recognised by 
anti-SM14 serum (7031m) and significantly expressed only in the SM14(37) induced 
extract (OEX). Furthermore, this protein is not recognised by pre-immune serum 
(703PIm), thereby confirming this species as the over-expressed SM14(37) protein 
(designated as such since it contains 37kDa of SM 14). In addition, a band present at 
the same molecular mass in the endogenously-expressing SM14 extract (B), is only 
detected with the anti-SM14 serum. This species may therefore represent the 
endogenously expressed SM 14 protein. 
5.4 	Analysis of Serum Sm24# Reactivity with an SM14(37) Over-expressing 
Yeast Protein Extract 
SM14(37) over-expressing and endogenously-expressing yeast protein 
extracts (2.5.4) were subjected to SDS-polyacrylamide electrophoresis (2.5.6) and 
immunoblotting (2.5.8). Blots were probed with Sm24# and anti-SM14 sera. Figure 
5.3(A) shows that 5m24# serum fails to react with the denatured yeast SM14(37) 
protein on immunoblots, whereas the anti-SM14 serum (7031m) clearly identifies 
this species. 
Immunoprecipitation with protein A-sepharose-bound Sm24# and anti-SM 14 
antibodies (2.5.14; 2.5.15) was carried out from an SM14(37) over-expressing 
extract. Each immunoprecipitate was divided in two and, in addition to an SM14(37) 
over-expressing extract (OEX; positive control), subjected to SDS-polyacrylamide 
gel electrophoresis (10.5%(w/v) acrylamide; 2.5.6), and immunoblot analysis (2.5.8) 
with Sm24# and anti-5M14 sera. Figure 5.3(B) demonstrates that the SM14(37) 
protein is precipitated from an over-expressing extract by both Sm24# and 7031m 
antibodies, but only the latter recognises this species on immunoblots. It is possible 
that the 5M14(37) species binds non-specifically to the protein A-sepharose beads 
and therefore its detection in these immunoblots may not be indicative of 
precipitation with antibodies. Nevertheless, the SM14(37) species detected in Figure 
5.3(B) immunoprecipitations does appear to be more enriched than in the control 
yeast extract (OEX). This uncertainty could be clarified experimentally by 
immunoprecipitation from an SM14(37) over-expressing extract with (1) pre-immune 
serum or (2) buffer alone. 
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Figure 5.2 Reactivity of Anti-SM14 and Pre-immune Rabbit Sera with E. 
coli and Yeast Protein Extracts 
Immunoblot of E. coli protein extracts, induced for 3-gal-SM14 (1), 
TrpE-SM14 (2) or TrpE (3) expression. Blots were probed with anti-SM14 (7031m) 
or pre-immune (703PIm) sera. The f3-gal-SM14 and TrpE-5M14 species, and 
molecular weight markers (kDa) are indicated. 
Immunoblot of yeast splicing extract (YSE), probed with anti-SM14 
(7031m) or pre-immune (703PIm) sera. The SM14 species and molecular weight 
markers (kDa) are indicated. 
Immunoblot of yeast extracts, over-expressing (OEX) or 
endogenously-expressing (E) SM14. Blots were probed with anti-SM14 (7031m) or 
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Figure 5.3 	Reactivity of Serum 5m24# with Yeast Protein Extracts 
Immunoblot of yeast protein extracts prepared from cells over-
expressing (OEX), or endogenously-expressing (E) the SM14(37) protein. Blots 
were probed with Sm24# and anti-SM14 sera (7031m). The SM14 species and 
molecular weight markers (kDa) are indicated. 
Immunoblot of an SM14(37) over-expressing extract and proteins 
immunoprecipitated with anti-SM14 (7031m) or Sm24# sera. Blots were probed 
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5.5 	Discussion 
This chapter describes the production of anti-SM14 rabbit sera and analyses 
their reactivity with various SM14 proteins expressed in E. coli or yeast. In addition, 
the reactivity of serum 5m24# with endogenously or over-expressed forms of yeast 
SM14 has been assessed, thereby facilitating definition of the 5M14 epitope(s). 
Anti-SM14 serum (7031m) was shown to react with two E. coli fusion 
proteins (3-gal-SM14(33) and TrpE-SM14(33)) on immunoblots. However, pre-
immune serum (703PIm) was also found to react with the 3-ga1-SM14(33) fusion on 
immunoblots. Since this same serum failed to react with the TrpE-SM14(33) and 
yeast SM14(37) proteins in similar experimental conditions, it must be concluded that 
the observed reactivity is a property of the -galactosidase portion of this fusion. 
A 37kDa protein was found to be reactive with anti-SM 14 serum (7031m) on 
immunoblots, but only significantly expressed in an extract prepared from yeast cells 
induced for SM14(37) synthesis. This species was not recognised by pre-immune 
serum (703PIm). This demonstrates that yeast cells can over-express the SM14(37) 
protein (the primary sequence of which is derived from cDNA and genomic DNA 
nucleotide sequences) under an inducible promoter, and that this species migrates at 
the expected molecular weight of 37kDa. In addition, anti-SM14 rabbit sera have 
identified a protein of identical molecular mass on immunoblots (not recognised by 
the corresponding pre-immune serum) which may be a candidate for the 
endogenously expressed 5M14 protein. 
Anti-SM14 serum (7031m) demonstrated the ability to immunoprecipitate the 
over-expressed form of the SM14(37) protein from an in vitro yeast extract. Since 
rabbits were immunised with denatured 3-gal-SM 14(33), epitopes of the latter must 
be accessible in the native yeast protein. 
The reactivity of the serum Sm24# with the denatured and native forms of 
the over-expressed yeast SM14(37) protein was assessed. Serum Sm24# failed to 
recognise the denatured protein in immunoblots, but precipitated this species from an 
SM14(37) over-expressing extract, suggesting that the SM14 epitope(s) may be 
conformational and not linear in nature. Therefore, the immunoreactivity of this 
protein may rely on its native conformation, a property of many SLE autoantigens 
(Tan, E.M., 1989). Despite this, the initial isolation of the SM14 cDNA sequence in 
the library screen, remains plausible, since the -ga1actosidase fusion proteins 
expressed by the kgtl 1 clones were transferred to nitrocellulose without denaturation 
(M. Dalrymple, personal communication). 
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CHAPTER 6 
An Attempt to Characterise the SM14 Protein 
	
6.1 	Introduction 
An attempt has been made to determine if the SM14 protein is a yeast snRNP 
constituent. 
An association of this protein with these particles may depend on molecular 
interactions with individual snRNAs and/or other snRNP proteins. As a 
spliceosomal snRNP component, the SM14 protein may also interact with the pre-
mRNA substrate during the splicing process. For these reasons, the RNA binding 
abilities of various SM14 species were studied by North-Western blot analysis. In 
addition, an analysis of the RNA and protein species immunoprecipitated by anti-
SM14, Sm24# and anti-PRP8 sera was undertaken. Precipitates were assessed by 
Northern and immunoblot analysis respectively. The RNA binding ability of US 
snRNP proteins was examined by North-Western analysis, in an attempt to identify 
the molecular masses of the nucleic acid binding proteins present within these 
particles. 
6.2 	The TrpE-SM14 Protein has RNA Binding Properties In Vitro 
Protein extracts were prepared (2.5.3; 2.5.4) from the following plasmid-
containing cells: 
(1) 	E. coli (BMH71-18) bearing pUR288-SM14; induced for f3-gal-SM14 
fusion protein synthesis (2.5.2). 
E. coli (BMH71-18) bearing pUR288-SM14; non- induced (2.5.2). 
E. coli (1113101) bearing pATH3-SM14; induced for TrpE-SM14 
fusion protein synthesis (2.5.2). 
E. coli (HB 101) bearing pATH3; induced for TrpE protein synthesis 
(2.5.2). 
Yeast (DJY84) bearing pBM125-SM14; grown in inducing medium 
(galactose). 
Yeast (DJY84) bearing pBM125-SM14; grown in non-inducing 
medium (glucose). 
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Aliquots of these extracts were subjected to North-Western analysis (Figure 
6.1; 2.5.9). The radiolabelled RNA probes in these experiments were synthesised by 
in vitro transcription from the linearised plasmids described in Table 6.1(2.4.24). 
Table 6.1 
Plasmid Gene! RNA Linearising Digest Excising Digest 
UsnRNA Polymerase (in vitro (radiolabelling 
species  transcription) probes) 
pBSKS-U1 SNR19/ T3 HindHI Kpn I/HindIII 
Ul  
pDF97 SNR20/ T7 EcoRI EcoRI/BamHI 
U2  
pJDI4 SNR20/ N/A N/A EcoRI/BamHI 
U2  
pTZ1 8U4G SNR14/ T7 HindJH EcoRI/HindilI 
U4  
pFN-1 SNR7/ T7 HpaI BamHJ/HpaI 
U5  
pTaq-6 SNR6/ T7 HindIII EcoRJIHindlII 
U6  
pTZrp28s RP28 T7 EcoRI N/A 
A protein of 70kda bound snRNA species Ui, U2, U4, US and U6 as well as 
an RP28 transcript in North-Western analysis of a TrpE-SM14(33) expressing extract 
(Extract 3; Figure 6.1). These signals were not observed in extracts synthesising the 
TrpE protein (37kDa; Extract 4) and therefore represent the TrpE-SM14(33) fusion 
protein. The variation in intensity of the 70kDa signals is not indicative of the 
relative affinity of the TrpE-SM14(33) fusion for the individual RNA species, but the 
strength of the radioactive probe. Protein extracts prepared from E. coli cells 
containing plasmid pUR288-SM14 (induced for I3-gal-SM133) synthesis; Extract 1) 
and yeast cells containing pBM125-SM14 (induced for SM14(37) synthesis; Extract 
5) did not contain RNA binding proteins of 139kDa and 37kDa respectively, by this 
assay. In addition, no difference was observed between the RNA binding proteins 
identified in non-induced (2 and 6) and their respective SM 14-induced extracts (1 
and 5). This suggests that the denatured 13-gal-SM14(33) and SM14(37) proteins do 
not bind RNA, using the North-Western blotting technique. 
129 
Figure 6.1 	North-Western Blot 
E. coli soluble protein extracts (Extract (3), TrpE-SM14(33); Extract (4), 
TrpE) were electrophoresed through SDS-polyacrylamide gels (8.5%(w/v) 
acrylamide), prior to North-Western analysis. Blots were probed with radiolabelled 
in vitro transcribed RNA probes (Ui, U2, U4, U5, U6 and RP28) as indicated. A 
species of 70kDa (putative TrpE-SM14(33) protein) present in the fusion protein 











6.3 	Analysis of the RNA Binding Abilities of the SM14 Proteins 
The TrpE-SM14(33) protein bound all RNA species tested in North-Western 
analysis. Conversely, the 3-gal-SM14(33) and SM14(37) proteins failed to bind these 
RNA species (data not shown). This discrepancy in the RNA binding abilities of the 
SM14 proteins, could be attributed to the relative sensitivity of each species to 
degradation. It has been suggested that TrpE fusion proteins degrade less readily 
than 3-galactosidase, hence the RNA binding ability of the latter species may be lost 
as degradation proceeds. Immunoblot analysis with anti-SM14 sera (7031m) 
indicates that degradation of the 3-gal-SM14 protein does occur, as demonstrated by 
the progressively smaller species detected (Figure 5.2(A)). Since the C-terminal 
region of 3-ga1actosidase is fused with the N-terminus of SM14(33), RNA binding 
ability may therefore require the full C-terminal sequence of SM14. Hence, the 
failure of the yeast SM14(37) protein to bind RNA would be supported by 
degradation of this species on immunoblots. This does not appear to be the case 
(Figure 5.2(C)). However, the loss of a few critical amino acids at the C-terminus of 
the SM14(37) protein may not be discernible by the antibodies employed in probing 
the immunoblot. 
Although the SM14(37) primary sequence does not contain a known RNA 
recognition motif, it does contain many basic residues, which have been suggested to 
facilitate associations with nucleic acids (Clarck, R.J. and Felsenfeld, G., 1971). As 
previously stated, the RNA binding ability of the SM14 proteins may depend on the 
presence of C-terminal amino acids. This is supported by the observed degradation 
of the 3-gal-SM14(33) fusion on immunoblots, in addition to the inability of this 
species to bind RNA in North-Western analysis. Six of the last ten residues of the 
predicted SM14 protein are basic (five of which are lysine; Figure 4.4). Therefore, it 
is possible that these C-terminal amino acids form part of or represent an RNA 
binding domain. Alternatively, the requirements for RNA binding may be 
conformational, in which case, the SM14 proteins denatured by SDS-polyacrylamide 
gel electrophoresis (prior to North-Western blotting) would not bind any of the RNA 
species tested. However, it is apparent that a degree of protein refolding/renaturation 
can occur following electroblotting (Rokeach, L.A. et al., 1992). Since the exact 
requirements for this process appear to vary between individual protein species, and 
there is as yet no method of determining the degree of refolding which may have 
ocurred, it is possible that only the TrpE-SM14(33) fusion protein refolds sufficiently 
to permit interaction with RNA. In addition, it has been observed that the N-
terminal portion of a fusion protein may determine its antibody binding capacity, 
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perhaps by altering its conformation or properties (Section 1.3.2). Hence, the RNA 
binding abilities of fusion proteins (such as TrpE-SM14(33) and 13-gal-5M14(33)) 
could similarly be affected. 
The universal binding of the TrpE-SM14(33) fusion protein to all RNA 
species tested, indicates the non-sequence-specific nature of this interaction. This 
may reflect the ability of the endogenous yeast SM14 protein to bind (1) individual 
snRNAs (at specific regions such as the Sm site or stem-loop sequences) and 
transpose this activity onto other non-related RNA species, or (2) many RNA species 
(for example, all RNA polymerase II transcripts) thereby not requiring stringent 
sequence elements. If the latter were correct, it would be expected that 
immunoprecipitation experiments with serum 5m24# from a yeast splicing extract 
(in which all precipitated RNA species were radiolabelled), would result in the 
precipitation of many RNA species. However, this has not been observed (Figure 
1.1) suggesting that the SM14 protein may associate with a specific RNA species. 
6.4 	Immunoprecipitation Experiments 
Immunoprecipitation was performed from a yeast splicing extract (2.5.15) 
with antibodies from anti-SM14, pre-immune, anti-PRP8 or Sm24# sera. Antibodies 
were covalently coupled to protein A-sepharose beads when protein precipitates 
were examined (2.5.14). Immunoprecipitates were analysed by 
SDS -poly acrylamide gel electrophoresis (12.5 %(wlv) acrylamide; 
2.5.6), followed by immunoblot analysis (2.5.8) with affinity-purified antibodies 
(purified against the TrpE-SM14(33) fusion; 2.5.13). 
Denaturing polyacrylamide gel electrophoresis (2.4.13), followed by 
Northern blotting (2.4.23). Specific RNA species were detected by hybridisation 
(2.4.19) with probes synthesised by radioactively labelling (2.4.17) the DNA 
fragments described in Table 6.1. 
SDS-polyacrylamide gel electrophoresis (1 O%(wfv) acrylamide; 
2.5.6), followed by North-Western blotting (2.5.9). Blots were probed with a 
radiolabelled in vitro transcript (RP28, Table 6.1; 2.4.24). 
6.4.1 Detection and Analysis of Immunoprecipitated Proteins 
A 37kDa protein was observed in anti-SM14, PRP8 and Sm24# 
immunoprecipitates and recognised on immunoblots by affinity-purified SM14 
antibodies (Figure 6.2(A)). This 37kDa species co-migrates with a protein present in 
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a yeast splicing extract, which is similarly detected by SM14 antibodies. This could 
suggest that SM14 is a snRNP constituent, as anti-PRP8 and Sm24# antibodies 
precipitate the U5 snRNP, and the Ui, U2 U4/U6 and U5 snRNPs respectively. 
However, the anti-PRP8 serum is polyclonal and therefore contains antibodies 
directed against many species. These additional antibodies or those directed against 
PRP8 may cross-react with SM14 or an SM14-associated factor, especially since 
such species may be constituents of RNA/protein complexes and therefore share 
primary peptide sequence similarities. A more definitive result in determining if 
SM14 is snRNP-associated could be obtained by using affinity-purified PRP8 and 
anti-TMG antibodies in such immunoprecipitation experiments. 
6.4.2 Detection and Analysis of Immunoprecipitated SnRNA Species 
The five snRNA species, Ui, U2, U4, U5 and U6 are precipitated by 
antibodies in anti-SM14 (7021m), pre-immune (702PIm) and Sm24# sera (Figure 
6.2(C)). The levels of snRNAs immunoprecipitated by anti-SM14 are significantly 
higher than pre-immune, but significantly less than Sm24# antibodies. 
The discrepancy in the efficiency of precipitation by both sources of SM14-
directed antibodies (Sm24# and anti-SM14) could be interpreted as indicative of a 
weak interaction of anti-SM14 rabbit antibodies with snRNPs. If SM14 is indeed a 
snRNP constituent, then this may signify that the SM14 epitopes (of rabbit anti-
SM14 antibodies) are partially or fully covered while this species is present within 
the snRNP. Conversely, Sm24# antibodies may interact more efficiently with SM14 
when situated in the quaternary structure of this RNP particle. An example of the 
latter has previously been observed with SLE autoantibodies directed solely against 
the RoRNP particle or the Ku complex (Boire, G. and Craft, J., 1989; Reeves, W.H. 
et at., 1991). Furthermore, the observed precipitation of snRNAs by Sm24# 
antibodies could include hitherto undetected antibodies, which also interact or cross-
react with other snRNP constituents. 
However, if SM14 is not snRNP-associated, then the weak interaction of 
anti-SM14 antibodies with these RNP particles, could be explained by the existence 
of cross-reactive epitopes on snRNP proteins, which are coincidentally shared with 
SM14. Since the peptide sequences of many of the yeast snRNP-associated species 
have not been identified, it is possible that SM14 contains highly homologous 
regions with such species, which may be simultaneously reactive with SLE 
autoantibodies. 
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Pre-immune SM14 serum does not react with the yeast endogenously 
expressed or over-expressed SM14(37) protein on immunoblots (Figures 5.3(B) and 
(C)). Therefore, the snRNA precipitation observed by these antibodies may 
represent a background level in such experiments. This could have arisen as a result 
of the snRNA species binding non-specifically to protein A-sepharose beads. This 
problem could be eliminated by optimising blocking conditions so that this non-
specific interaction does not occur. 
6.4.3 Detection and Analysis of RNA-Binding U5 SnRNP Proteins 
Immunoprecipitation was carried out from a yeast splicing extract using anti-
PRP8 antibodies. The species precipitated were examined for RNA binding ability. 
Several proteins demonstrated affinity for the RP28 transcript. However, only two 
proteins (40kDa and 50kDa) appeared enriched in signal in comparison with those 
present in a control yeast extract (Figure 6.2(B)). A weak band of approximately 
37kDa was also observed. In view of the failure of SM 14(37) to bind RNA by 
North-Western analysis (Section 6.3), it is unlikely that this species represents 
endogenous SM 14. 
134 
Figure 6.2(A) 	Western Blot 
Immunoprecipitation was performed from yeast splicing extract with anti-
SM14 (7031m), anti-PRP8 or Sm24# antibodies. Precipitated proteins and yeast 
splicing extract (YSE; positive control) were subjected to SDS-polyacrylamide gel 
electrophoresis (12.5%(w/v) acrylamide), prior to immunoblotting. The blot was 
probed with affinity-purified SM14 antibodies. The putative SM14 protein, signals 
due to IgG and molecular weight markers (kDa) are indicated. 
Figure 6.2(B) 	North-Western Blot 
Immunoprecipitation was carried out from a yeast splicing extract using anti-
PRP8 antisera. The precipitate and YSE (positive control) were subjected to SDS-
polyacrylamide gel electrophoresis (10%(w/v) acrylamide), followed by North-
Western analysis. The blot was probed with an in vitro transcribed radiolabelled 
RNA species (RP28). The sizes of molecular weight markers (kDa) are indicated. 
Figure 6.2(C) 	Northern Blot 
Immunoprecipitation was performed from yeast splicing extract with anti-
SM14 (7021m), pre-immune (702PIm) or Sm24# antibodies. RNA species were 
electrophoresed through a denaturing polyacrylamide gel, prior to Northern blotting. 
Blots were probed with radiolabelled DNA probes, synthesized from snRNA gene 
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6.5 	Discussion 
6.5.1 The RNA Binding Ability of the Yeast SM14 Protein 
The experiments described in this chapter have shown that the SM14 protein 
has a general RNA binding ability as part of a TrpE-SM14 fusion. 
Immunoprecipitation experiments with Sm24# serum do not precipitate many RNA 
species (Figure 1.1), implying that SM14 may associate with a specific RNA. The 
RNA binding ability of the TrpE-SM14 fusion protein may require the C-terminal 
ten amino acids and/or a particular conformation, which may reflect the properties of 
the endogenous yeast SM14 protein. This could be tested by expressing a TrpE-
SM14 species in E. coli which (1) does not contain the C-terminal amino acids or (2) 
contains substituted (e.g. negative or neutral) residues. These fusion proteins could 
be analysed in comparison with the TrpE-SM14(33) species by North-Western 
analysis. 
If SM14 is not a snRNP component and its RNA binding ability is not 
associated with these complexes, then it may bind another specific RNA transcript. 
In view of the predominance of ribosomal factors isolated in this library screen, then 
SM14 may be such a species. Hence, SM14 may interact with ribosome-associated 
RNA species, such as 5S RNA. However, no RNA species of this size (120nts) is 
precipitated with Sm24# antibodies (M. Dalrymple, unpublished results). 
6.5.2 SM14 may be SnRNP-associated 
A 37kDa protein present in an anti-PRP8 immunoprecipitate, co-migrates 
with SM14 and is recognised by affinity-purified SM14 antibodies. This suggests 
that SM14 could be a U5 snRNP constituent. In addition, antibodies in anti-SM14 
sera precipitate snRNA species Ui, U2, U4, U6 and U5 , albeit weakly. Hence, 
5M14 may be snRNP-associated. 
The protein constituents of yeast snRNPs have been isolated (by affinity 
purification with anti-TMG antibodies) and analysed (Fabrizio, P. et al., 1994; 
Section 1.4). A 36kDa species has been identified as Ui snRNP-specific, but no 
other proteins of the similar molecular mass to that of 5M14 have been suggested as 
components of yeast snRNPs (other than those of 34kDa and 33kDa which are 
believed to represent the products of the SNPJ and MUD] genes respectively). If 
SM14 represents this Ui-specific 36kDa species, then the precipitation of snRNAs 
U2, U4, U5 and U6 by anti-SM14 antibodies could signify the presence of cross- 
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reactive epitopes between SM14 and other U2, U4/U6, and U5 snRNP species. 
Alternatively, the observed immunoprecipitation of snRNA species Ui, U2, U4, U5 
and U6 with Sm24# autoantibodies may indicate several snRNP-directed 
specificities. However, this would not explain the precipitation of SM14 by an anti-
PRP8 serum. It is possible, that the Ui snRNP-specific 36kDa species identified by 
Fabrizio et al. (1994), is loosely associated with other snRNPs. That there are 
different categories of snRNP-associated species, has been demonstrated by the 
isolation of a 69kDa protein, which is thought not to be an intrinsic member of these 
particles (Hack!, W. et al., 1994). In addition, the method of snRNP isolation from 
mammalian cells has recently been revised, since the discovery of many more 
snRNP-associated species when using low salt buffer conditions (Lührmann, R. et 
al., 1990). Hence, SM14 may be loosely associated with snRNPs, but more easily 
isolated as a constituent of the U 1 particle. 
The SM14 protein, although bearing no regions of sequence identity with any 
of the mammalian Sm proteins, is closest in molecular mass and p1 value to the B/B' 
proteins (SM14=37kDa, p1=10.46; B/B'=28/29kDa, pT-10.6!10.7 respectively). The 
lack of an RRM in the predicted 5M14 protein sequence, but ability to bind RNA (as 
predicted from TrpE-SM14(33) North-Western analysis) is comparable to that of the 
common snRNP Dl protein, which also does not contain such an element and has 
demonstrated an affinity for RNA without sequence specific requirements (Tazi, J et 
al., 1986). At present only the common snRNP protein G has been shown to 
specifically bind an snRNA species (at the Sm site of Ui snRNA; Heinrichs, V. et 
al., 1992). 
An SS serum has been described (Fujii, T. et al., 1992) which 
immunoprecipitates a mammalian protein of 36kDa, possibly associated with the 
U4/U6 snRNP. This serum failed to react with this species on an immunoblot (as 
does Sm24# with SM14), implying that the immunoreactive epitope(s) is perhaps 
conformational. However, this could also signify that this 36kDa protein is 
precipitated only by virtue of its association with the U4/U6 snRNP and so is not 
directly antigenic. It would be interesting to discover whether the mammalian 
36kDa protein described here (also found to be reactive with an anti-Sm serum), is 
the eukaryotic homologue of the SM14 protein. 
The efficiency of SM14 protein precipitation by anti-SM14 and serum 
Sm24# antibodies is similar (as observed on immunoblots; Figure 6.2(A)). 
Conversely, the levels of snRNAs precipitated by these antibodies are dissimilar 
(Figure 6.2(C)). If the 5M14 protein is a snRNP constituent, then this discrepancy 
could be explained as follows. The level of precipitation of snRNAs by Sm24# and 
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anti-SM14 antibodies depends on the accessibility of the corresponding epitopes. 
This may depend on the proportion of cellular SM14 which is snRNP-associated. 
Hence, snRNA precipitation by either antibody species only reflects epitope 
accessibility within the snRNP, whereas SM14 precipitation may include reactivity 
with noncomplexed SM14. The discrepancy in the level of snRNAs precipitated 
could therefore indicate that a significant proportion of the SM14 cellular pool is not 
snRNP-associated This would be in contrast to other yeast snRNP proteins (e.g. 
PRP8), which appear to exist predominantly as part of their associated entities at a 
cellular level. However, Sm24# serum may contain additional antibodies to other 
snRNP constituents, thereby explaining the higher levels of snRNA precipitation. 
6.6 Summary 
The experiments described in this chapter suggest that a protein co-migrating 
with SM14 and recognised by affinity-purified SM14 antibodies on immunoblots is 
immunoprecipitated by an anti-PRP8 serum. This protein has a general RNA 
binding ability as part of a TrpE-SM14 fusion, possibly requiring the C-terminal ten 
amino acids or a particular conformation. On the basis of these results, it is possible 
that the SM14 protein is a snRNP constituent which has RNA binding properties. A 
small proportion of the total SM14 protein may be complexed in snRNPs, implying 
that this species may not be an intrinsic snRNP constituent. However, more 
definitive characterisation of SM14-associated species, perhaps using affinity 





7.1 	Yeast Species Identified as SLE-Reactive 
Most of the species isolated in this work as reactive with the SLE serum 
Sm24#, are cytoplasmic constituents of the yeast cells. Furthermore, a number of 
these are associated with the translation apparatus. The proportion of SLE sera 
which contain antibodies to rRNPs is 10% (Table 1.1). Of the yeast species 
identified here (Categoryl), 4/21 (17%) are known rRNP constituents. This could 
signify a bias of antibody specificity in serum Sm24# to these particles, or that these 
ribosomal factor transcripts are abundant. Alternatively, the epitopes of these 
ribosomal factors may be most highly conserved and/or remain most accessible to 
Sm24# antibodies during the library screen procedure, thereby explaining the 
relatively higher percentage of these factors isolated. 
The primary sequences of the hypothetical and novel species (Categories 2 
and 3) isolated in this work, were found not to contain the characteristic motifs 
observed in the Sm B/B", Dl and D3 proteins, or any of the SLE epitopes defined in 
Tables 1.3 and 1.4. Hence, no obvious candidates for yeast snRNP proteins were 
identified. 
An overall preponderance of highly conserved, lysine-rich proteins was 
noticed in all categories of species. This supports previous observations, which have 
revealed a tendency for SLE autoantigens to contain long stretches of highly charged 
residues (Brendel, V. et al., 1990). Furthermore, many of the yeast species 
identified were found to be encoded by more than one gene, and/or conditionally 
expressed. It could be speculated that conditionally expressed, lysine-rich species, 
have a propensity to be SLE autoantigens. This association of properties could be 
mediated by a post-translational modification on lysine residues, which could 
specifiy a factor as a host target and indeed form part of an autoepitope. 
Furthermore, an inappropriate modification (perhaps in chemical nature or 
positioning) could contribute to the triggering or progression of the autoimmune 
response in SLE. Antigen processing leads to antibodies targeting many regions of a 
protein. Therefore, the yeast species isolated in this work need not retain the precise 
nature or position of the higher eukaryotic modification, since secondary epitopes 
would suffice the isolation of the lower eukaryotic species. In an attempt to 
investigate a possible role for modified lysine residues in SLE autoantigens, it would 
139 
be necessary to obtain autoantibodies directed against such a modified, lysine-rich 
epitope. By comparing the immunoreactivity of these purified antibodies with 
modified (eukaryotically synthesised) and unmodified peptide regions (bacterially 
synthesised), the significance of such a biochemical alteration could be determined. 
7.2 	A Novel Yeast Species (SM14) has been Identified and Partially 
Characterised. 
One cDNA sequence was obtained in the library screen on four independent 
occasions. The yeast gene (SM14) encoding this species was studied and its product 
partially characterised. 
7.2.1 The SM14 Gene 
SM14 is a S. cerevisiae gene which is single copy and encodes a 37kDa 
protein (SM14). The SM14 protein can be conditionally over-expressed in yeast. 
Antibodies in serum Sm24# appear to react with the native but not the denatured 
form of SM14. Hence, the epitope responsible for the initial isolation of this species, 
may have been conformational in nature. 
7.2.2 Function and Molecular Associations of the SM14 Protein 
The aim of this work was to identify yeast homologues of the mammalian 
common (or specific) snRNP proteins. The SM14 protein most closely resembles 
the common snRNP BIB' proteins, in molecular mass and p1. However, no primary 
sequence identity with these Sm proteins has been observed. The results of Fabrizio, 
et al. (1994), suggest that there are no yeast common snRNP proteins of similar 
molecular mass to that of the mammalian 5mB/B' proteins. 
Anti-5M14 rabbit sera weakly precipitated yeast snRNAs Ui, U2, U4, U5 
and U6, implying that 5M14 may be snRNP-associated. The low level of 
precipitation could be due to the inaccessibility of SM14 epitopes while a snRNP 
constituent to antibodies raised against the denatured form of the protein. 
Alternatively, the inefficiency of the rabbit antibodies in precipitating yeast snRNPs 
and failure of Fabrizio et al. (1994), to identify a snRNP-associated species with the 
molecular mass of SM14, could be due to its transient association with these yeast 
particles. The number of human snRNP-associated factors has recently been revised, 
as a result of an alteration in the snRNP purification method (Lührmann, R et al., 
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1990). Using low salt purification conditions many more proteins have been found 
to be loosely associated with snRNPs. Hence, SM14 may represent a lower 
eukaryotic homologue of such a factor and therefore not be intrinsically associated 
with yeast snRNPs. 
The SM14 protein may bind RNA in vivo, as a bacterially expressed fusion 
protein of this species binds RNA (non-specifically) in vitro. The primary sequence 
of SM14 does not contain an RRM, but this element is not necessarily a prerequisite 
for an RNA-binding species. Hence, SM14 may be associated with RNA 
processing, synthesis or translation and therefore could be a snRNP or rRNP 
component. 
Many of the immunoreactive species identified in this work are associated 
with protein biosynthesis, particularly translation. Many ribosomal proteins are 
basic and SM14 complies with this. The amino acid sequences of approximately 
half of the 77 protein constituents of yeast ribosomes have been determined 
(Woolford, J.L., 1991), hence there is a possibility that SM14 is such a factor. 
However, unlike SM14, the genes encoding such species in yeast often contain 
introns and are present in two copies. In addition, certain sequence elements are 
often present upstream of RPGs (Ribosomal Protein Genes) which have not been 
found in this region of SM14. 
7.2.3 Future Work 
Future work would aim to determine the cellular function and molecular 
associations of SM14. In particular, it would be interesting to discover if this species 
is associated with snRNPs or rRNPs, especially as constituents of the latter particles 
have been frequently identified in this work. 
Two approaches can be used in achieving this aim, firstly genetic, and 
secondly biochemical. The first approach requires the genetic manipulation of the 
SM14 gene. A gene-disrupted haploid strain could be generated, which is 
complemented with a plasmid-carried, conditionally expressed copy of SM14. 
Extracts would be prepared from such plasmid-carrying cells prior to and following 
SM14 depletion. These extracts can be subsequently assayed for efficiency of either 
in vitro splicing or translation. This approach requires the gene in question to be 
essential for cell growth. However, the SM14 gene has recently been shown to be 
inessential (V.Vidal, personal communication). 
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The biochemical approach in attempting to determine the cellular role of 
SM14 would be facilitated by a source of (1) purified full length SM14 protein, and 
(2) affinity-purified anti-SM14 antibodies from serum Sm24#. 
The former could be achieved by manipulation of the nucleotide sequence of 
the SM14 coding region, such that an N-terminal polyhistidine tag (with a Factor Xa 
cleavage site) is introduced at the beginning of the SM14 protein sequence. Large 
quantities of his-SM14 protein could be synthesised in yeast cells, from which 
extracts could be prepared. His-tagged proteins can be purified from heterogeneous 
extracts over Ni2+ columns (Hoffman, A. and Roeder, R.A., 1991). A Ni2+  binding 
competitor (imidazole) would be used to elute the purified his-SM14 species from 
the column. 
Antibodies purified against native SM14 from serum Sm24# may provide a 
source reactive with a conformational epitope(s) of this species. The latter could be 
obtained by using the his-tagged SM14 fusion in native blots, from which 
autoantibodies could be purified. These antibodies may be inherently more efficient 
in precipitating SM14-associated yeast species. In addition, it would be helpful to 
generate rabbit antibodies to the full length SM14 protein, which may also 
precipitate the latter more successfully, depending on the molecular accessibility of 
the extra N-terminal 30 amino acids. This could be achieved as previously described 
(Chapter 5) except that PCR from yeast genomic DNA (encompassing the entire 
SM14 coding region) would be used to generate the fragment which is cloned into 
the E. coli LacZ gene. As with the 5m24# serum, these SM14-directed rabbit 
antibodies could be purified against native blots of the his-SM14 species. 
Purified SM14-directed antibodies could be used in immunoprecipitation 
analysis. RNA precipitates would be Northern blotted and detected with probes 
derived from ribosomal (5S, 18S or 25S) or snRNP-associated (Ui, U2, U4, U5 and 
U6) RNA species. Precipitated proteins would be electrophoresed through SDS-
polyacrylamide gels and immunoblotted (probed with anti-PRP8 antibodies) or 
Coomassie blue stained. However, the latter would only reveal the molecular 
masses of SM14-associated ribosome species, since these particles are significantly 
more abundant than snRNPs. In addition, SM14-directed antibodies could be used 
in immunoblot analysis of purified rRNPs or snRNPs, where identification of a 
37kDa species would suggest that SM14 may be a constituent of such particles. 
The relative affinities of SM14 for different RNA species may indicate the 
cellular function of this protein. Purified his-SM 14 protein could be incubated with 
anti-his antibodies which have been covalently attatched to protein A-sepharose. 
Various radiolabelled in vitro transcripts (e.g. ribosomal, small nuclear, intron- 
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containing or polyadenylated) could be added to the his-SM14 mixture. Following 
proteinase K treatment, the radioactivity of bound RNA speices could be measured 
by scintillation counting. This would demonstrate the binding affinity of the his-
SM14 species for these different RNAs. However, it is possible that SM14 is 
associated with other species in a cellular complex. Therefore, its affinity for RNA 
while present in such a complex may be altered. Hence, various RNA species (as 
above) could be incubated with in vitro his-SM14 yeast extracts, followed by 
immunoprecipitation with anti-his or anti-SM14 antibodies. Northern blotting and 
scanning densitometry of precipitated radiolabelled species would indicate the 
affinity of this 5M14 species for different RNA species. 
It would be interesting to determine the significance (if any) of the lysine-
rich C-terminal tail of the SM14 protein. Genetic manipulation of the SM14 coding 
region of pBM125-SM14 (possibly by PCR mutagenesis), such that the C-terminal 
lysine residues are replaced with (1) alternative positively charged residues, e.g. 
arginine, (2) non-polar residues, e.g. glycine or (3) negatively charged residues, e.g. 
aspartate or glutamate, would provide a source of mutant SM14 species which can 
be expressed in yeast and therefore may (or may not if lysine-specific) retain any 
post-translational modifications. In addition an SM14 mutant could be created 
which would not contain the C-terminal four lysine residues. The 
immunoprecipitability and RNA binding affinities of these mutants could be 
examined (as described above) in comparison with wild-type SM14. The results 
may indicate the importance of the lysine-rich C-terminal tail with respect to (1) the 
nature of the epitope of SM14-directed Sm24# antibodies and (2) the ability of 
SM14 to bind RNA. 
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